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Synopsis
Biomarkers are critically important in clinical oncology. In addition to providing valuable
prognostic information, biomarkers assist in patient risk assessment, prediction of response to
treatment, and monitoring progress of disease, all key factors in improving the individualisation
and delivery of treatment. Furthermore, biomarkers provide insight into the mechanisms of
cancer and identify novel targets for therapeutic agents. This thesis investigates both molecular
biomarkers in gastroesophageal cancer and clinical biomarkers in colon cancer and identifies
several molecular targets and clinical markers of interest.
Chapter 1 provides a summary of the literature on the selected biomarkers in gastrointestinal
cancer, concentrating on cancer stem cells (CSC), the urokinase plasminogen activation system,
and circulating tumour cells in gastroesophageal cancer, and clinical biomarkers in colon
cancer.
Chapter 2 examines the role of the urokinase plasminogen activation system, including the
urokinase plasminogen activator receptor (uPAR), in resected primary gastroesophageal
cancers. In this comprehensive systematic review and meta-analysis, the results of 41 studies
containing 2689 patients were analysed and summarised, providing level 1 evidence identifying
uPA, uPAR, and plasminogen activator inhibitor 1 (PAI-1) as novel, clinically relevant,
biomarkers in resected gastroesophageal cancer.
These results are then extended in Chapter 3, which details an immunohistochemical study
exploring expression of CSC markers and uPAR on metastatic deposits of gastroesophageal
cancer. CD44, a CSC marker in gastroesophageal cancers, and uPAR are shown to be
independent prognostic factors associated with poorer overall survival in multivariate analysis.
CD44 expression is also shown to be associated with uPAR expression providing evidence of
the links between the stem cell phenotype and the uPA system.
Circulating tumour cells (CTCs) provide the essential link between the primary tumour and the
distant metastatic disease. After confirming uPAR as a clinically relevant biomarker in both
primary and metastatic gastroesophageal cancer, we explored uPAR as a biomarker on CTCs.
Due to logistical constraints, it was necessary to develop a method for the cryopreservation of
patient samples for subsequent CTC analysis. Chapter 4 outlines a robust and feasible protocol
for the delayed isolation of CTCs, and demonstrates the validity of this approach by confirming
CTC enumeration on cryopreserved specimens remains an independent prognostic factor. CTC
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uPAR expression did not improve on currently employed markers, but the technical issues
which are the likely cause of this result are addressed.
The biology of CTCs is further explored in Chapter 5, in which the establishment and
characterisation of two novel long term CTC cultures derived from CTCs from patients with
gastroesophageal cancer are described in detail. These two cell lines exhibit distinct and
contrasting phenotypic and genotypic profiles, accurately recapitulating the features of the
source tumour and highlighting the marked heterogeneity seen between patients with
gastroesophageal cancers. In addition to extensive characterisation, cytotoxic and radiotherapy
assays on the cell lines were undertaken, with the results consistent with the molecular biology
of each line, as well as the clinical picture of the source patient.
Chapter 6 examines two key clinical biomarkers in locoregional colon cancer using a large
purpose built database derived from the NSW Clinical Cancer Registry, and linked to numerous
government datasets to reduce bias and provide additional validity for our results. We were able
to control for important confounders in our multivariate analyses including patient
comorbidities and treatment received, providing a uniquely detailed analysis of population level
data.
The first study explored importance of primary tumour location in early stage colon cancer.
Strong evidence of an association of right sided tumours with older age and poor tumour
clinicopathological factors was found. The impact of primary tumour location on overall
survival varied by stage; patients with right sided colon cancer had a lower all-cause mortality
in stage II, but a higher mortality in stage III disease, likely driven by underlying differences in
tumour biology.
The second study examined the use of chronological age as a biomarker to select suitability for
adjuvant chemotherapy in stage III colon cancer, a hotly debated and controversial topic. It was
first demonstrated that elderly patients (defined as 70 years and older) were less likely to receive
the standard adjuvant chemotherapy than younger patients. Multivariable cox hazard regression
models were then used to show a persistent survival benefit to adjuvant oxaliplatin doublet
chemotherapy in those elderly patients deemed fit enough to receive it. However this survival
benefit came at the cost of a modest increase in toxicity, as reflected by an increase in hospital
admissions.
Chapter 7 addresses the main findings of each study, placing the coalesced results in the
context of the overall thesis and wider literature, and completes the thesis with a discussion of
future directions for research.
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1.1 Gastrointestinal cancers
Gastrointestinal cancers are a leading cause of cancer related death. They arise in the
gastrointestinal tract and accessory digestive organs of digestion, including the oesophagus,
stomach, biliary system, pancreas, small intestine, large intestine, rectum and anus.
Gastrointestinal cancers are classified and treated according to anatomical site of origin. This
thesis focuses on gastric, oesophageal and colon cancer.

1.1.1

Gastric and oesophageal cancer

Gastroesophageal cancers are the most common gastrointestinal malignancy worldwide.
Gastric adenocarcinoma is the fifth most common type of cancer and the third leading cause of
cancer-related death worldwide, and oesophageal cancer is the eighth most common cancer
worldwide 1,2. Gastric and oesophageal cancers differ in incidence, geographic distribution, and
aetiology. Most gastric cancers are adenocarcinomas, although are highly heterogeneous in
molecular pathogenesis. Gastrointestinal stromal tumours (GIST), lymphomas, and
neuroendocrine tumours are found in a small minority of cases 3. There are several key risk
factors for gastric cancer. A small proportion of gastric cancers are due to heritable causes such
as E-cadherin gene (CDH1) mutations (leading to hereditary diffuse gastric cancer) and DNA
repair enzyme deficiency in Lynch Syndrome 4. The primary risk factor for most sporadic distal
gastric cancers is chronic inflammation caused by Helicobacter pylori infection 5-7.
The histology of oesophageal cancer varies by location; most upper and middle third
oesophageal cancers are squamous cell carcinomas (SCC), while the majority of lower
oesophageal and gastroesophageal junction (GEJ) tumours are adenocarincomas. Cigarette
smoking, alcohol consumption, and diets low in vegetables and fruits are the predominate
causes of oesophageal SCC 8. The aetiology and incidence of gastroesophageal cancers in
Western countries is changing, with upper oesophageal SCC and distal gastric cancer becoming
more uncommon, while incidence of adenocarcinomas of gastric cardia and gastroesophageal
junction are rapidly rising 9,10. This is thought to be due to lifestyle changes with increasing
obesity and gastroesophageal reflux disease 8.
The Cancer Genome Atlas has described 4 major gastroesophageal adenocarcinoma subtypes
(Figure 1). Of note, oesophageal SCC (ESCC) is a distinct disease entity and is not discussed
further in this thesis. 1) EBV tumours which are positive for the Epstein Barr virus (EBV).
These tumours display recurrent PIK3CA mutations, extreme DNA hypermethylation, JAK2
amplification, and overexpression of PD-L1 and PD-L2. 2) Microsatellite unstable tumours
(MSI) with high mutation rates including in key targetable oncogenic pathways. 3) Genomically
stable (GS) tumours with mutations of RHOA or fusions involving RHO-family GTPaseactivating proteins. 4) Tumours with chromosomal instability (CIN), with TP53 mutation, RTK2

RAS activation and marked aneuploidy 11. Analysis of oesophageal adenocarcinomas show
marked similarity with the CIN subtype of the gastric cancers, suggesting these tumours can be
considered a single disease entity 12.

Figure 1: Gradation of molecular subclass of gastroesophageal carcinoma.
Schematic representing shifting proportion of subtypes of gastroesophageal carcinoma from the
proximal oesophagus to the distal stomach. The widths of the colour bands represent the
proportion of the subtypes present within anatomic regions. Taken from The Cancer Genome
Atlas 12 .
Similarly, despite differences in epidemiology, currently employed systemic treatments have not
shown significant differences in efficacy or toxicity between distal oesophageal,
gastroesophageal and gastric adenocarcinoma. Consequently these malignancies are treated in a
similar fashion in the advanced setting, with most clinical trials including patients with distal
oesophageal, GEJ, and gastric adenocarcinomas 13.
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1.1.2

Colorectal cancer

Colorectal cancer (CRC) is one of the most common cancers worldwide and projected to
account for 13% of all new cancer cases diagnosed in Australia in 201514. While CRC remains
the fourth most common cause of cancer death worldwide, mortality is improving in Western
countries due to the institution of cancer screening programs with the subsequent detection and
removal of adenomas and early cancerous lesions15.
CRC is a disease related to aging, with almost 40% of CRC diagnosed above the age of 75 years
in Australia, and occurring only rarely in patients younger than 4016. Apart from age, there are
two broad categories of risk factors for developing colon cancer, genetic determinants and
lifestyle factors. A minority of colon cancers (5-10%) are due to inherited syndromes such as
Familial Adenomatous Polyposis (FAP) or Lynch associated syndromes17. In addition, patients
with a personal history of adenoma, colon cancer or inflammatory bowel disease, as well as a
significant family history of CRC, are considered at high risk of colon cancer and recommended
to undergo screening18. There are a large number of lifestyle factors which are associated with a
small increased risk in CRC including obesity, diabetes mellitus, red and processed meat,
smoking and alcohol intake18.
The molecular pathogenesis of CRC is a well characterised multistep process of inherited or
acquired genetic mutations driving the progression of normal colon epithelium to invasive
cancer via the intermediate precursor lesion, the adenomatous polyp19. Three key pathways have
been identified in CRC tumorigenesis. The chromosomal instability pathway (CIN) is
characterised by gross chromosomal abnormalities, from reduced activity of tumour suppressor
genes or activation of growth promoting pathways, due to inherited (typified by FAP) or
sporadic mutations20,21. In the DNA mismatch repair (MMR) pathway, seen in both Lynch
syndrome and sporadic CRCs, cells with aberrant DNA repair pathways, due to germline
mutations or epigenetic hypermethylation of the MMR gene promotor, accumulate widespread
DNA errors throughout the genome, presenting phenotypically with high levels of microsatellite
instability22. The hypermethylation phenotype (CIMP positive) is a distinct subtype of CRC,
characterised by CpG island hypermethylation and serrated adenoma precursors, associated with
microsatellite instability, BRAF mutations, and poor clinical outcomes 23.
While there are a number of important prognostic factors identified in CRC, tumour stage at
diagnosis remains the most important prognostic variable. While stage I colon cancer is cured
with surgical resection alone, stage II and III colon cancer is usually treated with curative intent
using a combination of surgery and adjuvant chemotherapy 18. Although Stage IV disease was
4

traditionally treated as palliative, aggressive local treatment of metastatic disease, combined
with chemotherapy and biological treatments (including VEGF and EGFR targeted agents) have
markedly improved patient outcomes 24.

1.2 Biomarkers in gastroesophageal adenocarcinoma
Tumour, node and metastasis (TNM) stage is the most important prognostic factor in
gastroesophageal cancers 25. Multimodality approaches which include chemotherapy,
radiotherapy, and surgical resection offer potential cure in localised disease 26. However the
majority of patients with gastroesophageal cancer present with locally advanced or metastatic
disease 27. Despite improvements in systemic treatments, and numerous active systemic agents,
prognosis remains poor with median overall survival of less than 12 months 28.
There is a paucity of biomarkers in gastroesophageal cancer to guide systemic treatment.
Molecular classification using the HER2 status is the sole routine tissue biomarker currently
used in gastroesophageal cancers. HER2 amplification or overexpression is seen in 22% of
patients with advanced disease29. There is contrasting evidence regarding the prognostic
importance of HER2 status, with some but not all studies reporting worse prognosis 30-32. The
TOGA trial demonstrated improved overall survival and progression free survival with the
addition of trastuzumab, a monoclonal antibody against HER2, in combination with
chemotherapy in HER2 positive locally advanced or metastatic gastroesophageal cancers,
leading to routine incorporation of HER2 testing in all advanced gastroesophageal cancers 33.
There is an increasing focus on the use of gene signatures as biomarkers to predict response to
chemotherapy34. While retrospective data is encouraging, prospective studies to validate these
findings are required prior to clinical use.
Similarly, there are very limited circulating biomarkers currently in clinical use. While
monitoring of blood levels of carcinoembryonic antigen (CEA) and Cancer Antigen 19.9
(Ca19.9) is routinely preformed in clinical practice to monitor disease response, these serum
markers are limited by poor sensitivity and specificity, and may not always reliably reflect
responses to treatment 35.
There are several key biomarkers identified from the literature that show promise as potential
clinically relevant biomarkers in gastroesophageal cancer. These include cancer stems cells
(CSC), the plasminogen activation system (PAS) and circulating tumour cells (CTCs) and are
discussed below.

5

1.2.1
1.2.1.1

Cancer Stem cells in Gastroesophageal cancer
Cancer Stem Cells (CSC)

A key oncological issue is whether cancer growth is driven by the majority of tumour cells, or
by a rare subpopulation of CSCs. There are several proposed models. The clonal evolution
model states that each cell within a tumour has equal potential to acquire genetic/epigenetic
changes which confer growth advantages and subsequent new tumour growth36. The CSC model
on the other hand proposes that the growth of a tumour is driven by a small population of selfsustaining cells with the stem-cell properties of longevity, infinite proliferation, and ability to
differentiate into the entire heterogeneous population of the tumour 37. Integral to the CSC
model is a subpopulation at the apex of the hierarchy (usually comprising less than 5% of the
cancer) responsible for the formation, maintenance and continued growth of the tumour 38. Stem
cells can symmetrically divide into self- renewing identical daughter stem cells with selfrenewal capacity, or asymmetrically divide to both a differentiated progenitor cell and a stem
cell 39 .
Recent refinements to the CSC theory propose a more dynamic model, with a fluid CSC
population regulated by the tumour-cell environment, rather than a rigid hierarchical structure
37,40

. It is now apparent that a CSC phenotype can be induced in differentiated cancer cells by

exposure to growth factors secreted from stromal cells, suggesting a bidirectional pathway
between the CSC and differentiated cell populations 41,42. Furthermore, some types of leukaemic
stem cells have been shown to be subjected to clonal evolution 43. The reacquisition of selfrenewal properties in non-CSC populations, in addition to genotypic and phenotypic
heterogeneity within CSCs, highlight that the CSC population is fluid in both numbers and
character (Figure 2).
Cancer stem cells are defined functionally rather than from cellular origin, with CSCs having
superior tumour initiating, growth, and metastatic potential than other tumour cells 44. In vitro
studies with cultured gastric CSCs indicate these cells to be more resistant to chemotherapy and
radiotherapy 45,46, possibly due to high expression of anti-apoptotic proteins, increased
efficiency of DNA repair, and alterations in cell cycle kinetics 37,39 . CSCs are responsible for
the renewal of tumour mass following systemic treatment, and the development of treatment
resistant subclones 39. The CSC’s long proliferative lifespan and repeated DNA replication
events renders them more susceptible to further mutations and epigenetic changes creating
further malignant clones 47.
The first definitive evidence of a CSC population was provided by Bonnet et al (1997), who
6

demonstrated that a cell population defined by the CD34+/38- phenotype was able to serially
reproduce acute myeloid leukaemia in immunodeficient mice 48. Crucially this cell population
did not only self-renew, but could reconstitute the full spectrum of cell populations seen in
AML. This approach has been used to isolate CSCs in solid malignancies including breast
cancer 49, prostate cancer 50, pancreatic cancer 51,52, melanoma 53, colon cancer 54,55, brain
cancer 56,57, and liver cancer 58, supporting the model of cancer growth initiated and maintained
by CSCs. The presence of CSCs in solid malignancy has been confirmed with lineage tracing
studies which identified a subpopulation of cells which reconstitute the entire tumour following
chemotherapy 59.
Experimental evidence for CSCs must demonstrate both self-renewal and ability to differentiate
into the heterogeneous cell population that constitute a tumour 60. Serial transplantation in
animal models fulfils these criteria and is proposed as the best functional assay to identify CSCs
60

. An alternative experimental model is in vitro spheroid colony formation of candidate CSCs

in culture media, as continued growth of colonies indicates self-renewal 61. Although serial
passage in animal models is considered the gold standard, the two methods seem to provide
similar results when identifying candidate CSCs 61.
The CSC model has important clinical implications, as it infers that anti-neoplastic treatments
should focus on eliminating both a small population of CSCs within the tumour, as well as the
rapidly dividing but terminally differentiated bulk of cancer 60. Figure 2 illustrates the various
models schematically.

7

Figure 2: Three models of tumour growth and their clinical implications (a) The clonal
model, where each cell has the potential to acquire additional mutations which confer a growth
advantage. Chemotherapy selects a treatment resistant subclone which subsequently
reconstitutes the tumour mass. (b) The hierarchic cancer stem cell (CSC) model, whereby a
small population of self-renewing CSCs are responsible for all tumour growth, giving rise to
progenitor cells, which subsequently de-differentiate into the bulk of the tumour which has lost
capacity to self renewal. The chemo-resistant CSC population is enriched by chemotherapy, and
is able to restore the tumour bulk. (c) The dynamic CSC model is a more refined CSC model,
demonstrating the bi-directional flow of cells between the stem cell and differentiated
compartments. This model highlights the need to combine a CSC targeted agent with
chemotherapy. The CSC targeted agent eliminates the chemo-resistant CSC population
preventing the reconstitution of the tumour bulk, while the chemotherapy reduces the tumour
bulk of differentiated cells, stopping these cells de-differentiating to replenish the CSC
population.

8

1.2.1.2

CSC and metastases

The CSCs unique properties of self-renewal and multi lineage differentiation suggest a likely
role in the initiation and progression of distant metastatic disease. Although there is no direct
experimental evidence of CSCs as the origin of metastases many studies provide supporting
data 62. The presence of unique tumour subpopulations with CSC markers have been shown to
be integral for the development of metastatic disease in a variety of malignancies including
pancreatic 51, colorectal 63, and breast 64 cancer, as depletion of this population prevented the
metastatic spread of the tumour 51. Dieter et al demonstrated differential contributions of
individual CSC clones to the growth of primary and metastatic tumours, and identified a
subpopulation of CSCs in colon cancer solely responsible for metastases formation 65. In
addition, immunohistochemical studies in gastric cancer have shown an increased risk of
metastatic disease associated with CSC marker expression in the primary tumour 66,67.
A proposed mechanism underlying the progression of cancer to metastases is the epithelialmesenchymal transition (EMT) 68. EMT is the process whereby tumour cells lose epithelial
characteristics and acquire a mesenchymal phenotype to facilitate cancer metastasis and
survival. It becomes more and more evident that EMT and CSC phenotypes are largely
overlapping and provide properties of invasion, tumour seeding, drug resistance, and survival. It
is thought that CSCs in primary tumours can metastasise to distant sites via EMT 69.
Furthermore a CSC phenotype can be obtained by inducing an EMT state 70,71. Tumour cells
disseminated in the blood (circulating tumour cells) are enriched for both an EMT and CSC
phenotype 72. Gastric cancer patients who have detectable circulating tumour cells (CTCs)
which express CSC markers have a poorer prognosis than those with CTCs without CSC
markers 73. This is reinforced by clinical evidence of an association between EMT and CSCs,
with immunohistochemical expression of CD44, a gastric CSC marker, significantly correlated
with expression of EMT markers such as Snail-1 and ZEB1 in resected gastric cancer 74. Gastric
CSCs isolated from a cell line showed increased expression of EMT markers (including Snail,
Twist, and vimentin) and CD44 75. Moreover, analysis of combined expression of CD44 with
EMT markers was predictive of a poorer disease free survival and overall survival (OS) in a
multivariate model, consistent with the aggressive phenotype of cells expressing CSC and EMT
markers 74.
1.2.1.3

Identification of Cancer Stem Cells

A key issue in the study of CSCs is development of reproducible and reliable methods for CSC
isolation and identification. The American Association for Cancer Research (AACR) defines
CSCs as subpopulations of cells within a tumour that possess the capacity for self-renewal and
cause the heterogeneous lineage of cancer cells that constitute the tumour 60. As discussed
above, the experimental methods used to confirm a population of cells as CSCs are serial
9

passage of tumours in animal models, or tumour-spheroid assays. Animal model serial
transplantation is regarded as the gold standard as it is considered a physiologically relevant
functional assay to demonstrate self-renewal and lineage capacity 60. However some groups
have questioned this paradigm as the rarity of CSCs found in human cancers may be due to an
inadequate local environment in the xenograft 76,77. Tumour spheroid assays are a more rapid
method (as serial transplantation can take several months), and have been shown to increase
expression of stem cell markers, but have potential pitfalls as not all isolated CSCs form
spheroids 46,78.
There are many challenges in identifying a CSC population within a tumour. Firstly, as
discussed above, the CSC population is dynamic with bidirectional flow between the CSC and
differentiated cell populations. Secondly, the currently utilised CSC markers are not specific,
and are expressed on non-malignant cells, as well as early progenitor cells which have lost stem
cell features but retained phenotypic markers. Thirdly, multiple populations of CSCs may exist
within a tumour mass, and combinations of multiple markers may be required to identify the
complete CSC population.
Candidate CSCs are currently identified predominantly by two methods: the side population
assay or expression of CSC surface markers.
1.2.1.3.1

Side Population Assay

The side population (SP) assay identifies the fraction of cells that efflux Hoechst dye by ATP
binding cassette (ABC). It is a highly preserved marker of stem cells across a variety of tissues
and tumours, with a higher capacity for self-renewal, leading some authors to suggest that the
SP subset may represent a universal CSC population 79. However the SP assay is hampered by
poor specificity, with differentiated adults cells in the gastrointestinal tract demonstrating a SP
phenotype 80.
There are inconsistent results regarding SP assays as a potential CSC marker in gastric cancer.
Zhange et al showed CSC properties in SP cells from the MKN-45 cell line, but not from the
BGC-823 cell line 81 . Although some studies in gastric cancer lines have shown CSC properties
in the SP 82,83, others have found no difference compared to a non-SP subset 45,84,85. Overall the
utility of the SP assay to identify gastric CSC remains controversial.
1.2.1.3.2

Expression of Cell Surface Markers

An integral tool in the identification and isolation of candidate CSCs is the expression of unique
combinations of cell surface markers. This approach has allowed isolation of CSCs in many
solid malignancies by flow cytometry or magnetic cell sorting. Currently identified CSC
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markers are expressed in an overlapping manner on a variety of tumours, as well as normal stem
cells. A summary of the most common markers described for solid tumours is provided in
Table 1. Many of these potential markers are found in gastric cancer.
Table 1: Cell Surface Expression of Cancer Stem Cell Markers in Different Solid Tumour
types.
Tumour

Described Cell Markers

Reference

Colon

CD133, CD44, CD166. EpCam, CD24,

Botchkina 2013 86

ALDH1
Pancreas

CD133, CD44/CD24, ALHD1

Zhan et al 2015 87

Breast

CD44+/CD24-, ALDH1

Carrasco et al 2014 88

Brain

CD133, CD44

Jackson et al 2015 89

Lung

CD133

Lundin et al 2013 90

Melanoma

CD20, CD133, CD271

Lang et al 2013 91

Prostate

CD44+/CD24-, CD133, ALDH,

Sharpe et al 2013 92

1.2.1.4
1.2.1.4.1

Gastric Cancer Stem Cells
Origin of gastric cancer stem cells

The origin of gastric CSCs remains uncertain. A possible source of gastric CSCs is gastric stem
cells which have lost regulated quiescence. The existence of multipotent gastric stem cells
which give rise to all major epithelial cell types has been demonstrated in mouse models 93.
There are multiple populations of gastric stem cells. The Lgr5+ cells arise at the base of the
gastric gland and continuously differentiate into all antral unit cells, while the Villin+ cells are
located at the isthmus and are a quiescent stem cell population which require cytokine
stimulation to activate, acting as a stem cell source if the Lgr5+ cells are damaged 94-96. Sox2+
cells, present in the antrum and corpus, are able to differentiate into all cell types found in a
gastric unit, and ablation of the Sox2+ population prevents renewal of gastric epithelium 97.
Further populations of differentiated gastric cells, such as chief cells expressing the marker
Troy, have been shown to de-differentiate and function as multipotent stem cells, acting as
reserve stem cell populations 98.
Aberrant genetic and epigenetic mutations in these gastric stem cells, in conjunction with
stimulating factors from the microenvironment, may lead to the formation of CSCs 47. For
example, APC deletion in Lgr5+ stem cells led to rapid development of adenomas in a mouse
model due to expansion of the stem cell compartment 95. Wu et al demonstrated co-localisation
of CSC markers (CD26, CD44, ALDH1, CD133) with Lgr5+ cells in gastric cancer suggesting
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they may be functionally related 94. Similarly Sox2 expression is altered during gastric cancer
pathogenesis 99,100, although reports are contradictory as to whether Sox2 is overexpressed and
oncogenic 101,102, or downregulated and anti-oncogenic, with lower Sox2 levels associated with
poorer clinical outcomes 99,103. Another proposed gastrointestinal stem cell marker,
doublecortin-like kinase (Dclk1), is highly expressed on cells in the stem cell zone of mouse
gastric glands 104. K-ras induced chronic inflammation in K19-K-ras-V12 transgenic mice led to
expansion of the Dclk1+ cell population during the development of high grade dysplasia 105.
An alternative hypothesis suggests that gastric CSCs arise from bone marrow derived
mesenchymal stem cells, pluripotent adult stem cells which are recruited to peripheral organs in
response to chronic inflammation. Their function is to assist in regeneration after failure of local
stem cells 106. Bone marrow derived cells (BMDC) have been shown to repopulate gastric
mucosa in response to chronic inflammation due to H. Pylori infection, and may contribute to
carcinogenesis 107,108. In a mouse model infected with H. pylori, almost a quarter of high grade
dysplastic gastric lesions included BMDC 109. The BMDC are proposed to differentiate in the
gastric mucosa by cell-cell fusion with local gastric epithelial cells, and in the context of further
chronic inflammation, induce EMT and the emergence of CSCs 106,110. It is important to note
however, despite these provocative findings, the majority of dysplastic lesions do not arise from
BMDC. Further studies are required to fully explore the pathogenesis of gastric CSCs.
1.2.1.4.2

Gastroesophgeal CSC markers:

1.2.1.4.2.1 CD44 and CD44 variants
CD44 is a transmembrane glycoprotein expressed on leukocytes, endothelial cells, hepatocytes,
and mesenchymal cells, and has a variety of physiological roles including matrix adhesion, cell
migration, and differentiation 111. CD44 is encoded by the 20 exon CD44 gene, with exon 1-5
encoding the constant region of the extracellular domain, and exon 16-20 spliced together to
form the standard isoform 112. The variant exons 6-15 are subject to alternative splicing and can
be assembled in different combinations with the standard exon to make variant isoforms 112.
CD44 variants (designated as CD44v) have been proposed as a more specific CSC marker than
CD44 due to their more restricted distribution pattern. Generally, expression of CD44v on
gastric cancers cells is well correlated with CD44 expression 66,112.
CD44 has been proposed to mediate signal transduction of oncogenic pathways such as the
human epidermal growth factor receptor (HER) pathway 113. Cancer cells with high CD44
expression have an enhanced resistance to reactive oxygen species due to increased glutathione
synthesis and upregulation of anti-oxidant genes 114. The first evidence of gastric CSCs was
demonstrated with the self-renewal and heterogeneous linage of a CD44+ subpopulation 45.
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There are now numerous studies which support CD44 as a marker for CSC in gastric cancer
(Table 2). Although most studies support CD44 as a CSC marker, two studies were unable to
demonstrate stem-cell properties in the CD44+ purified subset of patient derived gastric cancer
cells, perhaps due to inappropriate microenvironment in mouse models 115,116. CSC populations
have also been identified using a combination of CD44+ and other markers including EpCam
112,117

, CD54+ 118, and CD24 119.

Despite this, CD44 is not a specific or sensitive marker for gastric CSC. The true CSC
population has been estimated at <5% of CD44+ cells 45, and CD44 is widely expressed on nonmalignant tissue. Other markers are required in addition to CD44 to improve the specificity of
CSC identification.
There is only limited evidence of CD44v as a CSC marker. Lau et al showed CD44v8-10 was
the predominate CD44v expressed on CD44+ gastric cancer cells (79% of CD44+ cells), and
demonstrated self-renewal and heterogeneous linage in serial transplants of CD44v8-10 in
mouse models 112. Although the CD44v8-10+ fraction was more tumourigenic in mouse
models, both the CD44v8-10+ and CD44v8-10- cells were able to form tumour spheres 112.
While CD44v appears to be a more specific marker for gastric cancer than CD44, more research
needs to be performed to elucidate their biological role and confirm CSC characteristics.
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Table 2: Summary of cancer stem cell markers in gastric cancer (in vitro and mouse model
studies).
Stem Cell Characteristic

Marker

References

CD44+

Takaishi et al 2009 45,

(serial transplantation in mouse

CD44v8-10

Lau et al 2014 112

models, or maintained in serial?

CD133+

Nil study identified

spheroid culture for weeks)

ALDH1

Katsuno et al 2012 120, Nishikawa et al 2013 121

Multi lineage differentiation

CD44+

Takaishi et al 2009 45,

CD44v8-10

Lau et al 2014 112

CD133+

Fukamachi et al 2011 122

ALDH1

Katsuno et al 2012 120

CD44+

Takaishi et al 2009 45, Zhang 2011 119, Yoon et

Self –Renewal

Increased resistance to

al 2014 123,

chemotherapy/radiotherapy
CD133+

Zhu et al 2014 124

ALDH1

Zhi et al 2011 125, Nishikawa et al 2013 121

Increased tumourigenicity

CD44+

Takaishi et al 2009 45, Song et al 2011 119,

(faster growing tumours, or smaller

CD133+

Nil study identified

tumour seeding volume)

ALDH1

Zhi et al 2011 125, Katsuno et al 2012 120,
Nishikawa et al 2013 121,

Attenuation of stem cell

CD44+

Takaishi et al 2009 45

characteristics with knock-down

CD133+

Zhu et al 2014 124

model

ALDH1

Nil Study identified

Upregulated stem cell or

CD44+

Yu et al 2014 126

mesenchymal markers

CD133+

Song et al 2011 127

ALDH1

Zhi et al 2011 125, Nishikawa et al 2013 121,

1.2.1.4.2.2 CD133
CD133 is a transmembrane glycoprotein plasma membrane protein found on embryonic
epithelial structures and hematopoietic stem cells 128. It is proposed to function as an organiser
of plasma membrane topology, and have a role maintaining appropriate lipid composition of
plasma membrane 129. CD133 has been identified as a CSC marker in a variety of solid tumours
(Table 1).
Most studies have identified CSCs using AC133, an antibody which detects a glycosylated
epitope of CD133 130. Some authors have recommended caution using CD133 as a marker to
identify CSC after they showed downregulation of CD133 epitopes (including the target of
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AC133) during differentiation. However constant CD133 protein expression suggests
differentiated cells may express CD133, but with masked epitopes due to differential
glycosylation 131. Post translational modification of CD133 may have roles in invasion and
metastasis, and influence antibody binding by altering the epitope’s accessibility 130.
Consequently there is debate regarding the utility of CD133 as CSC marker in gastric cancer.
Although some studies have demonstrated CSC properties with the CD133+ subpopulation,
several groups have found contrasting results, with CD133- cells able to initiate tumours 45,112,115
(Table 2).
1.2.1.4.2.3 ALDH1
Aldehyde Dehydrogenase (ALDH) is a family of enzymes that have a role in cellular
detoxification, differentiation and drug resistance via oxidation of cellular aldehydes 132.
ALDH1 functions as a modulator of cell proliferation and stem cell differentiation, and is a
marker of CSCs in a variety of cancers (Table 1). High activity of ALDH1 confers resistance to
chemotherapeutic agents 133. ALDHhigh cell populations are identified with the Aldeflour assay
or by ALDH1 antibody, and have been shown to correlate with CD44 expression 121.
Katsuno et al 120 demonstrated CSC properties of ALDH1+ cells isolated from gastric cancer
cell lines including self-renewal, heterogeneous linage and increased tumourogenicity.
Interestingly, in contrast to other cancers, they found TGF-β inhibited the function of the CSC
population120. Studies demonstrating the CSC properties of ALDH1 in gastric cancer are
summarised in Table 2.
1.2.1.4.2.4 Other potential CSC markers
Numerous other molecules have been identified as potential gastric CSC markers and these are
addressed below. However, it must be borne in mind that the evidence for these molecules as
markers is either limited or contradictory. Further studies are thus required to either confirm or
refute their utility as markers of the CSC population.
CD24 is a cell surface adhesion molecule expressed on leukocytes, normal gastric parietal cells,
and intestinal stem cells 134. CD24 expression is associated with aggressive clinicopathological
features in gastric cancer, and facilitates cell migration and invasion of gastric cancer cells
134,135

. Evidence for CD24 as a CSC marker in gastric cancer is conflicting. Zang et al found that

the CD44+/CD24+ fraction isolated a CSC population in gastric cancer cell lines 119, while
Takaishi et al was unable to find evidence of CSC characteristics in a CD24+ population in
spheroid and mouse models 45.
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The epithelial cellular adhesion molecule (EpCam) is a transmembrane glycoprotein detected in
the majority of epithelial tissues, with roles in cell adhesion, signalling, migration, proliferation
and differentiation 136. EpCam is overexpressed in gastric cancer and gastric cancer cell lines
121,137

. Several studies have shown that gastric CSCs lie within the EpCam+ population, with the

EpCam- population unable to form tumours in mouse models or tumourspheres 112,117. However,
additional more specific markers are required in addition to EpCam as the majority of gastric
cancer cells are EpCam positive.
CD49f is a subunit of laminin receptors which has been used to isolate CSCs in prostate, breast,
brain and colon cancers 116. Fukamachi et al demonstrated CSC properties of self-renewal,
heterogeneous linage, and chemotherapy resistance to the CD49f selected cells from primary
gastric cancer mouse xenografts 116. Further studies are needed to confirm CD49f stem cell
properties.
CD54 (also known as intercellular adhesion molecule-1; ICAM-1) is an adhesion molecule
essential for arrest and transmigration of leukocytes out of blood vessels, and is widely
expressed on immune, stromal and malignant cells138. Decreased CD54 expression on resected
gastric cancer is associated with poorer prognosis and increased risk of lymphatic spread 139.
CD44+/54+ cells that were isolated from primary gastric cancers and peripheral blood samples,
demonstrated superior tumourigenicity, multiple linage capability and self-renewal, compared to
CD44- or CD54- cells, suggestive of a CSC population in both the primary tumour and in the
circulation 118.
CD90 is expressed in bone marrow derived mesenchymal stem cells, haematopoietic stem cells,
keratinocytic stem cells, and has been used to identify CSC populations in liver, breast and brain
cancer 140. CD90+ cells isolated from patient derived gastric cancer xenografts demonstrated
self-renewal and a heterogeneous linage 140. CSCs obtained by preconditioning a gastric cancer
cell line with chemotherapy displayed increased expression of CD90 as well as bonafide CSC
markers 75.
CD71 (also known as the transferrin receptor) is a membrane protein highly expressed on
myocytes, keratinocytes, hepatocytes, pancreatic cells, and erythroid precursors, with a
physiological role in mediating the uptake of transferrin-iron complexes. CD71 has been
proposed as a negative selection marker, with the CD71 negative subpopulation of a gastric
cancer cell line displaying chemoresistance, self-renewal, heterogeneous linage, and increased
tumourigenicity in mouse models 141.
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Finally, several transcription factors, including Sox2, Oct4, and Nanog are expressed on gastric
stem cells, and have been proposed as potential CSC markers. Gastric CSCs enriched by the
side population assay or spheroid formation have a higher expression of Sox2, Oct4 and Nanog
compared with parental cells 46. As discussed above however, studies evaluating the association
between clinicopathological variables with immunohistochemical expression of Sox2 in
resected gastric cancer have shown conflicting results 99,100,103,142. Similarly, although some
studies have shown poorer prognosis with Oct4 expression in resected gastric cancer 143,144,
another large patient series found the opposite result 101.

1.2.1.5
1.2.1.5.1

Clinical Implications of Gastric Cancer Stem Cells
Gastric CSC marker expression and patient prognosis

CSC marker expression in cancer tissue is emerging as a clinically relevant prognostic
biomarker in the management of gastric cancer. Most studies have shown a correlation between
advanced pathological features, such as tumour size, invasion and metastatic spread, and
expression of CSC markers. In addition, CD44 and CD133 expression was found to be an
independent predictor of poorer disease free survival (in resected gastric cancer) and overall
survival (see Table 3). These findings support the preclinical evidence of CD44 and CD133 as
CSC markers, as patients with tumours expressing these markers would be expected to have a
poorer prognosis due to the CSC traits of chemoradioresistance, increased tumourigenicity and
metastatic potential.
CD44 is expressed on up to 80% of primary gastric cancer resection specimens145 and is
associated with more advanced clinicopathological features and poorer prognosis (Table 3). A
meta-analysis which included 18 studies examining CD44 expression in gastric cancer, although
limited by significant methodological flaws, including no qualitative analysis of included
studies, and considerable heterogeneity in pooled result, found statistically significant
associations with advanced tumour stage (pooled odds ratio (OR) = 2.05, 95% confidence
interval (CI): 1.12-3.75, P = 0.02), tumor size (pooled OR = 1.42, 95% CI: 1.08-1.87, P = 0.01),
and lymph node (LN) metastasis (pooled OR = 1.50, 95% CI: 1.14-1.98, P = 0.004) 146.
Although four studies have shown CD44+ expression to be an independent predictor of survival,
it is important to note that the two largest case series did not show an impact of CD44
expression on overall survival 147,148. The heterogeneity in results is likely due to variation in
experimental procedures and patient populations.
Despite the contradictory pre-clinical data, CD133 role as a CSC marker is supported by
numerous immunohistochemical studies in resected primary gastric cancer which show a
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consistent association with numerous high risk clinicopathological features, and independent
correlation with poorer disease free and overall survival (Table 3). A recent meta-analysis found
strong evidence that CD133 expression in resected gastric cancer was associated with poorer 5
year overall survival (OR= 0.2, 95% CI 0.14-0.29, p<0.00001), although it should be noted that
all included studies were conducted in Asian populations, limiting the applicability to Western
patients 149. Furthermore, a recent study which detected circulating CSCs using CD133 and
ABCG2 as markers, found that the presence of peripheral blood CD133+ cells correlated with a
poorer prognosis, and isolated CD133+/ABCG2+ cells were able to be passaged in mouse
models and showed self-renewal, heterogeneous linage and increased tumourigenicity 150.
CD44 variant expression appears to be more specific for malignant tissue. Expression of CD44
variants, including v5, v6 and v9, in resected gastric cancer is associated with adverse clinical
outcomes including worse overall survival, more advanced tumours and lymphovascular
invasion. A meta-analysis found CD44v6 expression was related with LN metastasis (pooled
OR = 2.26, 95% CI: 1.40-3.64, P = 0.0008), lymphatic invasion (pooled OR = 1.45, 95% CI:
1.05-2.01, P = 0.02) , and venous invasion (pooled OR = 1.62, 95% CI: 1.20-2.18, P = 0.001) ,
but not tumour stage (pooled OR = 0.68, 95% CI: 0.36-1.28, P = 0.23) 146.
ALDH1 expression has been shown to be associated with poor prognostic clinicopathological
features in resected primary gastric cancer, although it is not significantly associated with poorer
survival 132.
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Table 3: Statistically significant clinicopathological and prognostic associations with CD44
and CD133 immunohistochemical expression in gastric cancer.
Association
Intestinal histology

CD44 References
Mayer et al 1993

66

CD133 References
Wakamatsu et al 2011 132

Hong et al 1995 151

Lee et al 2012 154

Ghaffarzadehgan et al 2008 152

Nosrati et al 2014 153

Nosrati et al 2014 153
Higher TNM stage

Wakamatsu et al 2012 132

Yu et al 2010 155

Chen et al 2013 67

Zhao et al 2010 156
Hashimoto et al 2014 157
Chen et al 2013 67

Larger tumour size / Deeper

Nosrati et al 2014 153

Yu et al 2010 155
Zhao et al 2010 156

invasion

Lee et al 2012 154
Chen et al 2013 67
Lymphovascular invasion

Nosrati et al 2014 153

Lee et al 2012 154

Higher grade / Poorer

Wang et al 2011 145

Zhao et al 2010 156

differentiation

Chen et al 2013 67

Jiang et al 2012 158
Hashimoto et al 2014 157

Presence of distant metastasis
Positive lymph nodes

Mayer et al 1993 66

Chen et al 2013 67

Chen et al 2013 67

Hashimoto et al 2014 157

Wakamatsu et al 2012 132

Yu et al 2010 155
Zhao et al 2010 156
Wakamatsu et al 2011 132
Hashimoto et al 2014 157

Poorer disease free survival

Mayer et al 1993 66

Lee et al 2012 154
Hashimoto et al 2014 157

(multivariate)
Poorer overall survival

Mayer et al 1993 66

Yu et al 2010 155

(multivariate)

Ghaffarzadehgan et al 2008 152

Zhao et al 2010 156

Wakamatsu et al 2012 132

Wang et al 2011 145

Chen et al 2013 67

Lee et al 2012 154
Chen et al 2013 67
Hashimoto et al 2014 157
Wakamatsu et al 2011 132
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1.2.2

Targeting CSCs in gastric cancer

The CSC model has important clinical implications for cancer treatment. There is strong
evidence that CSCs are resistant to traditional chemotherapy and radiotherapy, and are enriched
in the residual tumour after these treatments 45,119,123,159. The CSCs subsequently renew the
tumour bulk with the development of treatment resistant clones. Consequently, a specific and
efficacious CSC targeted treatment is required for the complete elimination of a cancer. These
targeted treatments should be administered in conjunction with conventional
chemotherapy/radiotherapy to reduce the tumour bulk and minimise the risk of differentiated
cancer cells acquiring CSC-like properties 40.

1.2.2.1

Targeting cancer stem cell surface markers

One proposed method of CSC specific treatment is drugs targeted at CSC surface markers. As
discussed above, there are significant challenges with this approach due to the widespread
expression of these markers on non-malignant tissue, and the rarity of CSCs in the tumour.
Although there is promising data emerging from the preclinical setting targeting CD44, CD133,
EpCam and CD90 (discussed below), the largest hurdle will be demonstrating safety and
efficacy in vivo.
Methodologies targeting CD44 include anti-CD44 monoclonal antibodies 160, and anti-CD44
antibody or aptamer labelled liposomes 161,162. The CD44 ligand, hyaluronic acid, has also been
used to label nanocarriers and conjugates, with demonstrated efficacy in reducing CD44+ cells
in pancreatic 163 and gastric cancer 164,165. Although these studies are promising in demonstrating
reduction in CSC populations, the clinical utility of these agents may be limited by off-target
toxicities 166,167.
Similarly, CD133 has been successfully targeted in preclinical models by anti-CD133 antibodycytotoxic conjugates in breast 168, ovarian 169, hepatocellular and gastric cancer 170. Smith et al
developed a CD133-cytotoxic conjugate which inhibited growth of gastric cancer cell lines in
vitro 170.
The anti-EpCam antibody MT201 has shown tumour suppression in preclinical studies in
prostate and colon cancer, and has advanced to human trials 170,171. A phase I study has shown
reasonable tolerability in combination with chemotherapy in heavily pre-treated breast cancer,
with further studies evaluating efficacy underway 172.
It may also be possible to reduce the CSC population through indirect targeting. Jiang et al
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noted candidate CSC marker CD90 correlated with HER2 expression in gastric cancer 140.While
chemotherapy enriched the CD90+ population in primary cancer culture, a combination of
chemotherapy and anti-HER2 treatment (trastuzumab) significantly reduced the CD90+
population and prevented tumour growth 140. The mechanism of this result remains unclear, but
suggests an interesting hypothesis to explain why some breast cancer patients with normal
HER2 gene expression benefit from trastuzumab 173.

1.2.2.2

Targeting the cancer stem cell signalling pathways

Aberrations in important normal stem cell signalling pathways, such as Hedgehog (HH), Notch,
and Wnt, result in the formation of CSCs 47. These pathways have been shown to be important
potential targets for treating CSCs 174.
The Wnt/β-catenin pathway has a physiological role in balancing proliferation, differentiation,
and “stemness” of cells, with over-activation leading to tumourigenesis 175. It is an important
pathway in CSC regulation, and many of the cell surface markers discussed above, including
CD44, CD24, EpCam, are Wnt targets 176. Blockage of the Wnt pathways reduces the selfrenewal capacity of gastric cancer tumourspheres 177. Gastric cancer cells overexpressing Wnt-1
resulted in larger mouse xenograft tumours, with increased expression of CSC markers such as
CD44, compared to control cells 178. When salinomycin was used to suppress Wnt and β-catenin
expression, the tumours were smaller with reduced CSC populations 178. Another group
disrupted Wnt signalling in CD44+ selected gastric cancer cells using a Wnt-1 antagonist
(Dickkopf-1) delivered by adenovirus serotype 5, inhibiting cancer cell survival, colony
formation and invasion 179. These agents are awaiting clinical validation.
Aberrant activation of the HH pathway causes neoplastic transformation in a variety of tumours
including gastric cancer 180. HH signalling maintains the CSC phenotype, and in vitro targeting
of the HH pathway decreases the tumourigenicity and invasion capability of gastric cancer
spheroids 123, and reverses chemoresistance 127. Yoon et al 123 retrospectively performed
immunohistochemistry on gastric cancer samples from a negative randomised phase II trial
examining the addition of a HH inhibitor (vismodegib) to chemotherapy in gastric cancer, and
found that there was improved survival in patients expressing CSC markers (CD44). This
exciting finding is the first evidence of CSC expression as a predictive biomarker in gastric
cancer, and demonstrates the immediate clinical applicability of targeting CSC pathways as an
adjunct to chemotherapy.
Notch signalling is important in gastric epithelial stem cell homeostasis, and is implicated in
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gastric cancer tumourigenesis 181-183. Gamma-Secretase inhibitors which block the Notch
pathway reduce CSC markers and cancer growth 184. They are currently in early clinical trials,
but may be limited by toxicity due to their non-specific activity.

1.2.3

Urokinase Plasminogen activation (uPA) system and gastro-oesophageal
cancer

1.2.3.1

The uPA system and malignancy

A key process in the development and progression of cancer, including establishment of
metastatic disease, is the invasion of malignant cells into normal tissue. This complex process
relies on tumour-associated proteolysis, resulting in the breakdown of extracellular matrix
(ECM) and basement membranes barriers 185. The plasminogen activation system is critical for
tumour associated proteolysis 186,187. Two distinct serine protease plasminogen activators,
urokinase-type plasminogen activator (uPA) and tissue-type plasminogen activator (tPA)
activate the circulating zymogen plasminogen to the broad spectrum serine protease plasmin,
which has a well-defined role in fibrinolysis of clots 186,188. While tPA is primarily associated
with vascular fibrinolysis, uPA has a more defined role in tissue degradation as well as
extravascular fibrinolysis and is thus considered to be responsible for most of the activated
plasminogen associated with cancer invasion and metastasis 186,189,190.
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Figure 3: Schematic representation of the urokinase plasminogen activation (uPA) system.
The membrane bound urokinase receptor (uPAR) binds circulating inactive pro-uPA,
facilitating the activation of pro-uPA to uPA which subsequently converts cell surface colocalised plasminogen to plasmin that can directly degrade components of the extracellular
matrix (ECM) and activate pro-matrix metalloproteases (MMP) to further break down ECM.
Plasminogen activator inhibitors 1 or 2 (PAI-1, PAI-2) are efficient endogenous inhibitors of
uPA.
The uPA protein is secreted as a zymogen (pro-urokinase), and is activated after it binds with
very high affinity to its specific cell surface receptor, uPAR, through cleavage of the uPA
Lys158-Ile159 peptide bond by various proteases, including plasmin 186,191. Once activated, the
disulphide-bonded two-chain uPA catalyses the activation of plasmin from co-localised
plasminogen, which in turn directly degrades components of the ECM, and promotes further
degradation and tissue remodelling by activating pro-metalloproteinases (MMPs) and by
releasing, thus activating, latent growth factors from the ECM 185,190. MMP-2 is overexpressed
in uPA/uPAR positive gastric cancer, suggesting that the MMP and uPA system cooperate
during tumour invasion 192. uPA has reported uPAR independent roles, including mitogentic
effects 193, and proteolysis of plasmin to allow cellular migration 194. As uPAR increases the
plasminogen activator activity of uPA several hundred fold, the majority of the uPA effect was
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traditionally thought to be uPAR dependent 190. However, this paradigm has been challenged
following a recent study which demonstrated that the development of metastases was dependent
on uPA, but not uPAR, in a murine transgenic MMTV-PyMT breast cancer model 195.
The uPAR protein has a glycosyl phosphatidyl anchor attaching it to the plasma membrane
196,197

. Invasion of cancer cells into lymphvascular spaces is facilitated by the expression of

uPAR on the invasive front of a tumour 198,199. This may be by focussing uPA, hence plasmin
activity, at the cell surface and/or through complex direct and indirect interactions with a range
of binding partners (including vitronectin, integrins, growth factor receptors, and others) 200,201,
through which uPAR affects cellular migration, angiogenesis, regulating cAMP levels, and is
thus essential for the intravasation of blood vessels 196,202,203. uPAR expression may represent a
suitable marker for early detection of the onset of invasion for both gastrointestinal and breast
cancers, expressed only on invasive carcinomas but not premalignant states such as Barrett’s
oesophagus or carcinoma in situ 204,205.
uPAis efficiently inhibited by two subtypes of serpin (serine proteinase inhibitor) family
members, plasminogen activator inhibitor-1 (PAI-1/SerpinE1) and -2 (PAI-2 /SerpinB2) which
have disparate roles in cancer growth and metastasis. PAI-1 is considered to be the major
inhibitor of the uPA system, forming a covalent complex with active uPA bound to uPAR,
leading to the internalisation of the entire complex via the Low Density Lipoprotein related
protein-1 and other endocytosis receptors of the LDLR family 206 . Following lysosome
degradation of the complex, uPAR is recycled back to the cell surface 207. Although believed to
have a physiological role as an inhibitor of the uPA system, PAI-1 has a paradoxical
protumourigenic role, increasing tumour invasion and angiogenesis, and correlated with poor
prognosis 208. Cancer cell models suggest that a critical balance of both uPA and PAI-1 is
required for invasion 209.
The role of PAI-2 in cancer is less clear. Although both PAIs mediate uPA/uPAR endocytosis in
an LDLR dependant process, the uPA-PAI-2 complex interacts with these endocytosis receptors
with different binding kinetics to those of uPA:PAI-1 and without stimulating intracellular
signalling events over and above that of uPA binding to uPAR 210-212. PAI-2 expression is
increased in tumour compared to normal tissue, perhaps due to a host inflammatory response,
but high stromal expression is associated with prolonged (in contrast to the other components of
the uPA system) survival in breast cancer 191.
The uPA system is expressed on both cancer cells and the supporting stroma 188. In one of the
original in-situ hybridization studies in colon cancer, uPA and uPAR were found to be mainly
expressed on the stromal and tumour cells, respectively, at the invasive front of a tumour,
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facilitating proteolysis required for invasion 213. While immunohistochemical studies in gastric
cancer have shown stromal uPA/uPAR expression, higher expression is seen on tumour cells,
and it is postulated that this tumour cell specific uPA/uPAR explains the aggressive biology
exhibited by these cancers, and is more relevant for prognostic outcomes 214-216.
Expression of the uPA system has been shown to be an important prognostic marker in a variety
of cancers including breast cancer217-219, lung cancer 220, and colorectal cancer 221, with the
combination of uPA and PAI-1 expression recommended to be incorporated into routine clinical
care of node negative breast cancer by the American Society of Clinical Oncologists222,223.

1.2.3.2

The uPA system and gastroesophageal cancer

The prognostic role of expression of the uPA system in gastroesophageal cancer is not clear.
While numerous studies have been performed to investigate this association, the studies have
employed differing methodology and included different patient populations, leading to
contrasting results. Conclusions from a previous meta-analysis are limited by significant
methodological flaws and the pooled analysis of gastric and colon cancer 224.
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1.2.4

Circulating tumour cells

As cancers form and grow, tumours cells are shed from the tumour mass into the circulation,
where they can be detected in blood samples. Study of these circulating tumour cells (CTCs) is
a rapidly developing field in oncology research. There is an increasing recognition of the
limitations of using primary tumour features to guide systemic cancer treatment, due to tumour
heterogeneity and the frequent disparity observed between primary and metastatic sites 225.
Metastatic biopsies are rarely undertaken however, due to both inaccessibility of metastatic sites
and procedure morbidity. CTC sampling therefore provides a ‘real time’ view of the cancer
using only peripheral blood samples, avoiding the need of repeat invasive biopsies 226.

1.2.4.1

Techniques for isolating CTCs – technical challenges

As CTCs occur at very low concentrations in the peripheral blood (ranging 1-10 cells per 10 ml
of blood in most cancer patients) there are considerable technical challenges in developing
robust detection protocols226.
Most CTC detection protocols require two steps. Initially the peripheral blood is enriched for
CTCs using physical properties (such as ficoll density gradient) or expression of cell surface
markers, using either positive selection or negative depletion. For example, the CellSearch
system (Menarini-Silicon Biosystems, Huntington Valley, PA, USA)- the only current FDA
approved CTC system, uses positive immunomagnetic isolation of EpCAM (an epithelial cell
marker) positive cells using anti human EpCAM antibody conjugated magnetic beads 227. The
CellSearch system immunoprobes the cells enriched by EpCAM targeting for cytokeratins (a
second epithelial marker to improve specificity), DAPI (nuclear stain), and excludes CD45 (a
leukocyte marker) positive cells. As such, CTCs are defined as EpCAM/cytokeratin(CK)/DAPI
positive and CD45 negative cells isolated from a blood sample. CTCs enumerated using this
approach have been shown to be clinically relevant prognostic biomarkers in a range of cancers
including breast 228, bowel 229, and prostate cancer 230. Other strategies of CTC enrichment rely
on physical differences of tumour cells versus blood cells, mainly size (filter enrichment of cells
larger than most blood cells) or the plasticity of cells. Nevertheless, these methods still need
CTC identification by usually immunostaining to verify the nature of CTCs versus residual
blood cells. CTC isolation approaches have been thoroughly reviewed by Alix-Panabières et al
222

.

Each approach to CTC enrichment has potential advantages and drawbacks. Positive selection
using techniques such as immunomagnetic separation based on cell molecular expression (eg
with EpCAM in the CellSearch System) is quite specific, reproducible and fully validated in
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regards to correlation of detected CTC numbers to clinical parameters. It is limited by the fact
that CTCs have to express the isolation target (usually EpCAM) and the identification marker
(usually cytokeratin). Overall the technology has relatively low sensitivity, high costs, and
further analysis of the enriched CTCs is often dependent on further purification of single or
pooled CTCs. In contrast, density gradient (eg Ficoll, OncoQUick) and size based filtrations are
simple, cheaper, but also limited by CTC molecular phenotype establishment using
immunostaining (usually EpCAM and/or cytokeratin probing). The advantages of some
methods are that they allow for easier subsequent analysis of CTCs. However they are limited
by poor enrichment and low specificity/sensitivity 231.
Similarly each detection method of CTCs within the enriched specimen has different strengths.
A cytometric approach allows the user to assess to some degree cell morphology and other
characteristics for enumeration and molecular characterisation. However ideal CTC markers
have yet to be identified, and there is the potential for lower sensitivity. Nucleic acid based (RTqPCR) techniques are antibody independent, highly sensitive and allow for multimarker assays,
but are limited by high false positive rates and the user is unable to isolate or assess CTCs.
There is therefore a need to identify new CTC biomarkers in order to overcome limitations of
the current approach.

1.2.4.2

EpCAM based CTC capture and enumeration in gastroesophageal
adenocarcinoma:

Enumeration of CTCs has been confirmed as a clinically relevant prognostic marker in
gastroesophageal cancer. The strongest evidence is from studies with EpCAM based capture
using the CellSearch platform, the most commonly used approach (studies summarised in Table
4).
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Table 4: CTC studies using EpCAM based capture (CellSearch platform) in
gastroesophageal cancers including resectable gastric cancer (RGC), advanced gastric cancer
(AGC), resectable esophageal cancer (REC), and advanced gastroesophageal cancer (AGOC).
Study

Patient

Collection

Population time points

Positive

Summary of results

cutoff
CTC/7.5ml

Allard et al
2004

9 AGC

227

Prior to

Detection rate 31%

≥2

Healthy volunteers 0%

treatment

Hiraiwa et al

17 RGC

Prior to

232

27 AGC

treatment

2008

≥2

Non metastatic: 14.3%
Metastatic 55.6%

Matasusaka et
al 2010

52 AGC

233

Prior to tx,

>4

2wks, 4 wks

Detected in 33% of cases
CTC levels at 2 and 4 weeks predictive
of response and prognostic

Uenosone

148 RGC

Prior to

et al 2013 234

103 AGC

treatment

≥1

No CTC detected in healthy volunteers
11.3% in RGC
60.2% in AGC
Average 3.5 CTCs / 7.5ml
Poorer DFS and OS with positive CTCs

Sclafani et al

18 AGC

2014 235

Prior to

≥2

treatment

44% at baseline
Small numbers, closure of commercial
support

Lee et al 2015

100 AGC

236

Prior to
treatment

Reeh et al

68 REC

Prior to

2015 237

(adeno)

treatment

Okabe et al

25 AGC

Prior to

2015

≥5

238

Li et al 2016239

Poorer OS and PFS with positive CTC
≥1

Prior to tx

≥1

2017

240

106 AGOC

Prior to

Detection rate 18.4%
Poorer PFS with positive CTCs

≥3

and 6 weeks
Pernot et al

Detection rate 20.6%
Poorer RFS and OS with positive CTCs

treatment
136 AGC

Detection rate 28%

Positive CTCs after 6 weeks associated
with poor PFS, response rate, and OS

≥2

Poorer DFS and OS with detectable

treatment and

CTCs

day 28

CTCs at day 28 predictive of disease
control
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These studies confirm the validity of EpCAM capture for enumeration of CTCs in
gastroesophageal cancer and demonstrate the following results: CTCs were detected in 11.6 –
60.2% of patients with gastroesophageal cancer; detectable and higher numbers of CTCs more
often occurs in patients with advanced stages of disease 238; higher CTC counts correlate with
worse clinicopathological features such as tumour size/invasion, lymphovascular invasion and
lymph node status234,238; similar to other solid tumours, a positive CTC count is an independent
risk factor associated with poorer clinical outcomes233,234,236-239; and dynamic changes in CTCs
with treatment may provide an early prediction of response238-240. A subsequent meta-analysis of
the above CTC studies confirm these findings 241.
Despite the utility of EpCAM, a major challenge in the use of CTCs as biomarkers is the
development of an ideal marker to detect the rare cancer cells in the large numbers of benign
cells – that is – a marker that is always and only expressed on malignant cells 226. Single
marker, such as CK expression alone, has high false positive results (from 20 to 50%), which is
reduced by using a second marker 242. Moreover, there are likely heterogeneous subpopulations
of CTCs which have differing malignant potential. For example, EpCAM and CK are
downregulated as cells undergo epithelial-mesenchymal transition (EMT), and consequently
methods using EpCAM capture do not detect CTCs in the EMT phenotype 243. Although
confirmed as prognostic, CTC enumeration using current markers has more limited success in
guiding treatments 244. Furthermore, modelling studies suggest that 1 in 60 million CTCs form
viable metastases 245, and there have been studies reporting long term (>22years) persisting
CTCs with no clinically visible disease 246. Therefore there is a need to develop novel CTCs
markers, beyond the currently utilised EpCAM/CK markers, to identify CTCs responsible for
metastatic disease. CSC biomarkers and the uPA system hold potential for the detection of
CTCs beyond traditional EpCAM methods.
1.2.4.3

CSC markers and CTCs

As discussed in section 1.2.1, CSC are the subpopulation of cancer cells that are capable of
initiating tumour growth and therefore responsible for the initiation and propagation of
metastatic disease. CTCs are therefore likely to be enriched for CSCs, and CSC markers may
provide an improved means for detecting biologically relevant CTCs 247. Several small studies
have explored the role of CSC markers in CTCs in gastroesophageal cancer using CD44 and
CD133. Li et al showed CK/CD44 positive cells within the peripheral blood mononuclear cell
(PMBC) layer was prognostic in patients with gastric cancer 73. Yuan et al used CD45 depletion
combined with CD44 positive selection to isolate tumourigenic CTCs 248. The CD44+ fraction
of EpCAM+ cells in peripheral blood samples isolated by flow cytometry shows correlation
with disease stage and venous invasion, as well as response to chemotherapy, while the CD4429

fraction did not 249. The number of CD133+ cells isolated in peripheral blood samples was
significantly associated with clinical outcomes for patients with gastric cancer 150. So far, no
study has compared the utility of CSC markers to identify CTCs to the widely accepted
EpCAM+/CK+/DAPI+/CD45- phenotype.
As indicated above, one important limitation of this approach is the widespread expression of
CD44 and CD133 on non-malignant tissue. For example, CD44 is expressed on many cells
found in the circulation including leukocytes and endothelial cells250, and may reduce specificity
of CTC detection, thus a combination strategy probing for EpCAM/CK/CD45 plus CD44 and
CD133 maybe a viable method.

1.2.4.4

CTCs and the uPA system

The uPA system is the key proteolytic pathway to facilitate invasion of cancer cells into stromal
tissue. uPAR has been identified as an important marker on CTCs in breast cancer, with uPAR+
CTCs enriched for stem cell pathways, and able to adhere, proliferate and invade 251. While
there are no studies examining expression of the uPA system in gastroesophageal cancer CTCs,
there are some compelling results supporting the importance of uPA system in disseminated
tumour cells (DTC) in bone marrow. DTCs are thought to represent the fraction of CTCs
capable of entering distant sites as the first step in establishing metastases 252. Allgayer et al
used CK18 to identify DTC in the bone marrow in 156 patients who had undergone a curative
resection for localised gastric cancer. They found while overall CK18+ DTC was not associated
with prognosis, the CK18+/uPAR+ subset was, suggesting uPAR identifies the critical
subpopulation of cells responsible for establishment of metastasis 253,254.

1.2.4.5

Circulating tumour cell culture

Research into the mechanism of metastasis initiation, formation, and propagation has been
hampered by limited access to cancer cells within the various stages of the metastatic cascade.
CTCs provide a unique window into the biology of cancer as it spreads through the blood
stream. As CTCs are very rare cells and few CTCs are isolated (often 1 – 10 cells per 10 ml of
blood) by current methodologies, this research has been hampered by the low number of cells
available for analysis. CTC culture provides an expanded cell population for expression
analysis, functional assays, and drug sensitivity 255,256. Moreover, long term primary CTC
cultures provide a laboratory tool for the investigation of the biology of metastasis formation 257.
However establishment of long term primary CTC cell cultures has proven to be challenging.
Despite intensive efforts, only four long term CTCs cultures have been established and reported
in the literature 258-261, with no reported success in gastroesophageal cancer (Table 5).
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Table 5: Long term CTC cell lines established worldwide
ULA – Ultra low attachment; Ab/Am – Antibiotic/Antimycotic; EGF – epithelial growth factor;
FGF – fibroblast growth factor
Study

Cancer

Isolation Method

Media / culture conditions

Yu et al
2014259

Breast

20ml EDTA
CTC-iChip

Cayrefourcq
et al 2015258

Colorectal 10ml EDTA
Stemcell
RosetteSep CD45
depletion

Zhang et al
2013261

Breast

20 – 45ml

Gao et al
2014260

Prostate

8ml EDTA

RPMI 1640
EGF 20ng/ml
FGF 20ng/ml
B27
1x Ab/Am
Hypoxic incubator
ULA plate
DMEM/F12 , Insulin 20ug/ml,
1% N2, EGF 20ng/ml, LGutamine 2mM
FGF2 10ng/ml, 2% FCS
24 well ULA plate,
Medium 1 (1wk)
DMEM/F12, Insulin 5mg/ml
Hydrocort 0.5mg/ml, EGF
20ng/ml, FGF-2 20ng/ml
Medium 2 (D7-D22)
EpiCult-C with 10% FBS and
1% P/S, T75 flask
Medium 3 (>22d)
DMEM/F12 , 10% FCS,
1%P/S
Complex media (see supp
materials)
DMEM/F12
EGF 50ng/ml
FGF10 10ng/ml
FGF2 1ng/ml
Testosterone, nicotinamide
R-spondin 1
B27
Glutamx
HEPES
Primocin

Stemcell
RosetteSep CD45
depletion
Seeded in growth
factor reduced
matrigrel
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Culture success
rate (successful
cultures/all
patients)
6/36

1/71

3/8

1/100

Short term cultures have also been developed in a variety of tumours. One group has used the
MetaCell assay and RPMI-1640 supplemented with fetal bovine serum to establish short term
(<14 days) CTC cultures in prostate, pancreatic, oesophageal, gastric and bladder cancer 262-265.
The EPISPOT assay detects cytokeratin secretion by CTCs during short term culture following
CD45 depletion as an enrichment step 266,267, and the Vitatex (Vitatex Inc, Stony Brook NY,
USA) detects the invasion ability of CTCs through a fluorescent matrix 268.
An alternative approach is to expand the CTC population by injecting them into
immunodeficient mice. This approach has been used successfully in breast cancer 269, although
required >1000 CTCs/7.5 ml blood, a far higher number than is seen in most patients. A CTC
xenograft model has also been demonstrated in gastric cancer. The CD45 negative fraction of
peripheral blood mononuclear cells from patients with gastric cancer formed tumour like
structures in nine immunodeficient mice. One of the nine tumours expressed gastric epithelial
markers and CSC markers, providing proof of concept of the xenograft as a functional CTC
assay 270.

1.3 Clinical Biomarkers in Colon Cancer
A key challenge in modern clinical oncology is the integration of diverse types of prognostic
information to provide an accurate, but highly individualised, estimate of prognosis. Despite
intensive efforts and hundreds of publications, there are very few biomarkers that are currently
routinely incorporated into the clinical care of patients with colon cancer 271. While there is
emerging evidence for many molecular markers, including microRNA, circulating tumour
DNA, tumour suppressor genes, and molecular signatures such as the Oncotype DX (Genomic
Health Inc, Redwood City, CA, USA) colon cancer assay, however these await further study
and external validation prior to clinical use. Despite initial promise, subsequent studies on the
same or related markers have demonstrated inconsistent or contradictory results 271 .
As noted above, the most important prognostic factor in colon cancer is pathological stage at
diagnosis 25. Other validated, clinically utilised, prognostic factors include lymphovascular and
perineural invasion 272-274, histological grade 275, and CEA level 276-278. Important molecular
biomarkers include microsatellite instability (MSI) 279, RAS and BRAF mutations 280-282, and
more recently, the consensus molecular subtype 283, although MSI is the only molecular
biomarker routinely used in early stage colon cancer in Australia.
The consensus molecular subtype (CMS, Figure 4), developed through an international
collaboration to resolve inconsistencies in molecular profiling between independent groups, is
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the most widely adopted approach to classify colorectal cancer into distinct molecular subtypes
with significant biological differences283. The CMS proposes 4 distinct molecular subtypes.
CMS1 (MSI-like) include hypermutated and microsatellite instable tumours, and are enriched
for CIMP and BRAF mutations. CMS2 (canonical) are tumours with chromosomal instability
and marked Wnt and MYC activation. CMS3 (metabolic) demonstrate disruption of metabolic
pathways and are enriched for KRAS mutations. CMS4 (mesenchymal) show prominent stromal
invasion, angiogenesis and a mesenchymal phenotype283. Importantly the CMS has shown
significant prognostic associations, with CMS4 tumours associated with the poorest survival284.
Although it is hoped that the CMS will facilitate molecular guidance for individuation of
treatments, the large number of genes included in the CMS has prevented widespread adoption
in routine clinical care285

Figure 4: The consensus molecular subtype (CMS) outlining key features and proportion
of the four subtypes of colorectal cancer. Taken from Guinney et al283
Clinical factors are known to act as surrogates for tumour biology. For example, Asian female
patients with advanced non-small cell lung cancer are enriched for the targetable EGFR
mutation 286. Identifying key clinical factors in colon cancer may not only identify prognostic
markers, but also provide insight into the underlying pathobiology.

1.3.1

Primary tumour location in colon cancer

There is an increasing interest in identifying the differences between right sided (RsCC) and left
sided colon cancer (LsCC), with a growing body of evidence to suggest that right sided colon
cancers follow a different disease process compared to left sided tumours. The proximal and
distal colons are physiologically separate, arising from distinct embryological origins, with
differences in tumour genetics, histology, presentation, and clinical features 287-289. Patients with
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right colon cancer are older, more likely to be female, have more comorbidities, with poorer
tumour histopathological features 290-293. Epidemiological studies suggest a recent shift from
right to left sided colon cancer 294. RsCCs are more likely to have adverse histological features,
higher rates of BRAF mutations and MSI, and demonstrate a molecular profile distinct from
LsCC 283,287,295-297.
Despite this, there is ongoing debate whether primary tumour location is an independent
prognostic factor in colon cancer. Most, but not all studies have found poorer survival with
right colon cancer 292,293,298-300. Tumour stage may play a role, with a large Surveillance,
Epidemiology, and End Results (SEER) program study showing worse overall survival in Stage
III RsCC patients, but not in Stage I or II 292, although these finding have been recently
challenged by a propensity score matched analysis of the SEER database, which showed a better
prognosis in RsCC patients 298. Further studies are required to elucidate the differences between
LsCC and RsCC, particularly in locoregional disease.

1.3.2

Age as a predictor of benefit to adjuvant chemotherapy

Adjuvant (post operative) chemotherapy is an essential component of treatment in stage III and
high risk stage II colon cancers. The fluoropyrimidines are the most efficacious single agent in
CRC and are commonly utilised as the backbone in combination treatments. Oral
fluropyrimidines (capecitabine) are as efficacious as intravenous (fluorouracil; 5-FU with
modulating leucovorin) with an improved safety profile 301,302. Large randomised control trials
establish fluoropyrimidine based chemotherapy as the standard of care in the adjuvant setting,
with pooled analysis including 3302 patients with stage II and III colorectal cancer showing a
30% reduction in risk of recurrence and 26% decreased risk of death with fluourouracil based
adjuvant chemotherapy 303. The MOSAIC trial demonstrated an additional 23% DFS and 20%
OS benefit by adding oxaliplatin to 5-FU in patients with stage III CRC 304, with a similar result
seen in the NSABP C-07 trial 305.
Despite the above evidence, the optimum regimen for elderly patients remains uncertain. As
only a minority of patients in clinical trials are older than 70 years, the efficacy and safety of
adjuvant chemotherapy with an oxaliplatin doublet in elderly patients is unclear. For example,
in the adjuvant colon cancer end points database (ACCENT) which includes individual patient
data from 14500 participants in 18 fluoropyrimidine - based adjuvant trials, only 18% are older
than 70 years 306.
Currently available trial data for adjuvant chemotherapy in elderly population is conflicting.
Subgroup analyses from the pivotal phase III MOSAIC and NSABP C-07 trials show a survival
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benefit only in patients <70 years 304,305. Similarly, there was no DFS) or OS improvement with
the addition of oxaliplatin in the 2575 patients ≥70 years in the ACCENT database 306. In
contrast however, pooled individual patient data from 904 patients ≥70 years from the NSABP
C-08, XELOXA, X-ACT, and AVANT studies showed an attenuated, but statistically
significant benefit to the addition of oxaliplatin, including those with comorbidities 307.
Similarly, retrospective patient series demonstrate contrasting results. While the largest series,
drawn from multiple USA databases including the SEER database, found a statistically
significant benefit to adjuvant oxaliplatin in elderly patients (70-74 years old) and those with
comorbidities 308, this was less clear in patients >75 309 and was not seen in other, smaller studies
310,311

.

As a consequence of these uncertainties, current guidelines recommend discussing incorporation
of oxaliplatin with patients over 70 years based on individual circumstances, although
fluoropyrimidine monotherapy is an appropriate choice for adjuvant therapy in the elderly
18,312,313

.

1.4 Aims and Objectives
It is clear that cancer biomarkers are critically important in clinical oncology. In addition to
providing valuable prognostic information, biomarkers assist in patient risk assessment,
prediction of response to treatment, and monitoring progress of disease, all key factors in
improving the individualisation and delivery of treatment. Furthermore, biomarkers provide
insight into the mechanisms of cancer and identify novel targets for therapeutic agents. Despite
improvements in systemic treatments, prognosis remains poor for the majority of patients with
gastroesophageal cancer. This is largely due to the lack of robust biomarkers available in
gastroesophageal cancer to guide systemic treatment.
The overall aim of this thesis was to identify clinical and molecular biomarkers of
gastrointestinal cancer to ultimately improve delivery of treatment to patients with these
diseases.
The specific aims of this work were to:
i)

Determine if expression of the urokinase plasminogen activator (uPA) system and
cancer stem cell (CSC) markers are biomarkers in gastroesophageal cancer

ii)

Develop and validate a protocol for the cryopreservation and thawing of samples
for circulating tumour cell (CTC) analysis
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iii)

Determine if uPA receptor (uPAR) expression improves the prognostic value of
circulating tumour cells above currently employed markers

iv)

Establish primary cancer cell cultures from circulating tumours cells isolated from
patients with gastroesophageal cancer

v)

Explore primary tumour location as biomarker in locoregional colon cancer.

vi)

Investigate the suitability of age as a predictive determinate of benefit to
oxaliplatin-based adjuvant chemotherapy in locoregional colon cancer
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Abstract
Background: The urokinase plasminogen activation (uPA) system is a crucial pathway for tumour
invasion and establishment of metastasis. Although there is good evidence that uPA system
expression is a clinically relevant biomarker in some solid tumours, its role in gastroesophageal
cancer is uncertain.
Methods: We undertook a systematic review evaluating expression of uPA, urokinase plasminogen
activator receptor (uPAR), plasminogen activator inhibitor-1 (PAI-1/SerpinE1) and plasminogen
activator inhibitor-2 (PAI-2/SerpinB2) on primary oesophageal, gastro-oesophageal junction, and
gastric adenocarcinomas. We performed a meta-analysis of clinicopathological associations, overall
survival (OS) and recurrence free survival (RFS).
Results: We identified 41 studies encompassing 2689 patients which fulfilled the inclusion criteria.
uPA, uPAR, or PAI-1 expression is significantly associated with high risk clinicopathological
features. High uPA expression is associated with a shorter RFS (HR 1.90 95% 1.16 – 3.11, p=0.01)
and OS (HR 2.21 95% CI 1.74 – 2.80, p<0.0001). High uPAR expression is associated with poorer
OS (HR 2.21 95%CI 1.82 – 2.69, p<0.0001). High PAI-1 expression is associated with shorter RFS
(HR 1.96 96% CI 1.07 – 3.58, p=0.03) and OS (HR 1.84 95%CI 1.28 – 2.64, p<0.0001). There was
no significant association between PAI-2 expression and OS (HR 0.97 95%CI 0.48 – 1.94, p<0.92)
although data was limited.
Conclusion: We conclude that the uPA system is a clinically relevant biomarker in primary
gastroesophageal cancer, with higher expression of uPA, uPAR and PAI-1 associated with higher risk
disease and poorer prognosis. This also highlights the potential utility of the uPA system as a
therapeutic target for improved treatment strategies.
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2.1

Introduction

Gastroesophageal cancer is a common and lethal malignancy, marked by modest response to systemic
therapies1. A deeper understanding of molecular events characterising carcinogenesis, invasion,
progression and metastasis is central for the development of novel therapies.

2.1.1

The uPA system

A key process in the development and progression of cancer, including establishment of metastatic
disease, is the invasion of malignant cells into normal tissue. The plasminogen activation system,
particularly the urokinase-type plasminogen activator (uPA) system, is critical for tumour-associated
proteolysis to breakdown extracellular matrix (ECM) and basement membranes barriers2,3. The uPA
system has a defined role in tissue degradation and extravascular fibrinolysis, and is responsible for
most of the activated plasminogen associated with cancer invasion and metastasis3,4 (Figure 1).

Figure 1: The uPA system: Schematic representation of the urokinase plasminogen activation (uPA)
system. The membrane bound urokinase receptor (uPAR) binds circulating inactive pro-uPA,
facilitating the activation of pro-uPA to uPA which subsequently converts co-localised plasminogen
to plasmin that can directly degrade components of the extracellular matrix (ECM) and activate promatrix metalloproteases (MMP) to further break down ECM. Plasminogen activator inhibitors 1 or 2
(PAI-1, PAI-2) are efficient endogenous inhibitors of uPA.
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The uPA protein is secreted as a zymogen and activated on high affinity binding to its specific cell
surface receptor uPAR. Once activated, uPA catalyses the activation of co-localised plasminogen to
plasmin, which in turn directly degrades components of the ECM, and promotes further degradation
and tissue remodelling by activating pro-metalloproteinases and by releasing, thus activating, latent
growth factors from the ECM2,4.
The uPA receptor (uPAR) is anchored to the plasma membrane, localising the uPA system to the cell
surface 5. High expression of uPAR on the invasive front of tumours facilitates invasion and other
roles in cellular migration and angiogenesis 6,7. uPAR expression may be a suitable marker for the
onset of invasion of both gastro-intestinal and breast cancer as it is expressed only on invasive
carcinomas, not premalignant states such as Barrett’s oesophagus 8.
Urokinase-type plasminogen activator is efficiently inhibited by two subtypes of serpin (serine
proteinase inhibitor) family members, plasminogen activator inhibitor-1 (PAI-1/SerpinE1) and -2
(PAI-2 /SerpinB2). Both form a covalent complex with uPA/uPAR leading to internalisation of the
entire complex 9 . Although believed to have a physiological role as an inhibitor of the uPA system,
PAI-1 has a paradoxical protumourgenic role, increasing tumour invasion and angiogenesis, and
correlated with poor prognosis 10. The role of PAI-2 in cancer is less clear. Although both PAIs
mediate uPA/uPAR endocytosis, the uPA-PAI-2 complex interacts with endocytosis receptors with
different binding kinetics to those of uPA: PAI-1 and without stimulating intracellular signalling
events over and above that of uPA binding to uPAR 11.
While the uPA system is expressed on both cancer cells and the supporting stroma, higher expression
is seen on tumour cells, and is postulated that the tumour cell specific uPA/uPAR explains the
aggressive biology exhibited by these cancers, and is more relevant for prognostic outcomes 12-15.
Expression of the uPA system has been shown to be an important prognostic marker in a variety of
cancers including breast cancer16, lung cancer17, and colorectal cancer18, with the combination of uPA
and PAI-1 expression recommended to be incorporated into routine clinical care of node negative
breast cancer19.
In this study we aim to perform a comprehensive systematic review of expression of the uPA system
encompassing uPA, uPAR, PAI-1, and PAI-2 in primary, resectable gastro-oesophageal cancer, and
undertake meta-analyses of prognostic outcomes (recurrence free survival and overall survival), and
association with relevant clinicopathological variables. To the best of our knowledge, this is the first
meta-analysis to examine and compare the expression of these key components of uPA system in
primary gastro-oesophageal cancer.
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2.2

Methods

Methods are reported according to Preferred Reporting for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines20.
2.2.1

Study eligibility/selection criteria

We included all studies which examined the following components of the urokinase plasminogen
activation system uPA, uPAR, PAI-1 or PAI-2, in resected primary esophageal, gastroesophageal
junction, or gastric adenocarcinomas. Other tumour pathologies were excluded. For inclusion in the
quantitative synthesis, studies were required to report the association of the following outcomes with
uPA system expression: overall survival (OS), recurrence-free survival (RFS), or clinicopathological
variables.
Two authors (DB, JC) independently performed the search and screened the studies. The primary
outcome was OS; secondary outcomes were RFS, and correlation of clinicopathological variables
with uPA system expression.
2.2.2

Study search strategy

We searched the following databases in February 2015 for all trials fulfilling the above criteria:
Medline (1950 – present); EMBASE (1966 – present); Cochrane Central Register of Controlled
Trials, and Cochrane Database of Systematic Reviews; PubMed.
To maximize sensitivity the following search terms were used: Stomach Neoplasms (MESH) OR
Esophageal neoplasms (MESH) OR Gastrointestinal neoplasms (MESH) OR Gastric cancer.mp OR
Gastric carcinoma.mp OR esophageal cancer.mp OR oesophageal cancer.mp OR gastroesophageal
cancer.mp AND Receptors, urokinase plasminogen activator (MESH) OR Urokinase-type
plasminogen activator (MESH) OR Plasminogen activator inhibitor 1 (MESH) OR Plasminogen
activator inhibitor.mp OR PAI-1.mp OR PAI-2.mp OR Urokinase* plasminogen.mp OR uPA*.mp.
Reference lists of included studies and review articles were hand searched. The search was restricted
to studies published in English.
2.2.3

Data collection

Study data was independently collected by two authors (DB, JC) using standardized electronic data
collection forms. The following was collected for each study: patient number, primary tumour
location (gastric/oesophageal/COJ), cancer stage, treatment received by patient; uPA components
assessed (uPA, uPAR, PAI-1, PAI-2) and method, patient followup; outcomes (OS or RFS),
clinicopathological correlations (including TMN stage, tumour grade, lymphatic invasion, vascular
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invasion). For studies which used IHC, expression analysis was restricted to tumour cells only
(stromal expression was not included in the meta-analysis). Any disagreement was resolved with
consensus by a third author (MR)
2.2.4

Assessment of bias within studies

All studies included in the meta-analyses were assessed for bias using the Quality In Prognosis
Studies (QUIPS) tool which assesses for potential sources of bias in six domains namely: study
participation; study attrition and loss to followup; prognostic factor measurement; outcome
measurement; study confounding; and statistical analysis and reporting21.
2.2.5

Statistical analysis

We extracted the hazard ratio (HR) and their 95% confidence intervals (CI) for time-to-event
outcomes including RFS and OS. If both univariate and multivariate HR were published the univariate
results were preferentially used. Where no HR was provided in published data, it was estimated from
available results or Kaplan-Meier survival curves using previously described methods22.
HRs were synthesized using the generic inverse variance method and a random effect model using
RevMan5.1 analysis software. Statistical heterogeneity was assessed using the I2 statistic. We
performed pre-specified subgroup analysis for overall survival for: primary location (gastric or
oesophageal), cancer cell specific expression (using IHC) compared to whole cell lysis (using RTPCR/ELISA).
Clinicopathological associations were summarized using odds ratios (OR) derived from published
results. This analysis was limited to studies using IHC, as other methods presented expression results
as means, rather than percentage of patients expressing. Expression rates were described with mean
and range, and compared using the student’s t-test.

2.3
2.3.1

Results
Included studies

The trial flow is provided in Figure 2. We identified 267 reports matching criteria for inclusion in the
study, of which 109 were selected for abstract review, and 60 subsequently for full text review. Forty
one studies (including 2689 patients) fulfilled criteria for inclusion in the systematic review. Of these,
22 studies (1966 patients) provided sufficient data for inclusion in the formal quantitative metaanalysis: 19 studies were excluded for the following reasons: 13 studies did not examine prognostic or
clinicopathological associations23-34, 3 reports were matched case control studies35-37, and 4 studies
reported insufficient published data to derive a HR38-42.
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267 reports identified
matching search criteria

102 abstracts screened

60 full text reports assessed
for suitability

41 studies

22 studies included in
formal meta-analysis.

42 reports excluded
33 not evaluating primary gastrooesophageal adenocarcinoma
9 circulating / soluble uPA studies

19 reports excluded
7 language other than English
10 duplicate reports
2 expression assessed on metastatic
tissue only

19 studies excluded from meta-analysis
12 did not evaluate OS/ RFS
3 matched case control
4 insufficient published data to derive
HR

Figure 2: Study selection flow diagram. HR –hazard ratio; OS – overall survival; RFS – recurrence
free survival.

The characteristics of the included studies are summarized in Supplementary Table 1. Eighteen
studies evaluated uPA system expression in gastric cancer (1732 patients), one study included
oesophageal, junctional and gastric cancers (39 patients), and two studies examined oesophageal
cancer only (105 patients). Expression of the uPA system was assessed using immunohistochemistry
(IHC, 12 studies, 1273 patients), enzyme-linked immunosorbent assay (ELISA, 5 studies, 344
patients), reverse transcription polymerase chain reaction (RT-PCR, 3 studies, 153 patients), or in-situ
hybridisation (ISH, one study, 105 patients).
Hazard ratios directly extracted for 3 studies 8,12,43. The multivariate HR was used when univariate
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value was not provided 43. When only subgroup outcome data (tumour core or peripheral zone) were
available, the results for peripheral “invasion” zone were used 8,12. Hazard ratios were estimated for
the remaining studies using published data. 4 studies reported a “non-statistically significant OS”
result for uPA system expression, but did not publish sufficient data for inclusion in meta-analysis 3942

.

2.3.2

Bias risk

The risk of bias summary is summarized in Figure 3. Only 4 studies 43-46 were deemed low risk in all
bias domains. Fourteen studies did not clearly define the study population 8,13,14,47-57 and 11 studies
did not report completeness of followup 8,13,14,47-50,53,55,56,58. Most studies adequately reported method
of measurement of the uPA system, although 5 studies did not report whether there was a second
independent reviewer or blinding to clinical information14,52,56,57,59. The follow-up protocol was
underreported in 14 studies 8,12-14,47-53,55-57, although this is unlikely to bias the results for overall
survival analyses. Most studies did not report details of the surgical, medical, or radiation treatments
received by patients, and were Urokinase plasminogen activator (uPA)
Bias Domain
Study
Allott 2012
Alpizar Alpizar 2012
Bayer 2006
Cho 1997
Ganesh 1996
Heiss 1995
Ito 1996
Kaneko 2003
Kawasaki 1998
Laerum 2012
Lee 2004
Luebke 2006
Maeda 1996
Murata 1998
Nekarda 1994
Nekarda 1998
Okusa 1999
Plebani 1997
Sakakibara 2006

Study
Participation

Study Attrition

Prognostic
factor
Measurement

Outcome
Measurement

Study
Confounding

Statistical
analysis and
reporting

Taniguchi 1998
Yonemura 1997
Zhang 2006

Figure 3: Risk of bias summary. For each bias domain: green = “low risk” means that sufficient
data was available to allow assessment of quality and fulfilled criteria for each domain, and
accordingly is deemed low risk of bias. Orange = “unclear risk” means that insufficient data was
presented to adequately assess the quality of the domain and accordingly the study has potentially
high risk of bias. There were no studies deemed high risk of bias.
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2.3.3

uPA system expression rates

The expression rates are summarized in table 1. There was no significant difference in expression
rates seen between cell specific (IHC, ISH) or whole tissue lysate (RT-PCR, ELISA).
Number of Studies

Mean expression

Mean expression

p value (students t-

(number of patients)

IHC/ISH (%)

ELISA/RT-PCR (%)

test)

uPA

19 (1629)

59.5

42.6

0.1

uPAR

15 (1352)

55.1

56.7

0.4

PAI-1

15 (1337)

63.7

42.9

0.1

PAI-2

3 (300)

43

-

-

Table 1: Expression of the uPA system in gastroesophageal cancer . IHC –
immunohistochemistry, IHC – immunohistochemistry, RT-PCT - reverse transcription polymerase
chain reaction; ISH – in-situ hybridisation; ELISA - enzyme-linked immunosorbent assay
2.3.4

Urokinase plasminogen activator (uPA)

2.3.4.1 uPA and clinicopathological associations
uPA expression is significantly associated with poorer clinicopathological features in resected
gastroesophageal cancer including: Advanced T stage (T3/4 vs T1/2) (OR 2.79 95% CI 1.80 – 4.32,
p<0.0001), nodal metastases (OR 2.30 95% CI 1.63 – 3.51, p<0.0001), liver metastases (RR 6.77
95% CI 2.70 – 16.96, p<0.0001), peritoneal metastases (OR 2.09 95% CI 1.29 – 3.36, p=0.003),
lymphatic invasion (OR 2.28 95% CI 1.31 – 3.97, p=0.0003), and vascular invasion (OR=2.43 95%
CI 1.53 – 3.86, p=0.0002) (5 studies, 522 patients, supplementary Figure 1). There is no significant
association with histology (poorly differentiated vs well differentiated).
2.3.4.2 uPA expression and prognosis
uPA expression was significantly associated with a worse RFS (3 studies, 467 participants, HR 1.90
95% 1.16 – 3.11, p=0.01) (see supplementary Figure 2). There was no significant difference in RFS
seen between studies using IHC (HR 1.77) or ELISA (HR 2.36) to assess uPA expression (test for
subgroup differences Chi2=0.37, p=0.54).
uPA expression is significantly associated with poorer OS (12 studies, 1094 participants, HR 2.21
95% CI 1.74 – 2.80, p<0.0001) (see Figure 4). There was no significant difference in OS between
studies which used IHC (HR 1.94) or ELISA (HR=2.99) to assess uPA expression (p=0.38).
Sensitivity analysis showed similar results when analysis was restricted to gastric cancer only (HR
2.07, p<0.00001).
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Figure 4: Pooled estimate of hazard ratio (HR) for uPA expression and overall survival (OS).
Pooled estimate of hazard ratio (HR) for overall survival. The square on each bar represents the HR
for an individual trial, and the bar shows the 95% confidence interval (CI). The diamond represents a
pooled estimate with the centre of the diamond giving the HR estimate, and the extremes of the
diamond representing the 95% CI.
2.3.5

Urokinase plasminogen activator receptor (uPAR)

2.3.5.1 uPAR expression and clinicopathological associations
uPAR expression on primary resected gastroesophageal cancer is significantly associated with poorer
clinicopathological features including: advanced TMN stage (stage III/IV vs I/II, OR 3.41 91% CI
1.55 – 7.53, p=0.002), advanced T stage (OR 2.33 95% CI 1.53 to 3.56, p<0.0001), nodal metastases
(OR 2.52 95% CI 1.70 – 3.72, p<0.0001), liver metastases (OR 2.53 95% CI 1.25 – 5.13, p=0.010),
peritoneal metastases (OR 3.15 95% CI 1.87 – 5.28, p<0.0001), lymphatic invasion (OR 2.82 95% CI
1.74 – 4.59, p<0.0001) and vascular invasion (OR 3.85 95% CI 2.53 – 5.88, p<0.0001) (six studies,
589 patients, supplementary Figure 3). There is no significant association seen with histology (p=0.6).
2.3.5.2 uPAR expression and prognosis
Only one study provided data for uPAR expression and RFS 59, showing a shorter RFS with uPAR
expression (203 patients, HR 2.69, p=0.03).
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uPAR expression is associated with poorer OS (11 studies, 1036 patients, HR 2.19 95%CI 1.80 –
2.66, p<0.0001) (Figure 5). There was no significant difference in OS seen between studies which
used IHC (HR 2.13), ISH (HR 2.34), ELISA (HR 2.19), or RT-PCR (2.66) to assess uPAR expression
(p=0.96).

Figure 5: Pooled estimate of hazard ratio (HR) for uPAR expression and overall survival (OS).
2.3.6

Plasminogen Activator Inhibitor-1 (PAI-1)

2.3.6.1 PAI-1 expression and clinicopathological variables
PAI-1 expression on primary resected gastroesophageal cancer is significantly associated with poorer
clinicopathological features including: advanced T stage (OR 2.59 95% CI 1.61 to 4.18, p<0.0001),
nodal metastases (OR 2.03 95% CI 1.27 – 3.22, p<0.003), lymphatic invasion (OR 2.09 95% CI 1.31
– 3.34, p<0.004) and vascular invasion (OR 1.90 95% CI 1.20 – 3.03, p<0.007) (three studies, 317
patients, supplementary Figure 4). There was no significant association of PAI-1 expression with
presence of liver metastases (OR 0.52, p=0.18), peritoneal metastases (OR 1.38, p=0.31), or histology
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(OR 0.93, p=0.74).
2.3.6.2 PAI-1 expression and prognosis
PAI-1 expression is associated with shorter RFS (3 studies, 467 patients, HR 1.96 96% CI 1.07 – 3.58,
p=0.03) (supplementary Figure 5). There was no significant difference in RFS between studies which
used IHC or ELISA to detect PAI-1 expression (p=0.86)
PAI-1 expression is significantly associated with a shorter OS (10 studies, 839 participants, HR 1.84
95%CI 1.28 – 2.64, p<0.0001, Figure 6). Pre-specified subgroup analysis showed a significant
difference between studies which assessed PAI-1 expression using IHC (HR 1.20, p=0.47) and ELISA
(HR 2.94, p<0.0001) or RT-PCR (HR 2.83, p<0.0001) (p=0.02).

Figure 6: Pooled estimate of hazard ratio (HR) for PAI-1 expression and overall survival (OS).
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2.3.7

Plasminogen Activator Inhibitor-2 (PAI-2)

2.3.7.1 PAI-2 expression and clinicopathological variables
There were no studies with sufficient data analyzing PAI-2 expression and clinicopathological
variables for inclusion in the meta-analysis.
2.3.7.2 PAI-2 expression and prognosis
No studies published data on PAI-2 expression and RFS. There was no significant association of
PAI-2 expression and OS (2 studies, 145 participants, HR 0.97 95%CI 0.48 – 1.94, p<0.92,
supplementary Figure 6).
2.3.8

Publication bias

Examination of the funnel plots for the OS analysis for uPA, uPAR and PAI-1 showed asymmetrical
plots for all analyses, suggesting absence of smaller negative trials (example plot for uPA provided in
supplementary Figure 7).
2.4

Discussion

This meta-analysis confirms the clinical utility of the uPA system as a biomarker in resected gastrooesophageal adenocarcinoma.
There is good evidence that high expression of uPA, uPAR, and PAI-1 is associated with most high
risk clinicopathological features, including advanced T stage, presence of nodal and distant
metastases, and lymphovascular invasion, in primary gastro-oesophageal adenocarcinoma. This
supports the central role of the uPA system in tumour invasion and metastasis. In contrast, there was
no significant association of expression found with poorly differentiated histology, consistent with
previously published work which shows that epithelial cell uPA system expression is higher in
malignant than benign tissue, but decreases as tumour becomes more poorly differentiated, with a
corresponding increase in stromal expression60.
We also demonstrated that uPA, uPAR, and PAI-1 expression is associated with poorer prognosis in
resected gastro-oesophageal cancer, with both a shorter RFS and OS in tumours which expressed
these markers. However this result should be interpreted with caution due to the following important
limitations in our study.
Firstly, only four of the included studies were deemed low risk for all bias domains as assessed by the
QUIPS tool. In particular, most studies did not report the treatments patients received which is an
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important potential source of confounding for RFS and OS analyses. Additionally, tumours with
higher risk clinicopathologic features could reasonably be expected to be more likely to have received
neoadjuvant treatment prior to surgery, which may in turn have impacted on the expression of the
uPA system. Despite this, it should be noted that similar results were seen in studies deemed low and
high risk of study confounding, and heterogeneity was low in both the uPA and uPAR OS metaanalyses (I2= 31% and 0% respectively, see Figure 4 and 5).
Secondly, there is evidence of underreporting of non-significant results. This is demonstrated by both
the funnel plot, as well the selective reporting of only statistically positive findings from included
studies. This important bias will cause an overestimation of the effect of expression.
Thirdly, as demonstrated above, tumours that expressed uPA, uPAR and PAI-1 had higher risk
features, and would be expected to recur or progress sooner than tumours that did not. The apparent
difference in prognostic outcomes may be due to unequal baseline characteristics of the included
participants.
We did not show a significant difference in the prognostic outcomes between studies which used a
tumour cell specific technique (e.g. IHC) compared to whole tissue lysates (e.g. RT-PCR, ELISA) for
uPA and uPAR. This is consistent with other studies which have shown correlation between IHC
score and median ELISA value, and supports the cancer cells as a major source of uPA and uPAR
expression in the tumour tissue61.
In contrast, there was a significant different in the expression methodology subgroups in the analysis
for PAI-1 and OS (p=0.02), with a non-significant outcome seen in studies using IHC (HR 1.20,
p=0.47), compared to significant results with ELISA (HR 2.94, p<0.0001) and RT-PCR (HR 2.83,
p=0.0007). This highlights the importance of the stromal production of PAI-1 within the tumour
microenvironment 10, as only methods that took into account both stromal and tumour PAI-1 showed
statistically significant prognostic outcomes. It has been postulated that in contrast to uPAR,
fibroblasts and endothelial cells provide the major source of PAI-1 within the tumour tissue 62. It is
possible that the PAI-1 detected on the tumour cells by IHC may be explained by internalization and
accumulation of stromal produced uPA-PAI-1 complexes mediated by tumour uPAR 63. No IHC
studies examined the association between stromal PAI-1 expression and prognostic outcomes in
gastro-oesophageal cancer.
All IHC study results used in the meta-analysis were restricted to tumour cell expression only.
Similar to other cancers, uPA system expression was highest at the invasive front of the tumour
8,12,13,48

. Only four studies reported stromal expression of the uPA system 8,12,13,59. Results were

conflicting, with only one study showing a significant association of OS with macrophage uPAR
73

expression8.
We were unable to show any significant associations with PAI-2 expression with either
clinicopathological features or prognostic outcomes, as available data was much more limited.
Similarly only 3 studies examined oesophageal cancer, which limits applicability of our results to this
subgroup. Sensitivity analysis did not show a different result when oesophageal cancer was excluded
from analysis.
In conclusion, expression of the uPA system is a clinically relevant biomarker in gastroesophageal
cancer. There is good evidence to support the association of uPA, uPAR, and PAI-1 expression and
high risk clinicopathological features. While we found a statistically significant association between
uPAR, uPAR and PAI-1 expression and poorer prognosis, our results are tempered by methodical
limitations discussed above. Prospective studies are required to further confirm its role as an
independent prognostic marker in this disease.
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Supplementary Figure 1: Pooled estimate of odds ratio (OR) for uPA expression and
clinicopathological factors.
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Supplementary Figure 2: Pooled estimate of hazard ratio (HR) for uPA expression and
recurrence free survival (RFS).
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Supplementary Figure 3: Pooled estimate of odds ratio (OR) for uPAR expression and
clinicopathological factors.
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Supplementary Figure 4: Pooled estimate of odds ratio (OR) for PAI-1 expression and
clinicopathological factors.
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Supplementary Figure 5: Pooled estimate of hazard ratio (HR) for PAI-1 expression and
recurrence free survival (RFS).
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Supplementary Figure 6: Pooled estimate of hazard ratio (HR) for PAI-2 expression and overall
survival (OS).
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Supplementary Figure 7: Funnel plot of uPA studies
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1
2
3

Supplementary Table 1: Characteristics of included studies.
Study (year)
Pt
Primary location
Analysis
No.
(TNM stage)
Method
Allott (2012) 47
39
Oesophageal (ND)
RT-PCR
Alpizar Alpizar (2012) 12 95
Gastric (I-IV)
IHC
Beyer (2006) 43
104
Gastric (I-IV)
IHC

4

Cho (1997) 44

160

Gastric (I – IV)

ELISA

5

Ganesh (1996) 46

50

Gastric (I – IV)

ELISA

6

Heiss (1995) 59

203

Gastric (I – IV)

IHC

7

Ito (1996) 48

125

Gastric (ND)

IHC

8

Kaneko (2003) 49

101

Gastric (ND)

IHC

9

Kawasaki (1998) 13

91

Gastric (I – IV)

IHC
ISH

10

Lærum (2012) 8

66

11
12

Lee (2004) 50
Luebke (2006) 58

35
105

13
14
15
16
17
18
19
20
21
22

Oesophageal, GOJ,
Gastric (I-IV)
Gastric (I – IV)
Gastric (I – IV)

IHC

PAI-1
uPAR

Expression Rate
(%)
50
90
91
88
90
28
33
42
11
75
69
71
66
50
52
23
33
37
33 (IHC)
20 (ISH)
39 (IHC)
29 (ISH)
90*

uPAR
63
uPA
84
PAI-1
93
64
Maeda (1996)
120
Gastric (I – IV)
IHC
uPA
61
PAI-2
63
Murata (1998) 52
26
Gastric (IV)
IHC
uPA
42
Nekarda (1994) 65
76
Gastric (I – IV)
ELISA
uPA
51
PAI-1
41
Nekarda (1998) 45
38
Oesophageal (I-IV)
ELISA
uPA
34
PAI-1
32
Okusa (1999) 53
71
Gastric (I – IV)
ELISA
uPA
50
Plebani (1997) 54
20
Gastric (I – IV)
ELISA
uPA
65
uPAR
65
PAI-1
75
Sakakibara (2006) 55
79
Gastric (I – IV)
RT-PCR
PAI-1
58
56
Taniguchi (1998)
102
Gastric (ND)
IHC
uPAR
40
Yonemura (1997) 14
155
Gastric (I – IV)
IHC
uPAR
14
Zhang (2006) 57
105
Gastric (ND)
ISH
uPA
58
uPAR
67
Pt No – number of patients; uPA – urokinase plasminogen activator; uPAR - urokinase plasminogen
activator receptor; PAI-1 – plasminogen activator receptor 1; PAI-2 - plasminogen activator receptor
2; IHC – immunohistochemistry, RT-PCT - reverse transcription polymerase chain reaction; ISH – insitu hybridisation; ELISA - enzyme-linked immunosorbent assay; GOJ –gastro-oesophageal junction.
*expression at invasive front
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RT-PCR
IHC

uPA
component
PAI-1
uPAR
uPA
uPAR
PAI-1
uPA
PAI-1
uPAR
PAI-1
uPA
uPAR
PAI-1
uPA
PAI-1
PAI-2
uPA
uPAR
PAI-1
uPAR
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Abstract
Background: Gastroesophageal adenocarcinoma is a common and highly lethal malignancy. There is
a growing evidence base to support the central role of cancer stem cells (CSCs) in the development
and progression of metastatic disease. While numerous studies have shown the poor clinical outcomes
associated with expression of the CSC markers CD44, CD133 and ALDH1 in locoregional
gastroesophageal cancer, there is a paucity of data in distant metastatic disease. We aimed to
investigate the prognostic significance associated with expression of CSC markers in metastatic
gastroesophageal cancer.
Methods: We examined the immunohistochemical expression of CD44, CD133, and ALDH1 on
metastatic deposits from gastroesophageal and gastric adenocarcinomas, and evaluated the association
of CSC expression with clinicopathological factors, metastases biomarker urokinase plasminogen
activator receptor (uPAR) expression, and overall survival (OS).
Results: Of the 36 patients included in the study, 16 (44%) were positive for CD44, 13 (36%) were
positive for CD133, and 26 (72%) were positive for ALDH1. CD44 expression was significantly
associated with poorer OS in univariate (HR 2.9 95%CI 1.3 – 6.9, p=0.008) and multivariate analyses
(HR 2.5 95%CI 1.1 – 6.2, p=0.04). ALDH1 expression was significantly associated with poorer OS in
univariate (HR 2.4 95% CI 1.01 – 5.7, p=0.04) analysis but was not significant in multivariate
analysis. Both CD44 and ALDH1 expression were significantly associated with uPAR expression. We
found no association between CD133 expression and OS.
Conclusions: CD44 expression on metastatic disease from gastroesophageal adenocarcinomas is an
independent prognostic marker associated with poorer OS. These results expand current evidence to
support the role of CSCs as biomarkers in metastatic gastroesophageal cancer.
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3.1

Introduction

Gastroesophageal adenocarcinoma, a common and lethal malignancy, is a leading cause of cancer
mortality worldwide1. Despite advances in treatment, prognosis remains poor due to high rates of
recurrence after curative surgery, and limited response to systemic treatment in advanced disease2.
There is an urgent need for novel therapeutic strategies to improve treatments for patients with
gastroesophageal cancer.
The cancer stem cell (CSC) hypothesis seeks to explain the high rate of relapse and resistance to
current anti-neoplastic treatments. The CSC model proposes that tumour formation, maintenance, and
growth is driven by a small population of self-sustaining cells which possess stem cell properties of
longevity and infinite proliferation, and are able to differentiate into the wide range of cells forming
the heterogeneous tumour mass3,4. CSCs, first demonstrated in acute myeloid leukaemia, have been
described in most solid tumours including breast cancer5, prostate cancer6, pancreatic cancer7,8,
melanoma9, colon cancer10,11, and brain cancer12,13.
CSC theory has important clinical implications, as it infers that treatment should be directed to the
small pool of CSCs, as well as the large, terminally differentiated tumour bulk. Lineage tracing
studies show that CSCs are able to reconstitute the entire tumour bulk following chemotherapy14.
Promising results from early clinical studies suggest that the inherent resistance of CSCs to
chemotherapy and radiotherapy can be overcome by the combination of chemotherapy with CSC
targeted treatment in gastric cancer15,16.
While numerous proteins have been identified as potential markers of CSC in gastroesophageal cancer
including CD24, CD49, Sox2, Oct4, and Nanog, the most consistent evidence is for three main
markers; CD44, CD133 and ALD17.
CD44 is a transmembrane glycoprotein with important roles in matrix adhesion, cell migration,
growth, and survival18,19. CD44 positive cells from gastric cancer cell lines are shown to be more
tumorigenic in mouse and in vitro models20-22, and resistant to chemotherapy and radiotherapy20,22.
CD44 is expressed in 44-63% of resected primary gastric cancers 23,24, and is associated with larger
tumour size, depth of invasion, advanced TNM stage, and positive LN24-26. Primary tumour CD44
expression is an independent prognostic factor associated with increased risk of recurrence and poorer
overall survival in resected gastric cancer25-27.
CD133 is a cell surface transmembrane glycoprotein with a proposed role as an organiser of plasma
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membrane topology28. Preclinical work shows that CD133 positive cells isolated from cell lines
demonstrate stem cell properties, and are more resistant to chemotherapy12,13,29. Rates of CD133
expression on primary gastric cancer resection specimens range from 25 – 90%30,31. Expression on
resected primary gastric tumours is associated with higher risk pathological features, and is an
independent factor associated with worse clinical outcomes24,30,32-35
ALDH1 is a member of a family of intracellular enzymes contributing to cellular detoxification,
differentiation, and drug resistance36. In vitro, ALDH1 positive cells from gastric cancer cell lines
show self-renewal, heterogeneous linage and increased tumourogenicity37. Primary tumour ALDH1
expression is associated with higher TNM stage and pathological factors24,38.
The CSC model proposes disseminated CSCs to be the source of metastases, either as primary
circulating CSCs or by dedifferentiation though phenotypic plasticity39. The expression of CSC
markers has been linked to the development of metastatic disease in a variety of malignancies
including gastric27,34, colorectal40, breast41 and pancreatic7 cancer.
A key step in the formation of metastatic deposits is invasion of the tumour cells into the surrounding
normal tissue. This is facilitated through the urokinase type plasminogen activator (uPA) system, the
critical proteolytic pathway and predominate source of malignant plasminogen activation42.
Expression of the uPA receptor uPAR is an important independent prognostic factor in many solid
malignancies including gastroesophageal cancer43-45, and has an emerging role in CSC signalling46,47.
Although the expression of CSCs markers have been well characterised in resected locoregional
gastroesophageal adenocarcinoma, there is no data on the expression of CSC markers in metastatic
disease. In the current study, we aimed to analyse the IHC expression of CD44, CD133 and ALDH1
on metastatic gastric cancer deposits, and correlate expression with prior treatment,
clinicopathological factors, uPAR expression, and clinical outcomes.

3.2

Material and Methods
3.2.1

Patient Population and Tissue samples

We retrospectively identified all patients with metastatic gastric or gastroesophageal junction
adenocarcinomas treated at two Australian Tertiary Hospitals (Wollongong Hospital, St George
Hospital) between 2010-2014 who had an available tissue sample from a metastatic site (n=50). 38
samples were suitable for staining and scoring. Clinicopathological variables extracted from patient
records included: age, sex, tumour histological type, grade, site of metastases, Eastern Cooperative
Oncology Group (ECOG) performance status, treatments, progression free survival (defined as the
time from the date of primary treatment to the date of progression or death) and overall survival (time
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from diagnosis to death from any cause). The study was approved by South Western Sydney Local
Health District Human Research Ethics Committee (Project Number 15/072).
3.2.2

Immunohistochemistry

We used formalin fixed, paraffin embedded tissues from patients who underwent biopsy of a
metastatic deposit from primary gastroesophageal adenocarcinoma. Immunohistochemical staining
was done as previously reported 24. Freshly cut 4 micron sections from patient tissue blocks were
mounted on aminopropylethoxysilane precoated glass slides. Sections were deparaffinised in EZ Prep
and washed in Reaction Buffer (Ventana Medical Systems, Arizona, US). The immunohistochemical
staining was performed using defined protocols with the Ventana BenchMark Ultra Automated
IHC/ISH slide staining system. Antigen retrieval was performed by incubation at 100°C at pH 9.0 for
between 24 to 32 minutes. Incubation with primary antibodies was carried out at 37°C for one hour.
Sections were incubated with the following antibody dilutions: anti-CD44 (clone EPR1013Y, Abcam)
1:200, CD133 (clone AC133, Miltenyi Biotec) 1:100, ALDH1 (clone 44, BD Transduction
Laboratories) 1:100, and uPAR (clone R4, Dako) 1:100. A post primary endogenous peroxidase
inhibition was performed by incubating the slides in 1% hydrogen peroxide for 15 min. Development
of colour was achieved by 15 minutes incubation with diaminobenzidine solution, followed by
counterstaining with haematoxylin. Sections from normal human epithelium, colon adenocarcinoma
and normal human appendix were used as positive controls for CD44, CD133 and ALDH1
respectively 24,36. All staining runs were accompanied by appropriate control slides.
3.2.3

Scoring of immunohistochemical staining

CSC scoring was performed by two independent pathologists blinded to clinical details (AL, and AI
or NH). Previous reports have shown a significant correlation between CD44, CD133 and ALDH1
expression and prognosis in primary gastroesophageal cancer 17 . To remain consistent with the
literature 24,27,48, CD44 and CD133 staining was considered positive if at least 10% of the tumour cells
were stained. We noted a much higher proportion of ADLH1 positive cases than previous studies
(only 5 negative cases using a 10% cutoff); accordingly we increased the threshold to 20% (positive
result if 20% or more of the tumour cells stained). Staining in surrounding stroma was not included in
the score for any CSC marker.
uPAR scoring was performed by a third blinded pathologist (MI) experienced with
immunohistochemical analyses of the uPA system in cancer 43,49. uPAR expression on cancer cells
varies between the tumour core, and the invading edge of the tumour 49. Analysis of uPAR expression
was restricted to the peripheral invasion zone as this has been shown to be prognostic in gastric cancer
44

. Neutrophils were used as internal positive controls on each slide. Scoring was performed as
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previously described; 0- No uPAR-positive cells; 1- Less than 1% uPAR-positive cells; 2- 1–5%
uPAR-positive cells; 3- 5–10% uPAR-positive cells; 4- More than 10% uPAR-positive cells as
previously reported for gastroesophageal cancer . Samples were considered to be uPAR positive if
>5% of tumour cells were stained 43,44.
3.2.4

Statistical analysis

The primary endpoint of this analysis was overall survival (OS) by CSC expression. Summary
statistics of patients’ demographic and clinicopathological details, and staining status were provided
in frequencies and percentages. Bivariate correlations between clinicopathological features and
CD44, CD133, and ALDH1 expression were performed using the Fisher’s exact test. A Cox
proportional hazard model was used to estimate effects of CD44, CD133 and ALDH1 positivity on
each survival endpoint; only covariates significant in univariate analysis were included in the
multivariate model. uPAR expression was not included in the multivariate model as staining was only
available for a subset of patients. All statistical analyses were performed using SAS 9.2 software
(SAS Institute, Inc., Cary, NC).

3.3

Results
3.3.1

Patient characteristics and correlation with CSC expression.

Characteristics of the 36 included patients are summarised in Table 1. Median follow-up was 5.2
months (Interquartile range 2.8 – 10.7 months). Consistent with the poor prognosis of this disease,
most patients (n=32, 89%) had died of their disease. 17 (45%) of patients received treatment for
loco-regional disease prior to developing metastases, although in all cases this was more than 6
months prior to biopsy. Most patients (n=32, 84%) received treatment for the metastatic
gastroesophageal cancer including chemotherapy (usually a platinum, fluoropyrimidine and
anthracycline combination), radiotherapy, or surgery (Table 1). Radiotherapy and surgery were
employed as palliative local treatments for symptomatic metastases.
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Table 1: Characteristics of included patients GOJ – gastroesophageal junction; * site of distal
lymph nodes include mediastinal, supraclavicular, and para-aortic; **All prior treatment was curative
intent
Characteristic
Age – median (range)
Sex, n (%)
Male
Female
Primary tumour location
GOJ
Gastric body
Site of metastatic biopsy
Pulmonary
Peritoneum/omentum/ascites
Liver
Bone
Distal lymph node*
Soft tissue
ECOG performance status
0–1
2–4
Prior Treatment**
Surgery
Chemotherapy
Radiotherapy
Nil
Treatment for metastatic disease
Chemotherapy
Immunotherapy
Radiotherapy
Surgery
Nil

Number (%)
64 (39 – 78)
29 (80)
7 (19)
16 (44)
20 (56)
4 (11)
18 (50)
7 (18)
2 (5)
4 (11)
2 (5)
31 (86)
5 (14)
13 (34)
13 (34)
5 (13)
21 (55)
26 (68)
1 (3)
7 (18)
3 (8)
6 (16)
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Figure 1: Representative staining of CSC markers on metastatic deposits with corresponding
Hematoxylin and eosin stain (20x magnification). (a) Hematoxylin and eosin stain (b) membranous
staining of CD44 (c) CD133 staining in apical membranes (d) cytoplasmic staining of ALDH1.
Of all cases, 16 (44%) were positive for CD44, 13 (36%) were positive for CD133, and 26 (72%)
were positive for ALDH1. We found no association between CSC markers and clinicopathological
features, including primary tumour location, site of metastatic disease or biopsy sample, previous
chemotherapy exposure, or histopathology (Table 2).
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Table 2: Association of CSC marker staining with clinicopathological features (n=36): GOJ –
gastroesophageal junction;
Total (%)
% positive cells (mean)
Primary location
GOJ
Gastric
Sites of Metastatic disease
Peritoneal/Omentum only
Other
Previous Chemotherapy
Yes
None
Histopathology
Well/mod differentiated
Poorly differentiated

3.3.2

CD44
16/36 (44%)
10 – 100% (62)
Positive rate P-value

CD133
13/36 (36%)
10 – 100% (38)
Positive rate P-value

ALDH1
26/36 (72%)
10 – 100% (76)
Positive rate
P-value

8/16
8/20

0.73

6/16
7/20

0.98

12/16
14/20

0.98

7/18
9/18

0.73

4/18
9/18

0.16

14/18
12/18

0.71

6/13
10/23

0.87

5/13
8/23

0.83

10/13
16/23

0.72

5/16
11/20

0.19

5/16
8/20

0.73

5/16
15/20

0.72

Correlation of CSC marker and uPAR expression

Samples including the peripheral invasion zone were available for 28 samples (8 samples excluded,
due to insufficient tissue n=4, or the biopsy included tumour core only n=4). 9/28 (32%) samples
were positive for cancer cell uPAR. CD44 and ALDH1 expression was significantly associated with
tumour cell uPAR (p=0.02 and 0.03 respectively, Table 3), with higher tumour uPAR expression in
CD44 and ALDH1 positive cases. There was no association between CD133 and uPAR expression.

Table 3: Association of CSC marker staining with uPAR staining (n=28). uPAR – urokinase
plasminogen activation receptor
CD44

Positive uPAR staining

P-value

Positive
Negative

7/15 (54%)
2/13 (13%)

0.02

Positive
Negative
ALDH1
Positive
Negative

1/9 (11%)
8/19 (42%)

0.10

9/12 (43%)
0/7 (0%)

0.03

CD133
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3.3.3

CSC marker expression and prognosis

In univariate analysis, CD44 positive cases had a poorer OS than CD44 negative cases (HR 2.9
95%CI 1.3 – 6.9, p=0.008, Table 4). Similarly, ALDH1 positive cases had a poorer OS than ALDH1
negative cases (HR 2.4 95%CI 1.1 – 5.7, p=0.04). There was no significant difference in OS between
CD133 positive and negative cases (HR 1.16 95% CI 0.57 – 2.4, p=0.67).

Figure 2: Kaplan-Meier survival curves for overall survival stratified by cancer stem cell marker
expression (a) CD44: univariate HR 2.9 95%CI 1.3 – 6.9, p=0.008. (b) CD133: univariate HR 1.16
95% CI 0.57 – 2.4, p=0.67. (c)ALDH1: univariate HR 2.4 95%CI 1.1 – 5.7, p=0.04
In multivariate analysis, after adjusting for performance status, tumour grade, and treatment, CD44
positivity remained a significant independent predictor of OS (HR 2.5 95%CI 1.1 – 6.2, p=0.04),
while ALDH1 became non-significant (HR 2.0 95%CI 0.86 – 5.1, p=0.1) (Table 4).
Expression of combinations of CSC markers was also assessed for association with OS. Patients with
CD44+ive/ALDH1+ive expression (14/36, 39%) had a significantly poorer OS in univariate (HR 4.1
95%CI 1.7 – 9.5, p=0.0006) and multivariate analysis (HR 4.0 95%CI 1.6 – 10.1, p=0.002). No
combination including CD133 was significantly associated with OS.
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Table 4: Univariate Analysis and Multivariate analysis (significant values in italics) ECOG –
Eastern Cooperative Oncology group; HR – Hazard ratio; GOJ –gastroesophageal junction; CI –
confidence interval; * Radiotherapy and surgery were given as palliative local treatments only and
therefore had no impact on survival, and were not incorporated into the multivariate model. Systemic
treatment included chemotherapy or immunotherapy.
Characteristic
ECOG performance status
0-1
2-4
Age
<65
≥65
Sex
Female
Male
Primary location
GOJ
Gastric
Site of Metastatic disease
Peritoneal/Omentum
only
All other sites
Histopathology
Well/mod
differentiated
Poorly differentiated
Treatment
None
Systemic Treatment
Radiotherapy
Surgery
CD44
Negative
Positive
CD133
Negative
Positive
ALDH1
Negative
Positive

Univariate
Hazard Ratio
(95% CI)

P

1
7.3 (2.1 – 25.0)

0.0014

1
1.1 (0.5 – 2.2)

0.79

1
1.5 (0.56 – 3.9)

0.42

1
0.55 (0.26 – 1.1)

0.09

1

0.16

Multivariate
Hazard Ratio
P
(95% CI)
1
1.2 (0.4 – 6.2)

0.75

1

0.007

0.60 (0.29 – 1.2)
1

0.0003

3.9 (1.8 – 8.6)

3.3 (1.4 – 7.9)

1
0.27 (0.12 – 0.62)
1.1 (0.5 – 2.9)
2.2 (0.6 – 7.5)

0.001

1
2.9 (1.3 – 6.9)

0.008

1
1.16 (0.57 – 2.4)

0.67

1
2.4 (1.01 – 5.7)

0.04
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0.71*
0.19*

1
0.28 (0.1 – 0.88)

0.03

1
2.5 (1.1 – 6.2)

0.04

1
2.0 (0.86 – 5.1)

0.1

3.4

Discussion

In the CSC model, establishment and progression of metastatic disease is due to the dissemination of
CSCs. While numerous previous studies have demonstrated expression of CSC markers in locoregional gastroesophageal cancer to be significantly associated with clinical outcomes, the current
study is the first to examine the expression of CSC markers in metastatic gastroesophageal cancer.
We found expression of CD44 and ALDH1, but not CD133, on metastatic deposits to be significantly
associated with poorer OS. In multivariate analysis, after adjusting for tumour grade, ECOG
performance status, and treatment received, CD44 expression remained a significant prognostic factor
associated with poorer OS (HR 2.5 95%CI 1.1 – 6.2, p=0.04). ALDH1 expression was not
significantly associated with OS in multivariate analysis (HR 2.0, 95% CI 0.86 – 5.1, p=0.1), although
the combination of CD44+/ALDH1+ive was strongly associated with poorer OS (HR 4.0 95%CI 1.6 –
10.1, p=0.002). This finding confirms previous work showing the importance of CSC expression,
particularly CD44, as a biomarker in gastroesophageal cancer24,27,34. Our results did not show any
association between CD133 with OS, either alone or in combination with CD44 or ALDH1. Recent
work suggests that only a subset of CD133 positive CSCs are essential for tumour metastases7. We
hypothesise that additional markers, such as CXCR4, are required in combination with CD133 to
identify this key subgroup.
We also found expression of CD44 and ALDH1 to be significantly associated with expression of
uPAR. Our results mirror previous work in other solid tumours showing co-expression of uPAR with
CSC markers50-52. In addition to a well characterised role in the uPA system, there is increasing
evidence suggesting uPAR has an important function in CSCs. uPAR overexpression is strongly
correlated with the CSC properties of an invasive phenotype, drug resistance, and poor prognosis53.
Moreover, signalling by uPAR induces stem cell like properties in breast, brain, lung and prostate
cancer cells46,47,54-56. To the best of our knowledge, this study is the first to show the co-expression of
CSC and uPAR in gastroesophageal cancers, and further supports the role of uPAR in CSCs.
In resected loco-regional gastroesophageal cancer, the proportion of CD44 and CD133 positive cases
is estimated at 17-77% and 10-44% respectively57. Our results demonstrated a similar proportion of
CD44 positive (44%) and CD133 positive (36%) cases, but a higher expression of ALHD1 than that
seen in locoregional disease (73% positive cases compared to 50-55%)24,38. This is despite using a
higher cut-off for positive cases (20% of cells stained compared to 10%). In addition, most ALDH1
cases were diffusely and strongly stained (mean proportion of positive cells 76%). Our results support
a previously identified trend of higher ALDH1 expression on local nodal deposits. In a study
comparing IHC expression of CSC between primary gastric cancers and matched lymph node
metastases, Wakamatsu et al also found a higher expression of ALDH1, but not CD44 or CD133, in
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the lymph nodes24. ALHD1 expression is strongly correlated with expression of matrix
metalloproteases (MMPs), which are essential for extracellular matrix degradation and establishment
of metastatic disease38.
We were unable to show any significant association between CSC staining and other important
clinicopathological factors. This is in contrast to other IHC studies which have shown strong
associations between poor pathological factors, such as TNM stage, tumour invasion and grade with
expression of CSCs17. The small sample size of our study is likely to be a contributing factor. It is
interesting to note we did not find a higher CSC expression in patients with previous chemotherapy
exposure. While CSCs are known to be relatively chemotherapy insensitive, leading to enrichment of
CSCs with chemotherapy, modern CSC models describe a dynamic CSC population with a
bidirectional pathway between CSC and differentiated cell populations58. As no patient had received
chemotherapy within 6 months prior to the biopsy, it is likely that the CSC population had reestablished equilibrium with the terminally differentiated tumour bulk.
The key role of CSCs in metastatic gastroesophageal cancer is supported by early clinical results of
agents targeting the CSC pathway. For example, in a phase II study using the hedgehog inhibitor
vismodegib with chemotherapy in metastatic gastric cancer, Yoon et al found a survival benefit
restricted to patients who had a high expression of CD4415. Even more novel approaches using the
combination of immunotherapy and CSCs are under investigation, with currently recruiting clinical
trials employing immune targeting of CSC using dendritic cells59. The coexpression of CSC markers
and uPAR may provide additional opportunities to target CSC using uPAR directed therapies52.
It is important to acknowledge several limitations of this study. Firstly, we found that most
gastroesophageal cancers, even when metastatic, have histological diagnosis on endoscopy and
biopsy, rather than biopsy of metastatic deposits. This limited the available patient population and
study size for the current work. Secondly, most samples used in the current study were biopsy
specimens, rather than larger resection specimens, which did not allow exploration of tumour
heterogeneity and differential expression of CSC makers. Thirdly, due to technical limitations, uPAR
staining was available for most, but not all patients, limiting incorporation into the multivariate OS
analysis.
In conclusion, expression of the CSC marker CD44 is an independent prognostic factor associated
with poorer OS in metastatic gastroesophageal cancer. This study provides further evidence that
expression of CSC markers a valid biomarker in gastroesophageal cancer, and highlights importance
of CSCs in all stages of gastroesophageal cancer.
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3.5 Appendix: uPAR expression in primary and metastatic gastroesophageal
adenocarcinoma (GOC).
3.5.1

Background

Expression of uPAR is a clinically relevant biomarker in resected gastroesophageal cancer (Chapter
245). High expression of uPAR in primary tumours is associated with high risk clinicopathological
features and poorer OS. Several studies have shown a strong association of uPAR staining in primary
tumours and the presence of lymph node and distant metastases in gastroesophageal cancer. As
demonstrated in Chapter 2 (Section 2.3.5) uPAR expression in the primary tumour was significantly
associated with nodal metastases (OR 2.5, p<0.0001), liver metastases (OR 2.5, p=0.01), and
peritoneal metastases (OR 3.2, p<0.0001).
There is however, much more limited evidence regarding uPAR expression on distant disease. One
study by Hong et al compared uPAR expression in primary tumours and matched regional lymph
nodes from 9 patients with gastric cancer, and found similar expression of uPAR in the primary (56%)
and lymph nodes (67%) 60. There are no studies directly comparing primary tumour uPAR expression
with distant metastases in gastroesophageal cancer. Using matched primary tumours and liver
metastases from 14 colorectal cancer patients, Illemann et al found only a minority of liver metastases
demonstrated a similar uPAR expression to the primary tumour, with most metastases exhibiting little
uPAR expression 61. In addition, as discussed in Chapter 1 (section 1.2.4.4), uPAR expression on
disseminated tumour cells (defined by CK+ phenotype) in the bone marrow following curative
treatment in locoregional disease, was significantly associated with subsequent disease relapse and
poorer clinical outcomes 62.
The uPA system is expressed on both cancer cells and the supporting stroma 42. uPAR is known to be
expressed by many cell types within the tumour, including cancer cells, macrophages, myofibroblasts,
neutrophils, and nerves. It is postulated that the expression of uPA and uPAR on stromal and tumour
cells, respectively, at the invasive front of a tumour, facilitate proteolysis required for invasion 63.
3.5.2

Aims

1) Compare uPAR expression between primary tumours and metastatic deposits in GOC
2) Determine the association of uPAR expression on GOC and overall survival using:
•

Expression at the tumour core or invading edge of tumour

•

Stromal (macrophages and myofibroblasts) and cancer cells uPAR expression
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3.5.3

Methods

uPAR expression of primary (n=12) and metastatic (n=33) tumour was analysed using IHC (methods
as per chapter 4). uPAR scoring was performed individually on cancer cells, macrophages, and
myofibroblasts. The proportion of uPAR positive cells was scored by evaluation of the whole slide.
Separate values were obtained for each cell type with the following scores: uPAR-score 0: No uPARpositive cells; uPAR-score 1: Less than 1% uPAR-positive cells; uPAR-score 2: 1–5% uPAR-positive
cells; uPAR-score 3: 5–10% uPAR-positive cells; uPAR-score 4: More than 10% uPAR-positive
cells. Neutrophil positive uPAR staining on each slide was used as an internal control.
In addition, all three cell types were scored separately for the invasion front at the tumour periphery,
and in the tumour core. As a consequence of limited tissue available in biopsy specimens, tumour
core scores were only available for 21 metastatic samples (63%), as most biopsy specimens included
only the invasion front of the tumour.
The association of uPAR expression and OS was determined for each cell type, at both the invasion
front and the tumour core. Given the small sample size and the absence of a standardised cut-off for
uPAR expression, a range of values for uPAR expression was tested on each cell type. The cut-off
with strongest association is presented.
3.5.4

Results

uPAR expression was evaluable on 45 samples in total (43 invasive front, 24 tumour core, 21 both).
Characteristics of included patients are shown in Table 1. Representative images of tumour and
stromal cell uPAR staining are shown in table A1.
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Table A1: Characteristics of included patients. Treatment subgroup total is greater than 45 as
individual patients may have received more than one treatment modality.
Characteristic
Age – median (range)
Age < 65 yrs
Age ≥ 65 yrs
Sex, n (%)
Male
Female
Primary tumour location
GOJ
Gastric body
Stage
II
III
IV
Site of biopsy
Primary tumour
Metastasis
Tumour Grade
Well/Mod diff
Poorly diff
ECOG performance status
0–1
2–4
Treatment
Chemotherapy
Radiotherapy
Surgery
Nil

Number (%)
65 (40 – 82)
21 (44)
24 (56)
37 (82)
8 (18)
17 (38)
28 (62)
8 (18)
3 (7)
34 (75)
12 (27)
33 (73)
23 (51)
22 (49)
39 (87)
6 (13)
29 (67)
7 (16)
14 (33)
8 (19)
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Figure A1: Three patterns of uPAR staining. a) There is widespread strong uPAR expression on
cancer cells (Ca) and macrophages and myofibroblasts (stromal cells, St). b) Strong stromal but weak
cancer cell staining. c) weak stroma staining with strong cancer cell
uPAR scores are summarised below (Table A2). There was non-significant trend to higher uPAR
expression on cancer cells in the invasion front (Chi Sq p= 0.069). There was no difference in
macrophage or myofibroblasts expression between tumour areas.

Table A2: uPAR expression score for Tumour Core and Invasion Front. Results are presented as
absolute values and percentages for each subgroup to facilitate comparison.
Cell Type
Tumour Core (n=24)
Cancer cell
Macrophage
Myofibroblast
Invasion Front (n=43)
Cancer cell
Macrophage
Myofibroblast

0 (%)

1 (%)

uPAR score
2 (%)

3 (%)

4 (%)

8 (33)
2 (8)
7 (29)

9 (38)
3 (13)
4 (17)

1 (4)
7 (29)
4 (17)

3 (13)
1 (4)
4 (17)

3 (13)
11 (46)
5 (21)

11 (26)
3 (7)
15 (35)

6 (14)
4 (9)
10 (23)

9 (21)
10 (23)
8 (19)

5 (12)
8 (19)
2 (5)

12 (28)
18 (19)
7 (16)
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3.5.4.1 uPAR expression at the tumour invasive Edge (n=43)
There was no significant difference in uPAR expression on tumour cells (mean uPAR score primary
tumours 1.8 vs 2.1, t-test p=0.62), myofibroblasts (mean 2.0 vs 1.2, p=0.1), or macrophages (mean 3.3
vs 2.6, p=0.08) (Figure A2) between primary and metastatic sample. Similarly, there was no
significant association between tumour cell uPAR score and clinicopathological variables such as
primary tumour location (Fishers exact p=0.08) or tumour grade (p=0.24).

Figure A2: Comparison of uPAR score between primary and metastatic samples. There was no
significant difference in uPAR score on a) tumour cells (p=0.62) b) macrophages (p=0.08) or c)
myofibroblasts (p=0.1)
In univariate analysis, uPAR expression on tumour cells was significantly associated with poorer OS
(uPAR score 2-4 compared to 0-1, HR 2.5 95% CI 1.1 – 5.6, p=0.02) (Figure A3, Table A3). In
contrast, there was no association with uPAR expression on macrophages (uPAR score 0-2 versus 3 4, p=0.9) or myofibroblasts (uPAR score 0-1 versus 2 -4, p=0.4), also it is interesting to note a trend
to improved survival with higher uPAR score on myofibroblasts, the opposite pattern seen on tumour
cells (Figure A2). As expected, other important prognostic factors including ECOG performance
status, primary tumour location, stage, histopathological grade, and receipt of treatment was
significantly associated with OS (Table A3).
The association of uPAR expression on tumour cells remained significant in multivariate analysis (HR
1.5 95% CI 1.1 – 2.1, p=0.0004) confirming uPAR expression as an independent prognostic factor
(Table 3).
When analysis is restricted to metastatic patients only (n=31), high uPAR score remains significantly
associated with poor OS in univariate (HR 2.5 95%CI 1.1 – 5.7, p=0.03) and multivariate analysis
(HR 1.5 95% CI 1.1 – 2.1, p<0.0001).
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Figure A3: Association of uPAR score with OS (n=43). Patients with a high uPAR score on a)
tumour cells have a significantly worse OS (p=0.02) but not b) macrophages (p=0.9) or c)
myofibroblasts (p=0.4)
Table A3: Univariate and multivariate analyses for invasion edge uPAR scores and OS. Cancer cell
uPAR expression was the only cell type with a significant univariate association with OS and
therefore the only uPAR score included in the multivariate model.
Characteristic
ECOG performance status
0-1
2-4
Age
<65
≥65
Sex
Female
Male
Primary location
GOJ
Gastric
Stage
II-III
IV
Histopathology
Well/mod differentiated
Poorly differentiated
Treatment
None
Yes
Cancer cell uPAR expression
0-1
2-4
Macrophage uPAR expression
0-2
3-4
Myofibroblast uPAR expression
0-1
2-4

Univariate
Hazard Ratio (95%
CI)

P

1
11.2 (3.2 – 39.9)

<0.0001

1
0.77 (0.4 – 1.6)

0.47

1
1.1 (0.4 – 3.0)

0.8

1
0.43 (0.20 – 0.90)

Multivariate
Hazard Ratio (95%
CI)

P

1
1.1 (0.2 – 5.8)

0.9

0.02

1
0.4 (0.1 – 0.9)

0.02

1
9.4 (2.2 – 40)

0.0002

1
6.3 (2.0 – 20.0)

0.001

1
4.3 (2.0 – 9.4)

<0.0001

1
1.7 (0.6 – 4.8)

0.3

1
0.23 (0.1 – 0.6)

0.004

1
0.5 (0.1 - .6)

0.0004

1
2.5 (1.1 – 5.6)

0.02

1
1.5 (1.1 – 2.1)

0.0004

1
1.0 (0.5 – 2.1)

0.9

1
0.75 (0.4 – 1.5)

0.4
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3.5.4.2 uPAR expression at the Tumour Core (n=24)
While there was no difference between uPAR expression on tumour cells between primary tumours
and metastatic deposits (p=0.8), we found a lower uPAR expression on macrophages (p=0.01) and
myofibroblasts (p=0.006) on metastatic sample (Figure A4).

Figure A4: Comparison of uPAR score between primary and metastatic samples (n=24). There was
no significant difference in uPAR score on a) tumour cells (t-test p=0.77) but significantly lower
uPAR scores on b) macrophages (mean uPAR score 3.5 vs 2.1, p=0.01) or c) myofibroblasts (mean
uPAR score 2.9 vs 1.2p=0.006)
Although limited by sample size, we did not find a significant association of tumour core cancer cell
(uPAR score 0-1 vs 2-4, p=0.2) or myofibroblasts (uPAR score 0-1 vs 2-4, p=0.9) uPAR score and
OS (figure A5). Patients with a higher uPAR score on macrophages had an improved OS (uPAR score
0-2 vs 3-4, HR 0.3 95% CI 0.1 – 0.7, p= 0.01). In view of the small sample size, no multivariate
analyses were undertaken.

Figure A5: Association of tumour core uPAR score and OS (n=24). While there was no significant
association between OS seen for a) cancer cell (p=0.2) or c) myofibroblasts (p=0.9), b) high
macrophage uPAR expression was significantly associated with improved OS (p=0.01)
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3.5.5

Discussion

Our results confirmed that uPAR expression on cancer cells at the invasive edge of tumours is an
independent prognostic factor in gastroesophageal cancer. After controlling for stage, primary tumour
location, ECOG performance status, and histopathological grade, cancer cell uPAR expression was
associated with poorer OS (HR 1.5, p=0.0004). This is consistent with previous studies as discussed
in chapter 2.
Moreover, we show that cancer cell uPAR expression at the invasive edge of tumours remains a
significant independent prognostic factor when analysis is restricted to metastatic deposits of
gastroesophageal cancers (HR 1.5, p<0.0001). uPAR expression on metastatic gastroesophageal
cancer has not been previously reported.
Consistent with the results of Hong et al 60, we found similar uPAR scores between primary and
metastatic tumour samples at the invading edge. Our results are in contrast to Illemann et al who
found all primary tumours, but only a minority (5/14 patients, 36%) of liver metastases, demonstrated
strong uPAR expression on tumour and stromal compartments on the invasive edge of the tumour61. It
is important to note however, that this study was conducted on liver metastases from colorectal
cancer, with most metastases exhibiting a pushing, rather than an invading, growth pattern.
Interestingly, we found contrasting results from the stromal uPAR staining in the tumour core. Not
only was there significantly lower expression of uPAR on stromal cells in the tumour core on
metastatic samples compared to primary tumours, higher macrophage uPAR score in the tumour core
was associated with an improved OS in univariate analyses (HR 0.3. p=0.01). Two previous studies
examining the prognostic association of uPAR expression on stromal cells within the tumour cores of
primary gastroesophageal cancers did not find significant prognostic associations43,64.
While provocative, there are three important caveats to these results. Firstly the metastatic samples
were taken from different patients to the primary samples, which introduce confounders into these
results. Ideally this study should be repeated using matched metastatic and primary tumour samples
from the same patient. Secondly, the uPAR score is presented as a proportion of cells expressing
uPAR, rather than an absolute number. Metastatic samples may have much higher numbers of
macrophages and myofibroblasts in the samples, leading to a lower proportion of uPAR positive cells
in primary tumours. We plan to re-stain these samples with CD68, a macrophage marker, to provide
clarity on this issue. Finally, it is important to acknowledge the limited numbers in this study which
limits definitive conclusion.
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3.5.6

Conclusion

uPAR expression on cancer cells at the invasive edge of metastatic tumours is an independent
prognostic factor in gastroesophageal cancer. We found provocative results regarding uPAR stromal
staining, particularly the improved survival associated with high macrophage uPAR expression in the
tumour core, which require further validation due to limitations addressed above.
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Abstract
Background/Aim: Circulating tumor cells (CTCs) are an important circulating biomarker in
gastroesophageal cancer. However current techniques for CTC isolation require prompt processing of
prospectively collected blood samples at specialised research facilities limiting widespread
application. This study aimed to demonstrate the feasibility of cryopreservation of peripheral blood
mononuclear cells (PBMCs) for prognostic CTCs detection in gastroesophageal cancer.
Method: 7.5 ml blood samples were collected in EDTA tubes from patients with gastroesopheagal
adenocarcinoma. CTCs were isolated by EpCAM based immunomagnetic capture using the IsoFlux
platform. Paired specimens from the same blood draw were used to compare CTC isolation from fresh
and cryopreserved peripheral blood mononuclear cells (PBMCs). CTCs isolated from pre-treatment
cryopreserved PBMCs were examined for associations with clinicopathological variables and survival
outcomes.
Results: While there was a significant trend to a decrease in CTC numbers associated with
cryopreserved specimens (mean number of CTCs 34.4 vs 51.5, p=0.04), this was predominately in
samples with a total CTC count of >50, with low CTC count samples less affected (p=0.06). Duration
of cryopreservation did not affect number of CTCs. CTCs were isolated in most patients (95.5%),
with higher CTC counts correlated with metastatic disease, and a CTC count >17 significantly
associated with a poorer overall survival in multivariate analysis (HR 3.7 95%CI 1.2 – 12.4, p=0.03).
Conclusion: We describe a feasible protocol for PBMC cryopreservation for delayed CTC isolation to
assist with sample collection, transporting and processing. A high number of CTCs in cryopreserved
specimens remained a poor prognostic factor in our validation cohort.
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4.1

Introduction

Circulating tumour cell (CTC) analysis continues to be a rapidly developing field in oncology,
offering a promising tool to both prognosticate and guide managements for patients1. Despite recent
advancements in the field, one persisting challenge to the widespread adoption of CTC analysis for
translational clinical trials or routine clinical care is the limited time frame considered best for blood
processing and CTC isolation. Usually fresh blood is processed for CTCs within 24 hours after blood
draw, requiring prompt transfer to specialised centres for CTC isolation and analysis, which offers
significant logistical challenges2. To overcome this issue, some studies use blood collection tubes that
contain fixatives. Fixation of blood samples can allow CTC processing delayed by several days which
has proven very useful for some CTC analyses3,4. However, fixatives may interfere with down-stream
molecular analyses that require isolation of nucleic acids5.
An alternative is the use of cryopreservation protocols for peripheral blood nuclear cells (PBMCs) to
allow delayed CTC isolation from these cells followed by CTC analysis. Cryopreservation should
overcome fixation related analysis limitations and allow a far more flexible time frames for batched
CTC processing. However, a defined, robust protocol that is proven to enable analysis of the same or
at least a relevant proportion of CTCs to that found in fresh samples, needs to be adopted and
confirmation is needed whether cryopreserved CTCs can still predict disease outcome.
The advantage of cryopreservation of PBMCs is that it requires only minimal local processing,
possible in most diagnostic settings, as well as feasible cryostorage and frozen transport of PBMC
samples.
While there are a large number of approaches used to isolate and identify circulating tumor cells
(recently reviewed by van der Toom et al6) , the best established and widely used is with the
CellSearchTM system (Menarini-Silicon Biosystems), which uses positive immunomagnetic isolation
of epithelial cell adhesion molecule (EpCAM, an epithelial cell marker) expressing cells followed by
cytokeratin (CK), CD45, and DAPI staining2. The CTCs are then identified with automated
immunofluorescence microscopy, defined by an EpCAM/CK/DAPI positive and CD45 negative
phenotype. CellSearch CTC counts have shown to be prognostic in large patient series in a variety of
cancers7-9, including gastroesophageal cancer10-12, but the instrument offers limited sensitivity in
resectable gastroesophageal cancer, with CTCs detected in less than 15% of patients10,13.
The IsoFlux system (Fluxion) uses a similar definition of CTCs to CellSearch (EpCAM/CK/DAPI
positive, CD45 negative phenotype), but has shown a greater sensitivity for CTC detection14-16. This
platform uses EpCAM targeted immunomagnetic isolation of CTCs within a microfluidic setting,
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improving isolation of CTCs with lower EpCAM expression, minimising leukocyte contamination,
and allowing downstream applications including staining, enumeration, or sequencing as shown for
fresh blood samples 16.
Here, we use a viable method of PBMC cryopreservation that allows subsequent isolation and
immunocytochemical analysis of CTCs. We demonstrate the feasibility of PBMC cryopreservation
for delayed CTC isolation using paired cryopreserved and freshly processed blood samples drawn at
the same time from patients with gastroesophageal adenocarcinoma. Importantly, we also provide
data confirming that cryopreserved CTCs remain clinically applicable as a circulating prognostic
marker for overall survival.

4.2
4.2.1

Methods
Patient Population

Blood samples were collected from patients with histologically confirmed distal oesophageal,
gastroesophageal junction, or gastric adenocarcinomas treated at Wollongong Hospital, Australia.
Blood samples were collected in 7.5 ml EDTA Vacutainer tubes (Sarstedt AG & Co.) and maintained
at room temperature until processing.
In the initial cohort (Cohort 1) to confirm the feasibility of cryopreservation, 15 patients with
gastroesophageal carcinomas had 2 specimens taken during the one blood draw, one processed within
24 h (“fresh” specimen), and one cryopreserved with delayed CTC isolation and analysis
(“cryopreserved” specimen). Pre-treatment blood samples were cryopreserved from a second, larger
cohort of patients for correlation with clinical outcomes (Cohort 2). The study was approved by
South Western Sydney Local Health District Human Research Ethics Committee (Project Number
15/072). A written informed consent was obtained from each participant before sample collection.
4.2.2

Sample Preparation

Blood samples were processed within 24 h to recover the PBMC fraction using 50 ml SepMate tubes
and Lymphoprep according to manufacturer’s instructions (Stemcell Technologies, Vancouver, BC,
Canada).
PBMCs used for fresh analysis were resuspended in Isoflux Binding Buffer and immediately
processed for CTC isolation (see below). PBMCs for cryopreservation were well resuspended in 1 ml
of diluted plasma (the supernatant of the PBMC preparation from the matching patient) with the
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addition of 7.5% final DMSO, and stored at -80°C until further processing. Cryopreserved samples
were thawed according to the protocol from Fluxion Biosciences, San Francisco, California, USA 17.
In brief, warmed (37°C) thawing buffer, consisting of RPMI 1640 with 10% Fetal Bovine Serum
(FBS, Bovogen Biologicals, Australia) and 50 Unit/ml Benzonase (Sigma-Aldrich, Germany), was
added to thawed samples, washed once in thawing buffer, and resuspended in IsoFlux Binding Buffer
with 5% FBS.
4.2.3

Circulating Tumor Cell Isolation, staining, and imaging

As per Fluxion protocol, immunomagnetic beads preconjugated with anti-EpCAM antibodies (CTC
Enrichment Kit; Fluxion Biosciences Inc) were added to PBMCs suspended in IsoFlux Binding
Buffer, and incubated for 90 min at 4°C with passive mixing on a rotator. Samples were then loaded
into the sample well of the microfluidic cartridge and underwent immunomagnetic isolation of CTCs
with the IsoFlux using the standard protocol (Fluxion Biosciences Inc).
Recovered CTCs were blocked with a final concentration of 1.2 µg/µl mouse IgG in binding buffer
(Jackson ImmunoResearch, Baltimore, PA) for 30 min, washed and fixed in fixing solution (Fluxion
Biosciences Inc). The CTCs were then blocked in 10% FBS in binding buffer for 15 min, then
underwent immunofluorence staining for anti-CD45 antibody conjugated to Alexa Fluor 647
(Biolegend, Clone HI30). The CTCs were also stained for urokinase plasminogen activator receptor
(uPAR, CD87), a key receptor in the plasminogen activator system and clinically relevant biomarker
in primary gastroesophageal cancer 18 (see also Chapter 5 Appendix), using anti-uPAR antibody
conjugated to AF594 (ThermoFischer, Clone R4). After permeabilization with 0.1% Triton X-100,
cells were probed with anti-cytokeratin antibody conjugated to FITC (Sigma-Aldrich, Clone PCK-26).
CTCs were finally stained with Hoechst and mounted using Isoflux mounting media to 24-well glass
bottom plates (MoBioTec, Goettingen, Germany) for imaging.
Imaging was performed with an inverted epifluorence microscope (Leica DMi8, Leica Microsystems
Pty Ltd) using the Leica Application Suite. Cells were considered CTCs if they were CK positive,
CD45 negative, nucleated and morphologically intact. The proportion of uPAR positive CTCs was
recorded.
4.2.4

Statistical Analysis

The CTC recovery from matched cryopreserved and fresh samples were compared with the paired ttest. Correlation between cryopreservation time and CTC number was described with a Pearson
correlation coefficient, and the Fisher exact test and t-test were used to compare the status of CTCs
with categorical clinicopathologic factors.
121

For survival analyses, in the absence of established cut-offs for prognostic CTC numbers, the median
CTC count (17) was used as the discriminator between high and low CTC counts. Survival analyses
are conducted using Kaplan-Meier methods, with median survival reported. Unadjusted and
multivariable Cox proportional hazards regression analyses were used to estimate the association
between CTC counts and survival, and to calculate corresponding hazard ratios (HRs) and 95%
confidence intervals (CIs). The following variables were included in the multivariate model: age, sex,
ECOG, TNM stage, primary tumor location, and CTC count. All statistical analyses were performed
using SAS 9.2 software (SAS Institute, Inc., Cary, NC).
4.3
4.3.1

Results
Matched fresh and cryopreserved specimens (Cohort 1)

Matching parallel blood samples, collected from 15 gastroesophageal cancer patients (10 patients had
blood taken prior to treatment, 5 patients were already on treatment), that had either been
cryopreserved before CTC processing or were processed fresh, were compared. Cryopreservation of
PMBCs lasted from 2 weeks to 25.2 months (median 14.6 months). There was no significant
correlation between cryopreservation time and CTC number (Pearson r -0.25, p=0.09). CTCs isolated
from cryopreserved samples appeared morphologically similar to fresh samples (Figure 1). There was
an overall trend for smaller detectable CTC numbers isolated from the cryopreserved samples
compared to fresh samples that reached significance (mean number of CTCs 34.4 cryopreserved vs
51.5 fresh, p=0.04, Figure 2), however this difference was predominately attributable to a larger fall in
CTC numbers in samples with very high CTC counts (>50 CTCs in the fresh specimen). There was no
significant difference in CTC count between cryopreserved and fresh samples for specimens with
CTC count less than 50 (n=11 patients, mean number of CTCs 10.7 vs 16.3, p=0.06). Thus CTC loss
by cryopreservation in patient samples with low CTC counts appears relatively minor (mean
proportion of CTCs lost in cryopreserved samples = 23.95%).
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Figure 1: Representative images of CTC isolation from fresh and cryopreserved samples
demonstrating preservation of leukocyte and CTC morphology. The fresh sample demonstrates a
nucleated CK+/CD45- CTC which is uPAR negative, as well as a CK-/CD45+ leukocyte. The
cryopreserved sample shows a uPAR positive CTC.

Figure 2: CTC enumeration by processing method. Mean number of CTCs isolated in the fresh
specimens were higher than in the matched cryopreserved sample (mean difference in CTCs 17.1
95%CI 0.7 – 33.6, p=0.043). This difference was mostly driven by larger falls in CTC counts in
samples with high numbers of CTCs (>50 CTCs in fresh samples), with no significant difference in
CTC counts for samples with less than 50 CTC in the fresh specimen (p=0.06).
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4.3.2

Cryopreserved CTCs and clinical outcomes (Cohort 2)

A larger cohort of 43 gastroesophageal cancer patients (Cohort 2) was analyzed to validate whether
detectable CTC counts post cryopreservation correlated to disease outcomes. All patient samples were
taken prior to treatment commencement and had undergone cryopreservation before CTC isolation.
Cohort 2 included the 10 treatment naive patients from Cohort 1. Patient characteristics of Cohort 2
are summarised in Table 1. 24 patients had resectable disease (Stage II or III). Post CTC evaluation,
11 of these patients received neoadjuvant chemoradiotherapy prior to resection (CROSS regimen19 –
weekly carboplatin AUC2 and paclitaxel 50mg/m2 with concurrent radiotherapy), 3 received
perioperative chemotherapy (MAGIC regimen20 – three preoperative and three postoperative cycles of
epirubicin 50mg/m2 and cisplatin 60mg/m2 on day 1, and continuous fluorouracil infusion
200mg/m2/day for 21 days), and 10 had surgery alone. 19 patients had metastatic disease (stage IV).
Most of these patients received chemotherapy (7 patients: platinum and capecitabine doublet, 3
patients: anthracycline, capecitabine, and platinum triplet, 1 patient: irinotecan or paclitaxel
monotherapy), immunotherapy (2 patients), and 6 patients received no active systemic treatments.

Age
Sex

CTC count

All Patients
[%]
n=43

Low
[CTC≤17]
n=23

High
[CTC >17]
n=20

Mean (range)

64 (39 – 89)

65 (39 – 89)

64 (48 – 83)

Male
Female

32 (74.4 %)
11 (25.6 %)

15 (65.2 %)
8 (34.8 %)

20 (85.0 %)
3 (15.0 %)

ECOG

0-1
36 (83.7 %)
22 (95.6 %)
14 (70.0 %)
2-4
7 (16.3 %)
1 (4.3 %)
6 (30.0 %)
Primary Tumor Location
Distal Oesophageal
12 (27.9 %)
8 (34.8 %)
4 (20.0 %)
Gastroesophageal junction
14 (32.6 %)
4 (17.4 %)
10 (50.0 %)
Gastric
17 (37.5 %)
11 (47.8 %)
6 (30.0 %)
Stage
II
18 (41.9 %)
13 (56.5 %)
5 (25.0 %)
III
6 (14.0 %)
4 (17.4 %)
2 (10.0 %)
IV
19 (44.2 %)
6 (26.1 %)
13 (65.0 %)
Table 1: Characteristics of patients in Cohort 2. CTC – circulating tumor cell; ECOG – Eastern
Cooperative Oncology Group performance status
CTCs were detected in 42/43 patients (95.5%), with a median CTC of 17 (interquartile range 8 – 38).
Patients with metastatic disease had a higher number of CTCs than those with resectable disease
(Figure 3, mean CTC count 53.8 vs 15.8, p=0.0013).
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Figure 3. Circulating tumor cell count by stage. CTC processing post cryopreservation produced a
higher mean CTC count in metastatic patients compared to the resectable patients (mean CTC in
metastatic 53.8 vs resectable 15.8, p=0.0013).
Currently there are no established cut-offs for prognostic CTC numbers detected using the IsoFlux in
gastroesophageal adenocarcinoma. Therefore we opted to divide our patients by their CTC counts,
above versus equal or lower than the median CTC count, to test for any correlation with clinical
outcomes. Patients with a high CTC count (>17) had a poorer overall survival (OS) than those with a
lower CTC count (≤17) (Figure 4, median OS 2.8 vs 23.2 months, HR 4.4: 95%CI 1.7 – 11.7,
p=0.0013).

Figure 4: Overall Survival by CTC count. Patients with >17 CTCs isolated from cryopreserved
specimens had a poorer overall survival compared to those with ≤17 CTCs (median OS 2.8 vs 23.2
months, HR 4.4: 95%CI 1.7 – 11.7, p=0.0013).
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In multivariate analysis, after controlling for sex, age, stage, ECOG performance status, and primary
tumor location, a high CTC count remained an independent prognostic factor associated with poor
OS (Table 2, HR 3.7 95%CI 1.2 – 12.4, p=0.03). This association was stronger when the analysis was
restricted to patients with metastatic disease (n=19, HR 5.5 95%CI 1.2 – 25.5, p=0.01), but not
observed in patients with resectable disease (n=24, p=0.39), although a high CTC count (>17) was
associated with a non-significant trend to shorter recurrence free survival in these patients (HR 3.1
95% CI 0.8 – 12.6, p = 0.09).

Factor
CTC count (high vs low)

Univariate
HR (95%CI)
P
4.4 (1.7 – 11.7)
0.001

Age (≥65 vs <65 years old)
ECOG (2-4 vs 0-1)

0.7 (0.3 – 1.8)
7.2 (2.2 – 23.7)

0.46
0.0002

Sex (male vs female)
Stage (IV vs II-III)

1.2 (0.4 – 3.8)
10.0 (3.3 – 30.8)

0.7
<0.0001

Multivariate
HR (95%CI)
P
3.7 (1.2 –
0.03
12.4)
1.0 (0.9 – 1.1)
0.76
2.3 (0.5 –
0.14
10.1)
0.7 (0.2 – 2.1)
0.49
9.9 (2.9 –
0.0003
33.8)
0.4 (0.2 – 1.6)
0.22

Primary tumor location (gastric vs
0.3 (0.1 – 1.01)
0.05
oesophageal/GOJ)
Table 2: Univariate and Multivariate analysis for overall survival for Cohort 2 (n=43). Significant

values are italicised. In both univariate and multivariate analysis, a high CTC count (>17) remained
statistically significant as an independent factor associated with poorer overall survival. CTC –
circulating tumor cell; ECOG – Eastern Cooperative Oncology Group performance status; GOJ –
gastroesophageal junction
Most patients had some uPAR positive CTCs (40/43, 93.0%), however the proportion of uPAR
positive CTCs was similar between patients with localised and metastatic disease (mean proportion
uPAR positive CTCs 48.8% vs 47.7% respectively, p=0.89), and there was no association with
survival outcomes (Supplementary Figure 1, median OS 17.0 vs 12.8 months, p=0.6).

4.4

Discussion

In this study we report the reliable isolation, immunocytochemical identification, and enumeration of
gastroesophageal cancer CTCs from cryopreserved PBMCs using the IsoFlux platform. The included
cohort is the largest reported study analysing cryopreservation of patient PBMCs for CTC detection.
Our data confirms that CTCs isolated from cryopreserved samples remain an independent prognostic
factor associated with overall survival.
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The timely processing of patient samples for CTC isolation, usually is recommended within 24 h for
most isolation methods21, presenting significant logistical challenges for researchers and prohibits
inclusion of patients from remote areas into clinical trials that would rely on CTCs as outcome
measures. This is mainly because current methods of CTC analysis require significant expertise,
instrumentation, time and laboratory resources, usually performed in specialised research centres.
Protocols using isolation of CTCs from cryopreserved specimens, even though they require some
basic processing and cryopreservation at the site of blood draw, offer many advantages, including the
ability to biobank patient samples for prolonged periods of time before central processing. This would
be a huge benefit for larger scale clinical trials as it would allow inclusion of geographically separated
sites.
Previous work has shown that the immunochemical properties CK, EpCAM and CD45, central to the
isolation and identification of CTCs, are not affected by cryopreservation and thawing22,23. In
agreement, our results demonstrate a similar morphological and immunofluorescent profile between
cryopreserved and fresh CTCs and leukocytes, suggesting current techniques are suitable for
cryopreserved samples. This approach is further supported by other work showing close concordance
in genetic alterations seen on paired fresh and frozen CTCs23.
Given our previous findings that the uPA system is a clinically relevant biomarker in primary
gastroesophageal cancer 18, we undertook and successfully probed for uPAR expression in CTCs
derived from cryopreserved and fresh samples. We previously have shown that higher expression of
uPA, uPAR and PAI-1 in the primary tumour is associated with higher risk disease and poorer
prognosis however, in this study there was no correlation between CTC uPAR expression with disease
parameters. This suggests that the selection of epithelial (EpCAM-positive) CTCs might have affected
any correlation of uPAR with patient outcome, as CTCs that present mesenchymal phenotypes, such
as uPAR expressing cells, can escape standard methods of isolation reliant on epithelial markers24.
Indeed Vishnoi et al. has previously reported the isolation of subsets of EpCAM-negative, uPAR and
integrin β1 positive breast cancer CTCs, which further supports the concept of CTC heterogeneity25.
Ultimately, we have successfully stained for a novel biomarker, uPAR, which further supports our
crypreservation method as a valid CTC isolation approach.
One important concern with cryopreservation is the potential for loss of CTCs due to cell loss during
freezing, storage, or thawing. In a study by Nejlund et al, who cryopreserved buffy coats in dimethyl
sulfoxide mixed with Roswell Park Memorial Institute 1640 medium, tumor cell recovery from
cryopreserved spiked tumor cells in normal controls was variable, with up to a 40% tumor cell loss22.
However in clinical samples using matched fresh and cryopreserved specimens from the same patient,
there was no consistent loss of CTCs, with the variation in CTC enumeration similar to those seen in
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paired fresh samples in other studies 2,22. Friedlander et al found that cryopreservation of PBMCs had
no significant effect on the cell recovery from patients with metastatic prostate cancer23. Similarly, Li
et al found no significant loss of spiked tumour cells in cryopreserved PMBCs, but reported a longer
elapsed time (greater then 2 hours) between blood draw and crypreservation reduced reproducibility
of CTC measurement, and altered cell morphology26. We noted a small loss of CTCs associated with
cryopreservation, however this was predominately in samples with large numbers of CTCs (>50),
where loss of some CTCs is more acceptable than samples with low CTC counts. We noted samples
with high numbers of CTCs were more prone to cell clumping despite benzonase. This is normally
due to the release of viscous DNA from cell death on thawing, leading to aggregates which prevent
accurate CTC counting. We speculate that the higher disease burden in these patients, coupled with a
corresponding systemic inflammatory response, lead to poorer cell viability within the PBMCs of
high CTC-count samples. Some loss of CTCs in these samples will have little impact for prognostic
and down-stream biomarker analysis purposes. There was no significant loss of CTCs in samples
where the total CTC count was ≤50 (p=0.06).
Similar to previously published work, we found that duration of cryopreservation was not correlated
with number of isolated CTCs22. Moreover, we were able to isolate CTCs from specimens stored at 80C for over two years, suggesting cryopreservation is a suitable approach for long term projects that
involve biobanking of patient samples.
Even using cryopreservation prior to CTC isolation, we found higher numbers of CTCs (median CTC
count 17) and a higher number of patient samples with CTCs (98%) compared to other studies using
EpCAM based CTC capture in gastroesophageal cancer10-12,27. The correlation of CTC numbers with
disease progression implies that the CTCs we identified are indeed disease related. Increased CTC
counts are consistent with the higher reported sensitivity of the IsoFlux system compared to other
platforms, particularly in isolating CTCs with a lower expression of EpCAM14-16. Our results confirm,
in the largest cohort of patients reported to date, that a high CTC count (>17) in cryopreserved
specimen was an independent prognostic factor associated with poorer OS (HR 3.7). As expected
from the minimal CTC loss during cryopreservation, these data indicate that indeed our method is
suitable for delayed and centralised CTC analysis which could help recruiting patients for major
clinical trials. In this setting it would be advantageous compared to fixation of blood which allows
CTC processing delayed by only several days rather than long term biobanking. We are currently
testing if cryopreservation is also able to overcome limitations associated with using fixative for
molecular down-stream analysis of CTCs that involves nucleic acid extraction4,5.
In conclusion, we have tested a robust PBMC cryopreservation protocol that allows successful CTC
isolation even 2 years post freezing. Cryopreservation of CTCs is feasible, with a small loss of tumor
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cells predominantly in samples with a high CTC load. Enumeration of CTCs from cryopreserved
samples remained a clinically important prognostic biomarker. Cryopreservation may assist with the
wider incorporation of CTC collection and analysis in biobanking, retrospective studies, and large
international clinical trials, by facilitating specimen storage, bulk transporting, and batch processing.
It may also help to develop diagnostic settings that can service even remote patients with diagnostic
CTC data potentially relevant for their disease management.
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Supplementary Figure 1: uPAR and CTCs (a) There was a similar proportion of uPAR positive
CTCs in patients with localised and metastatic disease (mean proportion uPAR positive CTCs 48.8%
vs 47.7% respectively, p=0.89) (b) Patients with >50% CTCs positive for uPAR had a similar overall
survival compared to those with ≤ 50% uPAR positive CTCs (median OS 12.8 vs 17.0 months,
p=0.60)
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4.5 Appendix: Expression of uPAR on CTCs in gastroesophageal cancer
4.5.1

Background

A major challenge in CTC research is the development of an ideal marker, or combination of markers,
to isolate and detect the rare CTCs within the large numbers of benign cells1. The CellSearch system
- the only current FDA approved CTC system, uses positive immunomagnetic isolation of EpCAM
(an epithelial cell marker) positive cells using anti human EpCAM antibody labelled magnetic beads.
The cells are counterstained post enrichment with cytokeratins (a second epithelial marker to improve
specificity), DAPI (nuclear stain), and CD45 (a leukocyte marker)2. The CTC is then identified with
automated immunofluourescence microscopy, defined by an EpCAM/CK/DAPI positive and CD45
negative phenotype. Enumeration of CTCs using this approach have been shown to be clinically
relevant prognostic biomarker in a range of cancers including breast7, bowel8, and prostate cancer9,
and is the most widely accepted definition of CTCs.
However there are increasing limitations recognised with this phenotype definition. CTCs undergoing
epithelial-mesenchymal transition (EMT), an essential step in the passage of malignant cells into the
blood steam for transit to distal metastatic sites, are known to downregulate EpCAM and CK which
leads to a reduced sensitivity in detecting CTCs28. In addition, modelling studies suggest that 1 in 60
million CTCs using the standard phenotype form viable metastases29, and there have been studies
reporting long term (>22 years) persisting CTCs with no clinically visible disease30. Therefore there is
a need to develop additional markers to improve sensitivity and specificity of CTC detection.
The uPA system is the key proteolytic pathway to facilitate invasion of cancer cells into stromal tissue
(Section 1.2.3.1). uPAR has been identified as an important marker on CTCs in breast cancer, with
uPAR+ CTCs enriched for stem cell pathways, as well as being able to adhere, proliferate and invade
in vitro 25. While there are no studies examining expression of the uPA system in gastroesophageal
cancer CTCs, there are some compelling results supporting the importance of uPA system in
disseminated tumour cells (DTC) in bone marrow. DTCs are thought to represent the fraction of
CTCs capable of entering distant sites as the first step in establishing metastases 31. Allgayer et al
used CK18 to identify DTC in the bone marrow in 156 patients who had undergone a curative
resection for localised gastric cancer. They found while overall CK18+ DTC was not associated with
prognosis, the CK18+/uPAR+ subset was, suggesting uPAR identifies the critical subpopulation for
establishment of metastases 32,33.

131

This study had two aims;
1. Correlate CTC uPAR expression with tumour tissue uPAR expression in patients with GOC and;
2. Determine the prognostic significance of CTC uPAR expression in GOC patients
4.5.2

Methods

CTC isolation and detection was performed as per Chapter 5 methods. It is important to note CTCs
were isolated using the Isoflux system with EpCAM based CTC capture. CTC uPAR expression was
characterised by proportion of CTCs (CK+/EpCAM+/DAPI+/CD45- cells) which stained positive for
uPAR.
Eighteen patients from the CTC cohort (18/43, 42%) had FFPE tissue available for uPAR staining
(see Chapter 4 for methods). uPAR expression in the tumour tissue was scored as followed: 0- No
uPAR-positive cells; 1- Less than 1% uPAR-positive cells; 2- 1–5% uPAR-positive cells; 3- 5–10%
uPAR-positive cells; 4- More than 10% uPAR-positive cells as previously reported for
gastroesophageal cancer 34,35. The tumour cell uPAR score at the invading edge was used for the
tumour tissue uPAR score as data was limited for tumour core samples and is further justified by
results from Chapter 3. Neutrophils were used as internal positive controls for uPAR staining on each
slide.
4.5.3

Results

4.5.3.1 CTC and tissue uPAR expression
There was a trend to increased proportion of uPAR positive CTCs with increased tumour tissue uPAR
score (Figure A1).
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Figure A1: Correlation of tumour tissue uPAR score and proportion of CTCs positive for uPAR (n =
18; p=0.03).
Different cut-off levels for %CTCs positive for uPAR were analysed for significant association with
tissue FFPE score (Figure A2). There was no significant association using a 50% cut-off (MannWhitney test, p=0.09). However, patients with ≥60% of CTCs positive for uPAR were more likely to
have a higher tumour tissue uPAR score than patients with <60% CTCs positive for uPAR (mean
tissue uPAR score 1.3 versus 3.3, p=0.0008).

Figure A2: Association of proportion of CTCs positive for uPAR and tumour tissue uPAR score
using a) 50% or b) 60% cut-off.
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4.5.3.2 CTC uPAR expression as a prognostic biomarker
While CTC number was significantly associated with prognosis (Chapter 4), the proportion of CTCs
positive for uPAR was not significantly associated with survival despite a variety of cut-offs tested.
Absolute number of CTCs positive for uPAR (using 10 uPAR positive CTCs) had a non-significant
trend for OS, but this appeared predominately driven by the total number of CTCs (Figure A3).

Figure A3: CTC counts and association with OS (n=43 for all analyses). a) Total CTC count is
significantly associated with OS (see Chapter 5 for details) b) number of uPAR positive CTCs shows
a non-significant trend with OS (p=0.06). There is no association with proportion of CTC uPAR
positive with OS using any cut-off including c) 50% (p=0.6) or d) 60% (p=0.5).
4.5.4

Discussion

There are three principle findings from this study. Firstly, we found only a weak association between
CTC uPAR expression and tumour tissue uPAR score, with patients ≥60% of CTCs positive for
uPAR having a higher tissue uPAR score than those with <60% CTCs positive for uPAR. Secondly,
while there were more CTC in metastatic disease than in localised disease, there was no significant
difference in proportion of CTCs positive for uPAR. Thirdly, we did not find any association between
CTC uPAR expression and OS. While there was a trend to poorer OS with < 10 uPAR+ CTCs
compared to ≥10 uPAR+ CTC, this was driven predominately by the total CTC number.
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The above conclusions are tempered by the selection bias of CTCs used in our study. We employed
EpCAM immunomagnetic positive selection of CTC prior to staining and enumeration, leading to the
omission of CTCs which have downregulated EpCAM as part of EMT. In the study by Allgayer et al,
which demonstrated the strong association of uPAR expression on bone marrow DTC with risk of
recurrent disease in resected gastroesophageal cancer 32, DTCs were defined solely by the CK+
phenotype. Although using EpCAM isolation improves the reliability and specificity of CTC
isolation, it introduces the potential to miss important subsets of CTCs. Indeed, it has been postulated
that the EpCAM- CTC population have the strongest potential to form distant metastases, and uPAR
expression on these CTCs is a key determinate in breast cancer dormancy mechanisms 25. We
hypothesise that poor prognosis of tumours associated with high uPAR expression may be
characterised by a higher proportion of EpCAM-/uPAR+ CTCs, which may be crucial for
establishment of metastases. New strategies to account for these EMT-CTCs are emerging in recent
years36,37 and it would be interesting to use such CTC isolation methods to study uPAR expression on
CTCs more comprehensively in gastric cancer.

4.5.5

Conclusion

There is no benefit to the addition of uPAR to the standard markers in EpCAM selected CTCs in
GOC.
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Abstract:
Most patients with advanced cancer have circulating tumour cells (CTCs) which can be detected in
peripheral blood samples. CTC enumeration and profiling has been established as a valuable clinical
tool in many solid malignancies including gastroesophageal cancer, particularly for prognostication
and monitoring of treatment efficacy. A key challenge in CTC research is the very limited number of
cells available for study. Long term CTC culture permits expansion of these rare cell populations for
detailed characterisation, functional assays including drug sensitivity testing, and investigation of the
pathobiology of metastases.
We report for the first time the establishment and characterisation of two long term CTC cultures
from patients with gastroesophageal cancer. The two cells lines (designated JICTC and RFCTC)
exhibit distinct genotypic and phenotypic profiles which are consistent with the tumours of origin.
JICTC exhibits an EpCAM+, cytokeratin+, CD44+ phenotype, while RFCTC which was derived from
a patient with metastatic neuroendocrine cancer, displays an EpCAM-, weak cytokeratin phenotype
with strong expression of neuroendocrine markers. Both cell lines demonstrated rapid tumorigenic
growth in immunodeficient mice.
Both cell lines have similar characteristics to their cancer of origin and show distinct differences to
drug and radiation treatment. The establishment of these two cancer CTC lines will now enable a
greater understanding of the biological processes driving gastroesophageal disease progression and act
as a valuable tool to study drug responsiveness both in vitro and in vivo.
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5.1

Introduction

Gastroesophageal cancers are among the most common and lethal cancers worldwide1. Most patients
present with locally advanced or metastatic disease, or develop recurrent disease following curative
surgery2. While many systemic treatment options are available, the prognosis of advanced
gastroesophageal cancer remains poor, with median survival less than 1 year3. Greater than >90% of
gastric and gastroesophageal junction cancers are adenocarcinomas, with gastrointestinal stromal
tumours (GIST), lymphomas, and neuroendocrine tumours found in a small minority of cases4.
Most patients with gastroesophageal cancer will require systemic treatment at some point in their
disease management3. There is an increasing recognition of the limitations of using primary tumour
features to guide systemic cancer treatment, due to tumour heterogeneity and the frequent disparity
observed between primary and metastatic sites5. Metastatic biopsies are rarely undertaken however
due to both inaccessibility of metastatic sites and procedure morbidity. Circulating tumour cells
(CTCs) are the likely intermediates of metastasis dissemination of cancer, and as such, can be
expected to include the subpopulations which are responsible for disease progression6. While CTC
enumeration has an established prognostic role, the true promise of CTCs is to provide a ‘real time’
view of the cancer using only peripheral blood samples, avoiding the need of repeat invasive
biopsies7.
Moreover, while most cancer deaths are due to the haematological spread of metastases, research into
the mechanism of metastasis initiation, formation, and propagation has been hampered by limited
access to cancer cells within the various stages of the metastatic cascade. CTCs provide a unique
window into the biology of cancer as it spreads through the blood stream. The rarity of CTCs
compared to normal blood cells has provided significant technical challenges for sensitive but also
specific isolation methods8.
CTC culture provides an expanded cell population for expression analysis, functional assays, and drug
sensitivity screening 9,10, and long term primary CTC cultures provide an ideal laboratory tool for the
investigation of the biology of metastasis formation11. Establishment of long term primary CTC cell
cultures has proved to be challenging. To date, despite intensive efforts, only several long term CTC
cultures have been reported worldwide, including in colorectal12, breast13, and prostate14 cancer, all
established with modest success rates, with 1-16% of blood samples producing stable cultures. To
improve culture rates, initial expansion of the CTC population using xenotransplation into
immunodeficient mice prior to in vitro culture has been trialled 15,16.
In this current work we describe the establishment and characterisation of two novel CTC cell lines
derived from patients with metastatic gastroesophageal cancer. To the best of our knowledge, this is
the first report of long term CTC cultures established in gastroesophageal cancer.
142

5.2

Methods
5.2.1

Patient selection and blood collection

Peripheral blood samples were collected from patients with metastatic gastroesophageal cancer prior
to treatment. Patients had histologically confirmed gastric or gastroesophageal cancer treated at the
Illawarra Cancer Centre, Wollongong Hospital, NSW Australia. Informed consent was obtained from
each patient prior to enrolment, and the study was approved by South Western Sydney Local Health
District Human Research Ethics Committee (Project Number 15/072).
Initially 7.5 ml of blood was collected in EDTA tubes. This was increased to 15 ml after seventeen
patients were enrolled for higher CTC capture to improve culture success rates. Blood samples were
transported immediately at room temperature for CTC isolation. A second 7.5 ml EDTA blood sample
was collected at the same blood draw from each patient for EpCAM based capture for CTC
enumeration using the Isoflux System, and processed as per manufacturer instructions17. Enumerated
CTCs were defined by the standard EpCAM/Cytokeratin/DAPI positive and CD45 negative
phenotype18.
5.2.2

CTC isolation and cell culture

Blood samples were incubated for 20 min with RosetteSep CTC Enrichment Cocktail with anti CD36
(Stemcell Technologies) prior to a density gradient separation with LeucoSep tubes (Stemcell
Technologies) to isolate a peripheral blood mononuclear cell (PBMC) layer. We found excessive
lymphocyte contamination prohibiting CTC growth with the RosetteSep Human CD45 Depletion
Cocktail which was improved with the CTC Enrichment Cocktail. The PBMC layer was washed twice
PBS, then immediately plated into 24 well ultra-low attachment plate (Corning) with serum free
Advanced DMEM (ADMEM; Sigma Aldrich) supplemented with epidermal growth factor, fibroblast
growth factor and N2 supplement, or ADMEM with 10% foetal calf serum (FCS) in hypoxic
conditions. All media was supplemented with antibiotics (see Supplementary Table 1 for media
formulations).
Patient 41 was noted to have marked peritoneal disease and gross ascites from gastric
adenocarcinoma. At the same time as the blood draw for CTC isolation, 200 ml of ascitic fluid was
collected from a peritoneal catheter. This sample was transferred immediately to the laboratory,
washed twice in ADMEM with 1% antibiotic/antimycotic (Sigma Aldrich), and cultured as per
conditions described above. Cultures derived from the CTC and ascites were maintained
independently under identical conditions. For all subsequent cell culture and experimental assays,
cells were maintained in ADMEM with 10% FCS and EGF.
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5.2.3

Immunohistochemical analysis of patient samples, cell lines, and mouse xenografts

Expression of key proteins on the cell lines, mouse xenografts, and representative sections from the
matching patient’s tumour specimen were compared using immunohistochemistry (IHC). For cell
lines, cells were collected, centrifuged with supernatant removed, then clotted with plasma and
commercially prepared thrombin (Fibriprest Automate from Stago) to prepare a cell block. All
samples were fixed in 10% formalin and then paraffin embedded, with 4 µm sections cut for staining.
Antigen retrieval and development was performed on the fully automated Bond system according to
manufactures instructions (See Supplementary Table 2 for antibody details), with positive controls
included on each slide.
5.2.4

DNA and RNA extraction

Tumour and cell culture nucleic acids were extracted using AllPrep DNA/RNA FFPE Kit (80234,
Qiagen) or AllPrep DNA/RNA/Protein Mini Kit (80004,Qiagen), respectively, according to the
manufacturer’s instructions. All samples were quantified using the NanoDrop (ND1000,
Thermoscientific). RNA samples had A260/280 ratio between 1.7 and 2.3 (see supplementary Table
3).
5.2.5

Nanostring Analysis

Cell line RNA expression was explored and compared to the corresponding patient tumour and mouse
xenograft using the Nanostring platform. 25 ng of RNA from fresh-frozen samples and 150 ng from
FFPE samples were run on the NanoString nCounter Sprint system using the 770 gene PanCancer
Pathways panel with additional cancer stem cell and proteolytic genes as per the manufacturer's
instructions (NanoString Technologies). Results were analysed using the NanoString nSolver 3.0 and
PanCancer Pathways Advanced Analysis Module, which normalizes gene expression to a set of
positive and negative control genes built into the platform. Differential expression of genes from key
pathways were compared between cell lines, with fold change and P values calculated using nCounter
default settings. As recommended, genes whose expression levels were at or below the level of the
negative controls were removed from analysis. With the remaining list of genes, a filter cutoff of ≥ ±2
fold change and P value < 0.05 were used to identify the significant gene expression changes based on
the nCounter analysis.
5.2.6

Short Tandem Repeat (STR) analysis

STR profiles for the cell lines and their matching patient FFPE tumour tissue were verified by the
PowerPlexR 18D System, using the following 18 markers (seventeen STR loci and Amelogenin):
D3S1358, TH01, D21S11, D18S51, Penta E, D5S818, D13S317, D7S820, D16S539, CSF1PO, Penta
D, Amelogenin, vWA, D8S1179, TPOX, FGA, D19S433 and D2S1338. As per standard practice, cell
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lines were considered to match if profiles are more than 80% identical to source patient sample.
5.2.7

Mouse xenograft tumourogenicity

For confirmation of tumourigenicity, 2x 106 cells from early passages of each cell line were injected
subcutaneously into the flank of NOD scid gamma (NOD.Cg-Prkdc<scid>IL2rg<tm1Wjl>/ SzJAusb)
mice. Mice were monitored for tumour growth and sacrificed when the tumour grew greater than 10
x10 mm, or the animal demonstrated signs of stress (such as >15% weight loss) or evidence of
impedance of tumour on movement. Tumours were collected from the sacrificed mice for culture,
RNA and DNA extraction, and histological analysis. For culture from xenografts, tumour tissues were
cut into approximately 1 mm pieces and then incubated with Milteny tumour dissociation enzymes in
ADMEM, after which the tumour homogenate was centrifuged, the pellet resuspended, and plated.
Epithelial cultures derived from JICTC and JIASC xenografts grew rapidly as loosely attached cells
and were easily separated from mouse stromal cells by mechanical pipetting at P0. These were
designated as RFCTC-M and JICTC-M respectively, to denote the fact that they were passaged
through mice. All procedures were carried out in accordance to the Australian Code for the Care and
Use of Animal for Scientific Purposes 2013, and approved by the University of Wollongong’s Animal
Ethics Committee (study AE15/17)
5.2.8

Cytotoxic Assay

Approximately 10,000 cells were seeded per well in triplicate into a 96-well plate 48 - 72 h prior to
drug treatment with carboplatin, etoposide, paclitaxel or oxaliplatin (obtained from excess patient
stock from private hospital). Cells were incubated with serial dilutions of each drug for 72 h with drug
vehicle (either water, 0.9% saline or DMSO, depending on drug solubility) dilution kept constant
across all drug concentrations and controls (final concentration of 0.2%). The viability of cells were
assayed using CellTitre 96® Aqueous One Solution Cell Proliferation Assay (Cat # G3581, Promega
Corporation, Fitchburg, Wisconsin, USA) using a Spectromax 250 UV plate reader and Softmax Pro
software (Molecular Devices, Sunnyvale, California, USA). Cell viability of treated cells were
normalized against cells receiving vehicle controls. This data were analysed using a logarithmic
sigmoidal dose–response curve using the variable slope parameter to determine IC50 (GraphPad Prism
6.0). (GraphPad Inc.). Data is presented as a mean ± standard deviation (SD) from ≥2 independent
experiments.
5.2.9

Radiotherapy Assay

The sensitivity of the cells to radiation with drug pretreatment was also investigated using clonogenic
survival as the radiobiological endpoint. Cells were first acclimated for at least a week in normoxic
conditions, then plated into 12.5 cm2 tissue culture flasks in regular cell culture media (as above) in
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order to reach ~60% confluency 3 days later. Cells were then pre-sensitized with 0, 1, 2 or 5 µM
Carboplatin for 48 h prior to exposure to 1 or 2 Gy X-Ray radiation. Cells were then passaged into
triplicate tissue-culture petri dishes (100 mm x 20 mm Falcon BD; Pacific Laboratory Products) in 10
mL of ADMEM with 10% FCS, pencillin/streptomycin, EGF and l-glutamine, at different cell
densities per dish (ranging from 1000 to 20000 cells per dish). After approximately 15 doubling times,
petri dishes were washed with PBS and adherent cell colonies fixed and stained with a 1:3 crystal
violet:ethanol solution. Colonies (> 50 cells/colony) were manually counted and presented as Mean
Plating Efficiency (MPE; [number of colonies]/[number of cells plated]*100) and surviving fraction
(SF; MPE of treatment group/MPE of control group) as previously described 19.
5.3 Results
5.3.1

Establishment of long term in vitro CTC cultures in patients with metastatic
gastroesophageal cancer

A total of 41 blood samples were processed for CTC culture, with 23 samples processed using the
optimised protocol (15 ml blood sample with negative selection using the CTC Enrichment Cocktail).
CTC were detected in 38/40 samples (93%) by the Isoflux system (one sample unable to be processed
for CTC enumeration due to clotted specimen), with ≥10 CTCs found in 22 (54%) of samples.
Numbers of CTCs detected ranged from 0 – 150, with the mean number of CTCs 27.3 (summarised in
Supplementary Table 4).
Long term CTC cultures were established from two patients by processing 15 ml blood samples using
the optimised protocol (Table 1). The first was established from patient 20 (cell line RFCTC), who
had a low CTC count of 3 by EpCAM based capture despite widespread nodal and bone metastases.
Patient 20 had a distal oesophageal/gastroesophageal junction carcinoma diagnosed on endoscopy.
The patient received concurrent chemoradiotherapy to the primary tumour and locoregional nodal
disease as planned neoadjuvant treatment. Despite an excellent local response to chemoradiotherapy,
the patient rapidly developed widespread metastatic disease including a dural metastasis causing
spinal cord compression. At the time of CTC sampling the patient underwent resection of this
metastasis, with histopathology demonstrating high grade neuroendocrine carcinoma, a rare and
highly lethal subtype of cancer occurring in <1% of patients with gastrointestinal cancers 20 .
The second long term culture was established from patient 41 (cell line JICTC) who had a high
EpCAM based CTC count (109). This patient presented with diffuse bone and peritoneal metastasis.
Endoscopy demonstrated a large ulcerated gastric mass confirmed on biopsy to be a gastric
adenocarcinoma. A matched culture was established simultaneously from the ascitic fluid sample
from the same patient (JIASC). Unfortunately both patients progressed rapidly prior to receiving
further treatment and passed away.
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Table 1: Characteristics of the source patients of long term CTC cell lines.
Patient

Primary

Number Tumour

Sites of

Treatment prior to

CTC

Key protein

metastatic

blood sampling

count by

expression of

disease at

Isoflux

cell line

blood draw

System
(7.5ml
sample)

20

Distal

Bone

Chemoradiotherapy

oesophageal

Widespread

with carboplatin and

CGA+ CD56+

high grade

nodal

paclitaxel to primary

EpCAM -

neuroendocrine

Hepatic

tumour and regional

Cytokeratin

nodal disease

weak/low

carcinoma
41

Gastric

Bone

Nil

adenocarcinoma Peritoneal

3

109

Synaptophysin +

EpCAM +
Cytokeratin +
CD44 +

In both CTC cultures, viable cell colonies were seen within 3 weeks. In the RFCTC culture a large
number of residual CD45+ lymphocytes persisted for the initial 4 passages. Cell populations
expanded rapidly, and have been maintained continuously for over 12 months to date. Once
established, the cultures have been adapted to grow in a variety of conditions, including serum free
media supplemented with various growth factors or with 10% fetal calf serum, hypoxic or normoxic
atmosphere, or ultra low attachment (ULA) or standard culture vessels, and remain viable after
freezing at various passages and thawing.
The cell lines display discrete in vitro growth characteristics. JICTC grows in long mucinous, loosely
aggregated strands (Figure 1). These strands are weakly attached to the flask surface and require only
gentle mechanical dissociation for passaging. Altering growth conditions (such as media) does not
have any discernible effect on JICTC phenotype. In contrast, RFCTC grow as an adherent culture,
requiring trypsinisation for passaging, although a loose adherent spheroid phenotype is inducible with
a hypoxic environment and serum free media (Figure 2). Similar growth characteristics were seen in
hypoxic and normoxic conditions once the cell line was established (data not shown).
5.3.2

CTC culture recapitulates the pathological characteristics of source patient

The two established CTC cell lines demonstrate markedly different phenotypes and protein and gene
expression patterns which faithfully recapitulate patterns of the source tumour (Figures 1, 2 and 3).
As discussed, cell line JICTC was established from a patient with metastatic gastric adenocarcinoma
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with widespread liver and peritoneal metastases. Both the patient’s primary tumour and JICTC
demonstrated high grade appearances by hematoxylin and eosin (H+E) stain (Figure 1) with a high
Ki67 (>80%). As expected in adenocarcinoma, both the tumour and cell line strongly expressed
cytokeratins (CAM5.2; Figure 3), in particular CK-20 (Figure 1). The JIASC cell line expressed an
almost identical phenotype to JICTC. Strikingly, the gastric cancer stem cell marker CD44, was
strongly positive in JICTC, while JIASC were negative (Figure 1).
In contrast, RFCTC, established from a patient with high grade gastroesophageal neuroendocrine
tumour, had only weak patchy cytokeratin staining, but as expected expressed high levels of the
neuroendocrine marker synaptophysin, CD56, and Chromogranin A typical of this cancer (Figure 2).
Protein expression was constant from cell line to mouse xenograft and subsequent cell culture created
from the mouse xenograft (Figure 2). This cell line had an otherwise bland IHC profile, with no
staining for epithelial or stem cell markers (Figure 2, 3). H+E staining showed a high grade poorly
differentiated tumour with high Ki67 (80 – 100%) (Figure 2). Differing media (10%FCS or serum
free media) did not change the phenotype detected by IHC (data not shown).
Neither cell line expressed mesenychmal markers (Vimentin or N-Cadherin) or urokinase
plasminogen activator receptor (uPAR), a key receptor for the initiation of the proteolytic cascade
(Figure 3). No cell line showed any CD45 expression at any stage confirming these cultures did not
derive from lymphocytes (Figure 3).
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Figure 1: JICTC cell culture. (A) Representative images of the loose aggregates formed by JICTC.
Scale bar 50 µm. (B) IHC analyses of primary tumour and cell line from patient 41 (cell line JICTC
and JIASC). Both cell lines showed a very similar IHC profile, with strong pan-cytokeratin and CK20 staining, and weak CK-7 staining, with an identical expression profile in tumours formed in the
mouse xenograft. Scale bar 100 µm. (C) Expression of cancer stem cell markers in JICTC and JIASC.
Scale bar 100 µm. (D) JICTC rapidly formed tumours in immunocompromised mice, with all mice
reaching tumour endpoints within 4 weeks (mean ±SD of n= 4 mice).
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Figure 2: RFCTC cell culture. (A) Representative images of late passage (passage 40) RFCTC in
varied culture conditions. While RFCTC grows attached to standard culture vessels in 10% FCS in
normoxia and hypoxia (top image), a loosely adhered spheroid phenotype is inducible with serum free
media and hypoxia (bottom image). Scale bar 50 µm. (B) IHC analyses of tumour, cell line, mouse
xenograft, and cell line derived from mouse xenograft (RFCTC-M) from patient 20 showing stable
and strong expression of the neuroendocrine marker synaptophysin, with consistent patchy
cytokeratin positivity. Scale bar 100 µm. (C) IHC analysis of RFCTC showing strong expression of
neuroendocrine markers (CD56 and CGA), a high Ki67, but no expression of CSC markers (CD44,
CD133, ALDH1). (D) RFCTC rapidly formed tumours in immunocompromised mice, with all tumour
endpoints reached within 3 weeks (data points are the mean ±SD of n= 4 mice).
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Figure 3: Comparison of JICTC and RFCTC (A) Immunohistochemical expression of key proteins.
The distinct phenotypes of the two CTC cell lines are highlighted in this figure; JICTC expresses
epithelial markers (EpCAM and E-Cadherin) as well as strong cytokeratin staining. In contrast
RFCTC has no epithelial staining and weak/patchy cytokeratin staining. Both cell lines show a high
Ki67 supporting a high proliferation rate. No CD45 staining was observed in any of the cell lines.
Scale bar 100 µm. (B) Heatmap of RNA expression profiling of CTC cell lines (RFCTC, JICTC)
with matching patient FFPE sample and mouse xenograft. Key highly differently expressed genes are
displayed. JIASC cell line, established simultaneously from an ascites sample from the same patient is
also reported (green = high expression, red = low expression) (C) Dose response curves for cytotoxic
drugs on RFCTC (top) and (JICTC). Cell culture for all analyses was performed under hypoxic
conditions. Cell viability of treated cells were normalised against vehicle controls, and presented as
mean ± standard deviation (SD) from ≥2 independent experiments. Cell survival of RFCTC
determined by clonogenic assay (bottom). Cells were irradiated with or without carboplatin (1μM)
pre-treatment. Surviving fractions of irradiated cells only (no drug) and drug only were normalized to
non-irradiated non drug treated control. Each data point represents the means ±SD of at least two
independent experiments performed in triplicate.
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5.3.3

Mouse Xenograft tumourigenicity

Both cell lines rapidly formed tumours when injected subcutaneously into the flanks of
immunodeficient mice. Tumour endpoints (>10 x10 mm) were reached within 3 weeks for JICTC
and 4 weeks for RFCTC cell injection. IHC on excised tumours confirmed identical expression of
human cytokeratins and cell surface protein markers to the original patient tumour and corresponding
cell line (Figure 1 and 2). Cell cultures were established from the two CTC cell lines from the mouse
xenograft (RFCTC-M and JICTC-M).
5.3.4

Tumour authentication

Detailed DNA analyses were limited by poor DNA quality from both source patient’s FFPE samples.
However, by STR analysis, 24/28 (85.8%) alleles of JIASC and JICTC were identical to the primary
tumour from patient 41 confirming the source of the cell lines (see Supplementary Material). Despite
multiple attempts, there was inadequate DNA extracted from FFPE samples of patient 20’s tumour
preventing analyses including STR. However we note the STR profile of RFCTC did not match any
known cell lines in the American Type Culture Collection (ATCC), Deutsche Sammlung von
Mikroorganismen und Zellkulturen (DSMZ), or Garvan internal databases, demonstrating the that
RFCTC is a novel high grade neuroendocrine cancer cell line.
5.3.5

CTC cell lines have distinct gene expression profiles

RNA expression analysis by Nanostring confirmed the IHC and STR findings showing two distinct
CTC cell lines which reflect the source patient’s tumour. While JICTC had a higher expression of
CDH1 (encoding e-cadherin), RFCTC, as expected, had higher expression of genes for
neuroendocrine markers including CNTFR, PAX-5 and NGFR21-23.
Interestingly, differential expression analysis demonstrated JICTC, when compared to RFCTC, had a
higher expression of genes known to be involved in Helicobater Pylori mediated carcinogenesis such
as AKT24, ETS225 and MYC26, supporting endoscopic finding that patient 41’s tumour was likely
related to H. Pylori gastritis. There was also overexpression of genes encoding the gastric cancer stem
cell markers CD44, ALDH1 and CD133, as well as key stem cell pathways such as NOTCH and
WNT, including the notch delta-like ligands (DLL-1 and DLL-4) and PLA2GA, an important regular
of metastases in gastric cancer and expressed with constitutively active Wnt 27-29. JICTC also showed
higher expression than RFCTC of targetable pathways including EGFR, FGFR2, HER-2, and MET,
as well as key genes in the JAK/STAT pathway, genes which overexpression are frequently reported
in gastric adenocarcinomas but not gastrointestinal neuroendocrine cancers20,30,31.
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RFCTC showed a high expression of DLL-3, which is known to be expressed on most high grade
neuroendocrine cancers, particularly small cell lung cancer. Importantly it is targetable with the
antibody-drug conjugate Rovalpituzumab tesirine32,33. RFCTC also showed a lower expression of key
DNA repair kinases, including ATM and ATR. We did not observe other reported molecular features
of high grade neuroendocrine cancers such as BCL-2 overexpression or Rb inactivation.
JICTC demonstrated a very similar RNA expression profile to JIASC. We did not find
overexpression of CSC or epithelial to mesenchymal transition (EMT) genes in JICTC compared to
JIASC.
Gene expression was preserved between cell lines and their corresponding mouse xenograft, with no
significant difference in expression observed (Supplementary figure 1).
5.3.6

Cytotoxic and Radiosensitivity Assay

In vitro sensitivity of both CTC cell lines to the following cytotoxic drugs; carboplatin, etoposide,
paclitaxel or oxaliplatin was evaluated using the MTS assay. JICTC and RFCTC demonstrated similar
sensitivity to carboplatin and oxaliplatin, with both IC50 values (0.18 and 0.93 respectively) consistent
with previously reported values for gastroesophageal cell lines (Table 2, Figure 3)34. Although patient
20 received chemotherapy with carboplatin and paclitaxel as a radiosensitiser prior to sampling for the
CTC culture, RFCTC remained sensitive to both agents compared to the JICTC cell line.
Table 2: IC50 values for carboplatin, etoposide, paclitaxel and oxaliplatin on RFCTC and JICTC (all
hypoxic conditions).
IC50 (µM)
Drugs

RFCTC

JICTC

Carboplatin

40.80 ± 2.94

33.40 ± 11.3

Etoposide

1.57 ± 0.40

0.04 ± 0.02

Paclitaxel

0.01 ± 0.03

0.55 ± 0.35

Oxaliplatin

0.93 ± 0.26

0.28 ± 0.13

We then investigated the sensitivity of each CTC cell line to radiotherapy with and without
carboplatin sensitisation using the clonogenic assay. Unfortunately JICTC was found to be unsuitable
for this assay due to the weak attachment to the culture plate. RFCTC displayed marked sensitivity to
radiotherapy alone with a mean surviving fraction of 67% and 18% after 1Gy and 2Gy respectively.
The prep-treatment of low dose carboplatin (1μM) significantly enhanced the effect of radiotherapy
despite being much lower that then IC50 of carboplatin in RFCTC (40.8 μM) (Figure 3).
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5.4 Discussion
We report the establishment and characteristation of two novel long term (>1 year, >40 passages)
gastroesophageal cancer cell lines derived from CTCs. These two cell lines are genotypically and
phenotypically distinct, reflective of differing tumour biology in the donor patients.
By IHC strong differences in the expression of key proteins were observed between the cell lines.
Similar to other reported CTC lines, JICTC displayed an EpCAM+, cytokeratin (Cam5.2)+ , CD44+,
phenotype. In contrast, RFCTC, isolated from a patient with neuroendocrine tumour, showed only
patchy weak cytokeratin (Cam5.2) by immunostaining with strong expression of neuroendocrine
markers (CD56+, synaptophysin+, chromogranin A+). RFCTC had no detectable EpCAM,
mesenchymal (NCAD-, Vimentin-), or cancer stem cell markers (CD44-, CD133-, ALDH1-). This
phenotype makes RFCTC a unique CTC cell line.
Overall both CTC derived cell lines as well as the ascites derived cell line recapitulated the phenotype
of the source patient’s tumour, highlighting that CTCs are a representative tumour source. It was
interesting to detect differences in CD44, ALDH1 protein and STAT3 gene expression between the
JICTC and JIASC, which probably reflects the different pathways of tumour cell dissemination. Of
note, higher expression of cancer stem cell markers (CSC) and key stem pathways was also found on
JICTC versus RFCTC, despite ALDH1, CD44, and CD133 reported as CSC markers in both
adenocarcinomas and high grade neuroendocrine tumours35,36. Both demonstrated rapid in vitro and in
vivo growth, had high grade histological appearance, and a high Ki67 (>80%), supportive of a stem
cell phenotype. The RNA expression profiling confirmed these data, with each cell line’s expression
clustered with the source patient’s tumour and the corresponding mouse xenograft.
STR analysis confirmed patient 41 as the source of JICTC. While we were unable to extract sufficient
quality DNA from patient 20’s FFPE tumour sample for any analysis, RFCTC’s STR profile was
unique.
Together with the confirmed tumourigenicity of the cell lines by the rapid development of tumours
(within 4 weeks of inoculation) in all xenografted mice, these data confirm the establishment of two
novel CTC derived immortalised cell lines. The tumours excised from the mice and the cell cultures
(JICTC-M, RFCTC-M) derived from these tumours retained the overall RNA expression profile and
IHC staining pattern seen in the corresponding cell line and source patient tumour. This highlights
that these procedures, at least in short term cultures, do not grossly alter the original tumour
characteristics, making CTC derived cell lines an excellent model to study tumour behaviour and
response to treatment.
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We also undertook limited cytotoxic and radiotherapy assays of the CTC cell lines based on standard
cytotoxic drugs used for these cancers. We found drug sensitivities were generally similar to those
previously reported for gastroesophageal cell lines34. We note the extreme sensitivity of RFCTC to
radiotherapy, and the synergistic effect of carboplatin. This is consistent with the clinical experience
of high grade neuroendocrine cancers, driven by low ATM and ATR expression, key DNA damage
response enzymes and associated with increased response to radiotherapy37-39. Decreased ATM
expression has been strongly associated with metastases in high grade neuroendocrine cancer from the
gastrointestinal cancer40. RFCTC showing very low ATM and ATR gene expression together with the
fact that the patient rapidly developed widespread metastatic disease indicates the capacity of CTCs
for establishing metastases.
Multiple other potential therapeutic targets were identified by RNA expression profiling. JICTC had
high expression of EGFR, FGFR2, ERBB2, and JAK/STAT pathway, suggesting potential sensitivity
to treatments directed at these validated targets. Targeting ERBB2 has improved clinical outcomes in
HER2 overexpressed gastric cancer, and ongoing clinical trials are exploring the use of FGFR2 and
JAK inhibitors in these cancers41-43. Relative to JICTC,RFCTC had high expression of DLL3, known
to be overexpressed in high grade neuroendocrine tumours, and targetable by Rovalpituzumab
tesirine. These data show that CTC derived cell lines can be used to define personalised drug
sensitivities for gastric cancer patients, an approach which has been shown to complement molecular
profiling in personalising systemic treatments in cancer44More comprehensive drug sensitivity testing
including drugs tailored against the suggested targets should be performed on these cell lines in the
future.
Other studies have suggested a high CTC count (>300) is necessary for successful culture12, however
this is complicated with the inherent biases when selecting the isolation method and definition used
for CTC enumeration. We employed the standard EpCAM based isolation and cytokeratin based
CTC identification in the matched blood sample. Due to the biological differences discussed above,
our successful cultures derived from samples with high (109) and low (3) CTC counts, subsequently
developing EpCAM positive and negative cell lines, respectively. This finding highlights a key issue
in the CTC field. While patient 20 has a low EpCAM+ CTC count, the successful establishment of a
CTC cell line argues that this patient had a high number of EpCAM- CTCs with the ability to
establish metastatic deposits. These biologically relevant cells are missed using standard CTC
isolation techniques. Moreover, it is important to emphasise that these neuroendocrine CTCs would
also not be well enumerated based on mesenchymal protein based CTC isolation, thus neuroendocrine
CTCs likely still represent an understudied yet potentially highly aggressive population of CTCs. The
negative selection used for CTC culture (CD45 depletion), rather than the positive selection used for
CTC enumeration (EpCAM capture) was critical to detect these cells. The optimal isolation method of
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CTCs continues to evolve in the face of these challenges and while more emphasis has been given to
epithelial to mesenchymal transition (EMT) phenotype CTCs in recent years45 the data presented here
highlight that better detection of neuroendocrine CTCs need to be considered as well.
The matched culture derived from ascitic fluid (JIASC) simultaneously established from patient 41 as
JICTC demonstrated an identical phenotype, with the exception of cancer stem cell expression.
JICTC was strongly positive for CD44, a key CSC marker in gastric cancer28, while JIASC was
negative for CD44. This is consistent with other results showing that CTC cultures exhibit a stem cell
phenotype. This further supports the notion that CTC cultures develop from the CTC population
which are able to establish metastases12,46 47.
In conclusion, we report the first two long term CTC cell lines developed from patients with
metastatic gastroesophageal cancer. The two cell lines displayed distinct profiles which faithfully
recapitulate the source patient’s tumour. Our results support the developing role of CTC culture as an
essential laboratory resource for the understanding of the biology of metastases and importantly
undertake personalised screening for therapeutic strategies.
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5.5 Supplementary Material
Supplementary Table 1: CTC culture media
Supplier

Concentration

Serum Free Media
Advanced DMEM/F12

Thermo Fisher Scientific

N2 Supplement

Life Technologies Australia Pty

1x

Ltd
Epidermal Growth Factor

Life Technologies Australia Pty

20ng/ml

Ltd
Fibroblast Growth Factor

Life Technologies Australia Pty

10ng/ml

Ltd
Penicillin Streptomycin Solution

Sigma-Aldrich

1X

L-gluatmine

Sigma-Aldrich

1x

10% Serum Media
Advanced DMEM/F12

Thermo Fisher Scientific

Foetal Bovine Serum

Bovogen

10%

Epidermal Growth Factor

Life Technologies Australia Pty

20ng/ml

Ltd
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Supplementary Table 2: Antibodies used in immunohistochemical analyses:
Retrieval Time
Antibody

Supplier

Dilution

(min)

CAM5.2

Leica

1:100

20

CK-7

Leica

1:50

20

CK-20

Leica

1:100

30

E-Cadherin

Leica

1:25

20

HER-2

Leica

1:100

20

Ki67

Dako

1:40

20

(CD45)

Dako

1:500

20

VIM

Dako

1:500

20

CDX-2

Dako

1:50

30

CD56

Leica

1:1

20

CHROM

Leica

1:200

20

Synapatophysin

Leica

1:100

20

Receptor

Dako

1:100

60

N-Cadherin

Sigma-Aldrich

1:100

60

Leukocyte Common Antibody

Urokinase Plasminogen Activator

161

Supplementary Table 3: RNA quality indicators for nanostring analysis
Sample #

Sample name

RNA concentration

A260/280

(ng/µl)
1

Pt 41 FFPE (primary tumour, JI)

34.8

2.05

2

Pt 20 FFPE (metastatic deposit, RF)

128.1

1.66

3

JIASC (early passage)

431.8

2.07

4

JICTC (early passage)

365.1

2.06

5

RFCTC (early passage)

536.7

1.9

6

RFCTC hypoxic, late passage (p33)

1973

2.1

7

RFCTC normoxic, late passage (p33)

1348

2.09

8

RFCTC C spheroid (early floating?)

248

1.8

9

RFDH mouse xenograft(DHM1)

1384

2.12

10

RFCTCM (post mouse xenograft

1517

2.09

culture, early passage)
11

JICTC mouse xenograft

1399

2.12

12

JIASC mouse xenograft

303

2.03
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Supplementary Table 4: Patient samples used for CTC culture
Patient CTC count by the Patient blood CTC enrichment cocktail
Number Isoflux System in
volume used
7.5ml blood
for CTC
sample
culture (ml)
1
150
7.5
CD45 only
2
0
7.5
CD45 only
3
38
7.5
CD45 only
4
27
7.5
CD45 only
5
12
7.5
CD45 only
6
4
7.5
CD45 only
7
2
7.5
CD45 only
8
26
7.5
CD45 only
9
49
7.5
CD45 only
10
18
7.5
CD45 only
11
18
7.5
CD45 only
12
67
7.5
CD45 only
13
62
7.5
CD45 only
14
8
7.5
CD45 only
15
1
7.5
CD45 only
16
3
7.5
CD45 only
17
4
15
CD45 only
18
2
15
CD45 only
19
13
15
CD45 and anti CD36
20
3
15
CD45 and anti CD36
21
15
15
CD45 and anti CD36
22
NA*
15
CD45 and anti CD36
23
0
15
CD45 and anti CD36
24
118
7.5
CD45 and anti CD36
25
26
15
CD45 and anti CD36
26
5
7.5
CD45 and anti CD36
27
19
15
CD45 and anti CD36
28
7
15
CD45 and anti CD36
29
1
15
CD45 and anti CD36
30
1
7.5
CD45 and anti CD36
31
6
15
CD45 and anti CD36
32
5
15
CD45 and anti CD36
33
16
15
CD45 and anti CD36
34
15
15
CD45 and anti CD36
35
14
15
CD45 and anti CD36
36
1
15
CD45 and anti CD36
37
2
15
CD45 and anti CD36
38
137
15
CD45 and anti CD36
39
77
15
CD45 and anti CD36
40
12
15
CD45 and anti CD36
41
109
15
CD45 and anti CD36
*CTC enumeration unable to be performed due to specimen clotting
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Long Term CTC
culture
established

Yes (RFCTC)

Yes (JICTC)

Supplementary Figure 1: Differential RNA expression between cell line and corresponding mouse
xenograft. We did not find a significant difference in expression for any genes (all results p<0.10).
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Abstract
Background/Aim: Right sided colon cancer (RsCC) is proposed to be a distinct disease entity to left
sided colon cancer (LsCC). We seek to confirm primary tumour location as an independent prognostic
factor in locoregional colorectal cancer.
Methods: All patients with stage I – III primary adenocarcinoma of colon were identified from the
New South Wales (NSW) clinical cancer registry (2006 – 2013). Primary tumour location (RsCC vs
LsCC) survival analyses were conducted using the Kaplan-Meier method, and adjusted hazard ratios
for 5-year all-cause mortality (OS) and 5-year cancer specific mortality (CSS) were obtained using
Cox proportional hazards regression.
Results: We identified 9509 patients including 5051 patients with RsCC and 4458 with LsCC.
Patients with RsCC were more likely to be older, female, have a higher Charlson comorbidity index,
and have worse tumour prognostic factors. In univariate analysis of all stages combined, those
patients with RsCC had a worse overall survival (OS, HR 1.20 95%CI 1.11 – 1.29, p<0.0001),
although this was not significant in the multivariate analysis (HR 0.96 95%CI 0.89 – 1.04, p=0.35).
Stage I patients with RsCC had a trend to improved OS (multivariate HR 0.84 95%CI 0.69 – 1.01,
p=0.07) and a significantly improved CSS (multivariate HR 0.51 95%CI 0.35 – 0.75, p=0.0006). In
stage II patients with RsCC there was a significantly improved OS (multivariate HR 0.85 95%CI 0.75
– 0.98, p=0.02) and CSS (multivariate HR 0.59 95%CI 0.45 – 0.78, p=0.0002) compared to LsCC. In
stage III patients, those with RsCC had a worse OS (multivariate HR 1.13 95%CI 1.01 – 1.26, p =
0.032) and a trend to worse CSS (multivariate HR 1.12 95%CI 0.94 – 1.33, p=0.22).
Conclusions: Primary tumour location is an important prognostic factor in locoregional colon cancer
with an effect that varies by stage. RsCC is associated with lower all-cause mortality in stage II, and
higher all-cause mortality in stage III.
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6.1.1

Background

Colorectal (CRC) is a common and lethal malignancy, projected to account for 13% of all new cancer
cases diagnosed in Australia in 2015, and 10% of Australian cancer deaths1. In recent years there has
been increasing interest in identifying the differences between right sided and left sided colon cancer,
and the potential for using this clinical marker as a surrogate marker of tumour biology, with the
intent of improved personalisation of systemic treatments.
There is a growing body of evidence to suggest that right sided colon cancers (RsCC) follow a
different disease process compared to left sided tumours (LsCC). The proximal and distal colons are
physiologically separate, arising from distinct embryological origins, with differences in tumour
genetics, histology, presentation, and clinical features2-4. Patients with RsCC are older, more likely to
be female, have more comorbidities, with poorer tumour histopathological features5-8.
Despite this, there is ongoing debate whether primary tumour location is an independent prognostic
factor in colon cancer. Most, but not all studies have found poorer survival with RsCC7-11. A recent
meta-analysis found a statistically significant worse overall survival in patients with RsCC, although
there was significant heterogeneity seen due the spectrum of included study designs, disease stage,
and limited information about treatment received by patients12. Tumour stage may play a role, with a
large Surveillance, Epidemiology, and End Results (SEER) program study showing worse overall
survival in Stage III RsCC patients, but not in Stage I or II 7, although these finding have been
recently challenged by a propensity score matched analysis of the SEER database, which showed a
better prognosis in RsCC patients9.
This current study aims to use a prospectively collected database of Australian patients to determine
whether primary tumour location is an independent prognostic factor in locoregional colon cancer,
and compare our findings to the literature.
6.1.2

Methods
6.1.2.1 Patient Cohort

The New South Wales (NSW) clinical cancer registry contains demographic and clinical data for
patients diagnosed or treated for cancer in NSW, covering approximately 30% of the Australian
population. Data is collected from pathological laboratories, hospitals and oncology departments
under mandatory notification of new cancer cases irrespective of treatment.
We identified all patients with Stage I, II or III colorectal cancer in NSW from Jan 2006 to 2013
(n=9509) as per third edition of the International Classification of Diseases for Oncology (ICD-O-3)13.
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The registry also contained adjuvant chemotherapy treatment details for a more limited group of
patients with stage II and III disease (n=4102).
Mortality data, including cause of death, was obtained with linkage to the NSW registry of Births,
Deaths and Marriages (BDM) by the Centre for Health Record Linkage (CHeReL)14. The censor data
for survival data was 1st December 2014. Primary tumour location was defined right sided (caecum to
transverse colon) or left sided (splenic flexure to rectosigmoid). Patients with rectal cancer were
excluded from analysis due to the different treatment paradigm to colon cancer in locoregional
disease. No data was available for cause of death in 935 patients (10.1%) which were therefore
excluded from the cancer specific death analyses. Patients were deemed to have died as a result of
colon cancer only if the underlying cause of death, rather than an associated cause of death, was coded
as C18-20.
Comorbidity data was obtained by CHeReL linkage of the clinical cancer registry data to the
Admitted Patient Data Collection (APDC). The APDC contains all admitted patient services provided
by New South Wales Public Hospitals, Public Psychiatric Hospitals, Public Multi-Purpose Services,
Private Hospitals, and Private Day Procedures Centres. Comorbidities of each patient were quantified
using the Charlson comorbidity index which predicts mortality from a range of 22 comorbid
conditions16. ICD-10 codes were extracted from admissions prior to diagnosis, then translated into a
Charlson comorbidity index (modified for cancer) using methods previously described15,16.
All data linkage was performed by the Centre for Health Record Linkage, with only de-identified
information provided to the researchers. The data sources used for this study required ethical and data
custodian approval to access, link (by an independent and approved authority) and release for
research. Approval for this project was provided by the NSW Population & Health Services Research
Ethics Committee (approval HREC/13/CIPHS/39).
6.1.2.2 Statistical analysis
Our primary outcome was all-cause 5-year overall survival (OS) stratified by stage, defined as death
within 5 years of primary diagnosis of colon cancer on basis of dates recorded in the cancer registry
and BDM databases. The secondary outcome was cancer specific 5 year survival (CSS) stratified by
stage, as per cause of death encoded on BDM data. Median values for OS and CSS-OS and
corresponding 95% CI were calculated using Kaplan-Meier methods. Unadjusted and multivariable
Cox proportional hazards regression analyses were used to estimate the association between tumour
location and survival and to calculate corresponding hazard ratios (HRs) and 95% confidence
intervals (CIs). The following variables were included in the multivariate model: age, sex, Charlson
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Comorbidity Index, TNM stage, year of diagnosis, grade, and adjuvant treatment (receipt and type of
adjuvant treatment performed in subset of patients only). All statistical analyses were performed
using SAS 9.2 software (SAS Institute, Inc., Cary, NC).
6.1.3

Results
6.1.3.1 Patient Characteristics (n=9509)

The characteristics of the NSW cohort is summarised in Table 1. The mean follow up was 46 months
(interquartile range 27 to 71months). At the end of 5 years of follow up, 2686 (28.2%) patients had
died, with 913 reported deaths (34.0% of deaths) due to colon cancer. 22% of patients had stage I
disease, 39% stage II, and 39% had Stage III. There were slightly more RsCC (53%) than LsCC
(47%). Patients with RsCC were older (61% vs 47% older than 70 years) , more likely to be female
(54% vs 42% female), had higher Charlson comorbidity indices (CCI, 40% vs 34% CCI ≥ 1), and had
worse prognostic features including higher TNM stage (79% vs 76% stage II/III), and higher grade
tumour (23% vs 11% poorly differentiated).
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Table 1: Patient Characteristics (n=9509)
Characteristic
All Patients (%)

Right sided
tumour (%)
TNM stage
I
2104 (22)
1055 (21)
II
3684 (39)
2059 (41)
III
3721 (39)
1937 (38)
T stage
1
1526 (16)
715 (14)
2
1030 (11)
558 (11)
3
5075 (53)
2741 (54)
4
1868 (20)
1031 (20)
N Stage
0
5788 (61)
3114 (62)
1
3065 (32)
1576 (31)
2
656 (7)
361 (7)
Grade
Well differentiated
1244 (13)
635 (13)
Mod. differentiated
6648 (70)
3278 (65)
Poorly Differentiated
1617 (17)
1138 (23)
Age group
≤60
1925 (20)
798 (16)
61– 70
2423 (25)
1189 (24)
71 – 80
2814 (30)
1600 (32)
>80
2347 (25)
1464 (29)
Sex
Male
4913 (52)
2317 (46)
Female
4596 (48)
2734 (54)
Charlson
0
5957 (63)
3027 (60)
Comorbidity
1–2
5083 (22)
1172 (23)
Index
3–4
1023 (11)
596 (12)
5
446 (5)
256 (5)
Adjuvant
None
1775 (19)
955 (46)
Chemotherapy
Fluorouracil based
1098 (12)
553 (27)
Oxaliplatin doublet
1233 (13)
568 (27)
Unknown*
5403
2975
Year Diagnosed 2006 – 2009
5018 (53)
2644 (52)
2010 – 2013
4491 (47)
2407 (48)
Totals
9509
5051 (53)
*not included in multivariate analysis in chemotherapy cohort.

Left sided
tumour (%)
1049 (24)
1625 (36)
1784 (40)
811 (18)
472 (11)
2334 (52)
837 (19)
2674 (60)
1489 (33)
295 (7)
609 (14)
3370 (76)
479 (11)
1127 (25)
1234 (28)
1214 (27)
883 (20)
2596 (58)
1862 (42)
2930 (66)
911 (20)
427 (10)
190 (4)
820 (40)
545 (27)
665 (33)
2428
2374 (53)
2084 (47)
4458 (47)

6.1.3.2 5 year all-cause mortality by primary tumour location.
The observed 5 year OS for patients with RsCC was 66% (95% CI 65 - 67%) compared to 70% (95%
CI 69 – 72%) for LsCC. Unadjusted survival analysis demonstrated a higher mortality with RsCC in
all stages combined (Figure 1, univariate HR 1.20 95%CI 1.11 – 1.29, p<0.0001). When stratified by
stage there was significant difference in OS seen only in stage III, with a higher mortality seen in
RsCC (Figure 1, HR 1.46 95%CI 1.31 – 1.63, p<0.0001) (Figure 1).
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P value
<0.0001
<0.0001

0.06
<0.0001
<0.0001

<0.0001
<0.0001

0.0002

0.38

Figure 1: 5 year all-cause mortality by primary tumour location n= 9509 patients with 2686 deaths
(Stage I = 2104 patients with 440 deaths, Stage II = 3684 patients with 883 deaths, Stage III = 3721
patients with 1363 deaths).
After adjusting for sex, age, comorbidities, stage, grade, and year of diagnosis there was no significant
difference in OS between RsCC and LsCC in patients from all stages (multivariate HR 0.96 95%CI
0.89 – 1.04 p=0.35) (Table 2). When the multivariate analysis was stratified by stage, patients with
RsCC had a trend to improved survival in stage I (HR 0.84 95% CI 0.69– 1.01, p=0.069), a
statistically significant improved survival in stage II (HR 0.85 95%CI 0.75 – 0.98, p=0.02), but a
shorter survival in stage III (HR 1.13 95%CI 1.01 – 1.26, p=0.03) (see Table 3.)
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Table 2. Multivariate model for overall survival for NSW cohort (n=9509).
Characteristic
Multivariate
HR (95% CI)
Sided
Left
1
Right
0.96 (0.89 – 1.04)
Age
≤60
1
61– 70
1.34 (1.15 – 1.56)
71 – 80
2.23 (1.93 – 2.56)
>80
3.97 (3.46 – 4.56)
Grade
Well differentiated
1
Moderately differentiated
1.22 (1.06 – 1.39)
Poorly Differentiated
1.87 (1.60 – 2.17)
TNM stage
I
1
II
1.05 (0.96 – 1.21)
III
2.00 (1.80 – 2.24)
Sex
Male
1
Female
0.90 (0.83 – 0.97)
Charlson Comorbidity Index 0
1
1–2
1.64 (1.49 – 1.79)
3–4
1.81 (1.62 – 2.03)
5
3.02 (2.63 – 3.46)
Year Diagnosed
2006 – 2009
1
2010 - 2013
0.98 (0.90 – 1.06)
HR – Hazard Ratio; CI – confidence interval.

Table 3. Univariate and multivariate Hazard Ratios for NSW cohort (n=9509) stratified by stage.
Statistically significant values in bold.
Overall Survival HR (95% CI)

Cancer Specific Survival HR (95% CI)

Univariate

Multivariate*

Univariate

Multivariate*

Left Sided

1

1

1

1

Right Sided

1.20 (1.11 – 1.29)

0.96 (0.89 – 1.04)

1.03 (0.91 – 1.18)

0.84 (0.73 – 0.96)

Stage I

Left Sided

1

1

1

1

(n=2104)

Right Sided

1.03 (0.91 – 1.18)

0.84 (0.69 – 1.01)

0.66 (0.45 – 0.95)

0.51 (0.35 – 0.75)

Stage II

Left Sided

1

1

1

1

(n=3684)

Right Sided

1.002 (0.88 – 1.14)

0.85 (0.75 – 0.98)

0.68 (0.52 – 0.88)

0.59 (0.45 – 0.78)

Stage III

Left Sided

1

1

1

1

(n=3721)

Right Sided

1.46 (1.31 – 1.63)

1.13 (1.01 – 1.26)

1.43 (1.21 – 1.69)

1.12 (0.94 – 1.33)

All Patients

*following variables were used in the multivariate analysis: age, sex, year diagnosed, Charlson
Comorbidity Index, TNM stage, grade.
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6.1.3.3 Cancer specific survival (CSS) primary tumour location
The 5 year cancer specific survival (CSS) was similar for RsCC (89%; 95%CI 88 – 90%) and LsCC
(89%; 95%CI 87-90%). Unadjusted CSS analysis did not show a significant difference between RsCC
and LsCC in all stages combined (Figure 2, univariate HR 1.03 95%CI 0.91 – 1.18, p=0.64). When
stratified by stage, there was a significantly improved CSS seen with RsCC in stage I (HR 0.66
95%CI 0.45 – 0.95, p=0.024) and stage II (HR 0.68 95%CI 0.52 – 0.88 p=0.0032), but a significantly
poorer survival for stage III patients (HR 1.43 95%CI 1.21 – 1.66, p<0.0001) (Figure 2, Table 3).

Figure 2: 5 year cancer specific mortality by primary tumour location n= 9509 patients with 2686
deaths (Stage I = 2104 patients with 116 deaths, Stage II = 3684 patients with 224 deaths, Stage III =
3721 patients with 573 deaths).
In the multivariate analysis, after adjusting for sex, age, comorbidities, stage, grade, and year of
diagnosis, patients with RsCC had a statistically significant improved CSS in all stages combined (HR
0.84, 95%CI 0.73 – 0.96, p=0.011), and for stage I (HR 0.51 95%CI 0.35 – 0.75, p=0.0006) and stage
II (HR 0.59 95% CI 0.45 -0.78, p=0.0002) patients, but a trend to worse survival in stage III (HR 1.12
95%CI 0.94 – 1.33, p=0.22) (Table 3).
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6.1.3.4 Effect of adjuvant chemotherapy
Adjuvant treatment details were available for 1631 (44%) of patients with stage II and 2441 (66%) of
patients with stage III disease (4102 patients total). Most patients in stage II disease did not receive
adjuvant chemotherapy (72%), with only a minority receiving fluorouracil monotherapy (24%) or an
oxaliplatin doublet combination (usually FOLFOX, 5%). In contrast, the majority of patients with
stage III disease received adjuvant chemotherapy (75%), with 28% treated with fluorouracil
monotherapy, and 47% with an oxaliplatin/ fluorouracil doublet. Higher TNM-substage was
associated with treatment with oxaliplatin doublet within both stage II (p<0.0001) and III (p=0.0001).
Consistent with current practice no patients received adjuvant treatment with monoclonal antibodies.
Patients with RsCC were less likely to receive adjuvant chemotherapy (p=0.0002, Table 1) despite
higher risk tumour features. Adjuvant chemotherapy improved survival in both RsCC (univariate OS
HR 0.68; 95%CI 0.58 – 0.80) and LsCC (univariate OS HR 0.48; 95%CI 0.40 – 0.58, supplementary
figures 1 and 2).
Inclusion of the adjuvant chemotherapy regimen into the multivariate model did not alter the effect of
primary tumour location, although the results for RsCC in stage II disease became non-significant
(multivariate OS HR 0.86 95%CI 0.69 – 1.09 p=0.19; multivariate CSS HR 0.67 95%CI 0.43 – 1.04,
p=0.07, table 4). Patients with RsCC in stage III colon cancer continued to have a significantly
inferior OS compared to LsCC even after adjustment for all above factors including receipt and type
of adjuvant chemotherapy (multivariate OS HR 1.29 95%CI 1.11 – 1.50 p=0.0012; multivariate CSS
HR 1.16 95%CI 0.92 – 1.47, p=0.22, table 4). When analyses were restricted to only those stage III
patients who received adjuvant oxaliplatin doublet chemotherapy (n=1233), RsCC remained
associated with a poorer OS (univariate OS HR 1.8 95%CI 1.4 – 2.4, p<0.0001).
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Table 4. Multivariate model for overall survival for chemotherapy cohort (n=4102).
Characteristic

Stage II (n=1631)
Multivariate
HR (95% CI)
Sided
Left
1
Right
0.86 (0.68 – 1.09)
Age
≤60
1
61– 70
1.90 (1.20 – 2.99)
71 – 80
2.97 (1.92 – 4.58)
>80
5.92 (3.82 – 9.19)
Grade
Well/mod differentiated
1
Poorly Differentiated
1.43 (1.08 – 1.90)
TNM stage
IIIa
1
IIIb
2.20 (1.71 – 2.82)*
IIIc
Sex
Male
1
Female
0.85 (0.68 – 1.07)
CCI
0
1
1–2
1.42 (1.09 – 1.52)
3–4
1.60 (1.12 – 2.28)
5
2.31 (1.45 – 3.69)
Year Diagnosed 2006 – 2009
1
2010 - 2013
0.99 (0.79 – 1.26)
Adjuvant
Nil
1
Chemotherapy
Fluorouracil monotherapy
0.79 (0.51 – 1.10)**
Oxaliplatin doublet
* IIa vs IIb/IIc, ** chemotherapy vs no chemotherapy

Stage III (n=2441)
Multivariate
HR (95% CI)
1
1.29 (1.11 – 1.50)
1
1.21 (0.94 – 1.54)
1.81 (1.43 – 2.30)
2.00 (1.54 – 2.60)
1
1.49 (1.26 – 1.75)
1
1.79 (1.33 – 2.43)
3.86 (2.84 – 5.24)
1
0.94 (0.82 – 1.10)
1
1.15 (0.96 – 1.38)
1.20 (0.94 – 1.53)
1.83 (1.36 – 2.46)
1
1.00 (0.86 – 1.17)
1
0.48 (0.40 – 0.57)
0.38 (0.27 – 0.42)

HR – Hazard Ratio; CI – confidence interval; CCI – Charlson Comorbity index.

6.1.4

Discussion:

There are well established differences in patient demographics, tumour factors and clinical
presentation between RsCC and LsCC7,9,10,17,18. However it remains uncertain whether primary tumour
location is an independent prognostic factor in locoregional colon cancer.
The strongest evidence comes from a recent meta-analysis of 66 studies including 1,437,846 patients
which showed LsCC is associated with a significantly reduced risk of death compared to RsCC (HR
0.82; 95%CI 0.79 – 0.84, P<0.01)12. This study included all stages of colon cancer and found that,
based on meta-regression, the effect of primary tumour location was independent of stage, race, year
of study, and quality of study.
It is important to consider the limitations of the above meta-analysis. Firstly, there was significant
heterogeneity seen in the results (I2=93%), which is likely due to the variety of included study
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designs, differing multivariate covariates from source studies, and patient populations, with the
estimate derived from overall populations with no stratification by stage.
Secondly, while most of the included studies controlled for tumour factors (such as stage and grade),
and patient demographic factors (eg., age, sex), only three studies included a comorbidity index in the
multivariate model7,17,19, and only 21% (14 of 66 studies) included performance status. RsCC is more
likely to occur in older patients who have more associated comorbidities17, and the substantial
imbalances in the baseline characteristics between LsCC and RsCC patients in these trials may be an
unmeasured confounder which explains the improved survival with LsCC. This issue has been
directly addressed by Warschkow et al who, in order to minimise confounding, used propensity score
matching to analyse survival in RsCC versus LsCC in 91,416 patients with stage I-III colon cancer
from the SEER database. These authors showed that RsCC had a better OS (HR 0.89, p<0.001) and
CSS (HR 0.71, p<0.001) in stage I and II, but a similar prognosis in stage III (OS HR 0.99, p = 0.49;
CSS HR 1.04, p=0.129).
Our current study, using a large series of Australian patients from a prospectively collected database,
and controlling for patient factors (including comorbidities), tumour factors, and adjuvant
chemotherapy, confirmed previous studies showing that RsCCs are more likely to have a more
advanced stage (p<0.0001) and grade (p<0.0001), and occur in older patients (p<0.0001) with more
comorbidities (p<0.0001). Despite higher risk tumour features, patients with RsCC are less likely to
receive adjuvant chemotherapy (p<0.0001) or oxaliplatin doublet chemotherapy (p=0.0002).
In the survival analysis, patients with RsCC have a lower all-cause mortality in stage II (HR 0.85,
p=0.02), but a higher mortality in stage III (HR 1.13, p=0.032). Moreover, patients with RsCC had an
improved 5-year CSS in Stage I (HR 0.51,p=0.0006) and Stage II (HR 0.59, p=0.0002), and a trend to
inferior CSS in Stage III.
As adjuvant chemotherapy has been shown to have a larger benefit in RsCC than LsCC20, we
subsequently undertook further multivariate analysis in a subset of patients with known adjuvant
chemotherapy protocols to validate our findings. Adjuvant chemotherapy improved survival in both
RsCC and LsCC. We found incorporation of adjuvant chemotherapy into the multivariate model did
not alter the effect of primary tumour location. Although definitive conclusions were limited in stage
II as chemotherapy regimens where only available in 44% of patients, there were similar hazard ratios
showing improved OS and CSS with RsCC (multivariate HR 0.86 and 0.67 respectively), although
statistically non-significant in the chemotherapy cohort. In stage III, where chemotherapy data was
available for the majority of patients (66%), the results of multivariate analysis was very similar to
overall cohort, with a significantly higher all-cause mortality with RsCC (HR 1.29, p = 0.0012) and
trend to higher cancer specific mortality (HR 1.16, p=0.21).
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Our findings are consistent with the results of Wiess et al 7, a large multivariate retrospective analysis
of 53,801 patients from the SEER database linked to Medicare data, and controlled for comorbidities
using Hierarchical Condition Categories risk score. Similar to our findings, in multivariate analysis,
patients with RsCC had a non-significant trend to lower mortality in stage I (HR 0.95, p=0.21), a
lower mortality in stage II (HR 0.92, p<0.0001), but a higher mortality in stage III (HR 1.12,
p<0.001), and a non-significant difference in mortality overall (HR 1.01, p=0.60). This stage
dependant effect, with an improved survival in RsCC in stage II, but higher mortality in stage III, has
been reported by multiple other series8-10,18,21.
The cause of the demonstrated inconsistent effect of primary tumour location by stage is unclear. Our
study, and the quoted literature, are retrospective analyses of large population databases, and are
susceptible to the inherent bias of confounding associated with this study design. However an
alternative explanation to consider is the increasingly described differences in tumour biology
between RsCC and LsCC. RsCCs are more likely to have adverse histological features (such as
advanced T stage, higher grade, or lymophvascular invasion) and mucinous histology2,22-24. Perhaps
more importantly, there are also marked differences in the molecular profile between these tumours25.
RsCC has a higher rate of BRAF mutations and high microsatellite instability (MSI-H), both which
have established prognostic importance, with MSI-H tumours shown to have a favourable prognosis,
and BRAF a strong poor prognostic marker in non-MSI-H but not in MSI-H tumours22,23,26,27. In
addition even within MSI-H tumours there are known differences in prognosis, with hereditary MSIH colon cancers shown to have a better survival than sporadic cases28. It is important to note that these
biomarkers are not uniformly distributed by stage, with MSI-H tumours associated with lower stage
(21% in stage II vs 14% stage III and 4% stage IV), and BRAF mutant tumours more likely to occur
at a higher stage22,29,30. Furthermore, previous studies have shown a differential effect of adjuvant
chemotherapy in between molecular subtypes. There is a reduced benefit with fluorouracil based
chemotherapy in MSI-H tumours, but preserved efficacy of oxaliplatin in MSI-H stage III colon
cancer patients31,32. Although our study demonstrated a persistent effect of primary tumour location
even when OS analysis was restricted to those patients who received adjuvant oxaliplatin doublet
chemotherapy, it is important to note that fewer patients with RsCC received oxaliplatin as part of the
adjuvant treatment.
Therefore, in the absence of both family history and molecular profiles in these population series, it is
reasonable to hypothesise that some of the observed survival difference in stage II and III may be due
to unequal distribution of these biomarkers. However, emerging evidence suggests that primary
tumour location may be a clinical surrogate for further, yet unidentified, predictive biomarkers as
highlighted by the recent data from the FIRE3 and CALGB/SWOG 80405 trials, which suggests a
reduced benefit to anti-EGFR treatment in RsCC independent of currently identified biomarkers 33.
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Recent retrospective analyses of these studies suggested that primary tumour site may impact the
benefit of the EGFR monoclonal antibodies in patients with RAS wild type metastatic colorectal
cancer. While the addition of EGFR antibodies to chemotherapy improved clinical outcomes in LsCC
compared to the anti vascular endothelial growth factor (VEGF) antibody bevacizumab, the opposite
was seen in LsCC. This intriguing result has prompted investigation for additional predictive
biomarkers informed by primary tumour location. A limitation of our study is the lack of associated
molecular data which is a potential source of unmeasured confounding to the results.
6.1.5

Conclusion

This population based study provides further evidence that primary tumour location is an important
independent clinical prognostic factor in stage II and III colon cancer with immediate implications for
clinical practice and trial design. This clinical biomarker is likely acting as a surrogate for as yet
unidentified molecular factors. Further studies with associated tumour molecular profiles are required
to clarify the underlying biological differences between RsCC and LsCC
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6.1.6

Supplementary Material

Supplementary Figure 1:Effect of adjuvant chemotherapy on overall survival in patients with right
sided colon cancer (n=2076).

Supplementary Figure 2: Effect of adjuvant chemotherapy on overall survival in patients with left
sided colon cancer (n=2030).
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Abstract
MicroAbstract: Due to poor representation in trials, the optimum adjuvant regimen for elderly patients
with stage III colon cancer is uncertain. We employed data from a cancer registry to show a survival
benefit with addition of oxaliplatin to fluoropyrimidine in patients ≥ 70 years. We note an increased
rate of hospital admissions and early chemotherapy cessation in elderly patients on oxaliplatin.
Background: Colon cancer is common in the elderly, but due to under-representation in clinical trials,
the benefit of standard therapies is uncertain in this age group. We aimed to clarify the efficacy and
complications of adjuvant oxaliplatin and fluoropyrimidine chemotherapy for patients 70 years and
older with stage III colon cancer.
Patients and Methods: All patients with stage III colon adenocarcinoma were identified from an
Australian cancer registry (2006 – 2013). Multivariable Cox hazard regression was used to determine
prognostic factors for all-cause mortality. Chemotherapy complications were quantified using
discontinuation rates, hospital admissions, and mortality for 12 months after starting chemotherapy
Results: 2164 patients fulfilled our inclusion criteria including 1080 (49.9%) ≥70 years. Patients ≥70
years were less likely to receive adjuvant chemotherapy (60.7% vs 89.6%) or oxaliplatin doublet
chemotherapy (18.8% vs 71.2%). Older patients receiving oxaliplatin were more likely to cease
treatment early (18.7% vs 7.6%), and require hospital admission (67.0% vs 53.5%). The addition of
oxaliplatin provided an overall survival benefit for patients <70 years (HR 0.44 95% CI 0.3 – 0.6,
p<0.0001), and for patients ≥70 years (HR 0.64 95%CI 0.5 – 0.9, p=0.005).
Conclusions: Despite a modestly increased rate of hospital admission and early chemotherapy
cessation, we demonstrate a persistent survival benefit for the addition of oxaliplatin to a
fluoropyrimidine as adjuvant treatment for stage III colon cancer in elderly patients.
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6.2.1

Introduction

Colon cancer is a common and lethal malignancy, with about 100,000 new cases diagnosed annually
in the United States34. It is a disease related to aging, with almost 40% of colon cancer diagnosed in
patients >75 years35-37.
Surgical resection is the only curative treatment for locoregional disease, although many patients will
develop disease recurrence due to micrometastases present at surgery. In resected stage III colon
cancer, standard treatment includes adjuvant doublet chemotherapy with oxaliplatin and a
fluoropyrimidine38, following the results of several large phase III randomised control trials which
showed a 30% reduction in disease recurrence and 22% reduction in risk of death with the addition of
oxaliplatin to fluoropyrimidine alone39-41.
Elderly patients appear to gain a similar benefit to fluoropyrimidine based adjuvant chemotherapy
compared to younger patients42. However as only a minority of patients in clinical trials are older than
70 years, the efficacy and safety of adjuvant chemotherapy with an oxaliplatin doublet in elderly
patients is unclear. For example, in the ACCENT database which includes individual patient data
from 14500 participants in 18 fluoropyrimidine - based adjuvant trials, only 18% are older than 70
years43.
Currently available trial data is conflicting. Subgroup analyses from the pivotal phase III MOSAIC
and NSABO-07 trials show a survival benefit only in patients <70 years39,40. Similarly, there was no
disease-free survival (DFS) or overall survival (OS) improvement with the addition of oxaliplatin in
the 2575 patients ≥70 years in the ACCENT database43. In contrast however, pooled individual patient
data from 904 patients ≥70 years from the NSABP C-08, XELOXA, X-ACT, and AVANT studies
showed an attenuated, but statistically significant benefit to the addition of oxaliplatin, including those
with comorbidities 44.
Similarly, retrospective patient series demonstrate contrasting results. While the largest series, drawn
from multiple USA databases including the SEER database, found a statistically significant benefit to
adjuvant oxaliplatin in elderly patients (70-74 years old) and those with comorbidities45, this was less
clear in patients >7546 and was not seen in other, smaller studies47,48.
As a consequence of these uncertainties, current guidelines recommend discussing incorporation of
oxaliplatin with patients over 70 years based on individual circumstances, although fluoropyrimidine
monotherapy is an appropriate choice for adjuvant therapy in the elderly38,49.
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The current study employs data from an Australian cancer registry to investigate the comparative
effectiveness of the addition of oxaliplatin to fluoropyrimidine monotherapy as adjuvant treatment for
stage III colon cancer in a “real world population” of patients older than 70.
6.2.2

Patients and Methods:

6.2.2.1 Patient Cohort
The New South Wales (NSW) clinical cancer registry contains demographic and clinical data for
patients diagnosed or treated for cancer in NSW, covering approximately 30% of the Australian
population. Data is collected from pathological laboratories, hospitals and oncology departments
under mandatory notification of new cancer cases. We included all patients ≥18 years with colon
cancer as per third edition of the International Classification of Diseases for Oncology (ICD-O-3)13.
We identified 2220 patients with stage III colon cancer with complete files including adjuvant
chemotherapy details. Fifty-six patients were excluded due to death within 30 days of surgery (n=23)
or delay starting chemotherapy past 120 days (n=33) (final sample n=2164).
Date of death was obtained with linkage to the NSW registry of Births, Deaths and Marriages (BDM)
by the Centre for Health Record Linkage (CHeReL) 14. The censor date for survival data was 1st
December 2014.
Comorbidity data and admissions during chemotherapy were obtained by CHeReL linkage of the
clinical cancer registry data to the Admitted Patient Data Collection (APDC). The APDC contains all
admitted patient services provided by New South Wales Public Hospitals, Public Multi-Purpose
Services, Private Hospitals, and Private Day Procedures Centres. Comorbidities of each patient were
quantified using the Charlson comorbidity index which predicts mortality from a range of 22
comorbid conditions16. ICD-10 codes were extracted from admissions prior to diagnosis, then
translated into a Charlson comorbidity index (modified for cancer) using methods previously
described15,16.
For quantification of chemotherapy complications, all admissions for 12 months following initiation
of chemotherapy were included apart from admissions for vascular implantation, chemotherapy,
routine surgery follow-up, and dialysis (ICD-10 codes Z45.2, Z51, Z48.815, Z49 respectively).
Admissions for febrile neutropenia were identified using neutropenia (ICD10 D70) with fever and/or
sepsis (ICD10 R50.8, R50.9, A419) and/or infection (ICD10 Chapter A, B) as previously described
for Australian patients50.
Linkage and use of the data from the New South Wales (NSW) clinical cancer registry, the NSW
registry of Births, Deaths and Marriages (BDM), Admitted Patient Data Collection (APDC) was
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approved by the NSW Population & Health Services Research Ethics Committee (approval
HREC/13/CIPHS/39).
6.2.2.2 Statistical analysis
Our primary outcome was all-cause mortality, on the basis of dates recorded in the cancer registry and
BDM databases. Median values for OS and corresponding 95% CI were calculated using KaplanMeier methods. To determine the impact of age, two separate cox proportional hazard models were
used to compare the effect of combination chemotherapy regimens on OS for patients ≥70 years and
<70 years. This age cut-off was used for consistency with previous publications and international
guidelines. The following variables were included in the multivariate model: age, sex, Charlson
Comorbidity Index (CCI), TNM stage, primary tumor location (defined as right sided - caecum to
transverse colon, or left sided - splenic flexure to rectosigmoid), year of diagnosis, grade, and
adjuvant treatment.
Our secondary objectives were complications of adjuvant chemotherapy by age group, as measured
by number and length of admissions for 12 months after starting treatment, and 12 month landmark
mortality, and treatment discontinuation rate by chemotherapy regimen. The number of admissions
was compared using ChiSq, and mean duration of each admission by the t-test. All statistical analyses
were performed using SAS 9.2 software (SAS Institute, Inc., Cary, NC).
6.2.3

Results:

6.2.3.1 Patient Characteristics (n=2164) and impact of age on receipt of chemotherapy
The characteristics of patients are summarised in Table 5. Approximately half the patients were ≥70
years (49.9%). Patients ≥70 were more likely to have right sided primary tumors (54.6% versus
42.7%) and poorly differentiated histology (24.3% versus 18.3%) but, despite these higher risk
features, were less likely to receive adjuvant chemotherapy (60.7% versus 89.6%) or oxaliplatin
doublet chemotherapy (18.8% vs 71.2%). Patients ≥80 years (n=371) were even less likely to receive
chemotherapy; only 29.4% received adjuvant fluoropyrimidine monotherapy and 3.0% received
oxaliplatin doublet. Increasing TNM stage was significantly associated with receipt of oxaliplatin
chemotherapy patients <70 years (p=0.0006) but not in those ≥70 years (p = 0.08).
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Table 5: Patient Characteristics

TNM stage
IIIa
IIIb
IIIc
Charlson Comordibity Index
0
1-2
3-4
5 or more
Primary Tumour Location
Right
Left
Age group
<60
60– 69
70 – 79
>=80
Sex
Male
Female
Grade
Well differentiated
Moderately differentiated
Poorly differentiated
Year Diagnosed
2009 – 2009
2010 – 2013
Adjuvant Chemotherapy
None
Fluoropyrimidine monotherapy
Oxaliplatin doublet

All Patients
n=2164
(%)

Pts < 70 years
n=1084 (50.1%)

Pts ≥ 70 years
n=1080
(49.9%)

P value

272 (12.6)
1284 (59.3)
608 (28.1)

141 (13.0)
638 (59.9)
305 (28.1)

131 (12.1)
646 (59.8)
303 (28.1)

0.81

1485 (68.6)
403 (18.6)
195 (9.0)
81 (3.7)

831 (76.7)
165 (15.2)
63 (5.8)
25 (2.3)

654 (60.6)
238 (22.1)
132 (12.2)
56 (5.2)

<0.0001

1053 (48.7)
1111 (51.3)

463 (42.7)
621 (57.3)

590 (54.6)
490 (45.4)

<0.0001

513 (23.7)
571 (26.4)
709 (32.8)
371 (17.1)

513 (47.3)
571 (52.7)

1125 (52.0)
1039 (48.0)

577 (53.2)
507 (46.8)

548 (50.8)
532 (49.3)

0.25

220 (10.2)
1484 (68.6)
460 (21.3)

112 (10.3)
774 (71.4)
198 (18.3)

108 (10.0)
710 (65.7)
262 (24.3)

0.0028

1096 (50.7)
1068 (49.4)

570 (52.6)
514 (47.4)

526 (48.7)
554 (51.3)

0.07

538 (24.9)
651 (30.1)
975 (45.0)

113 (10.4)
199 (18.4)
772 (71.2)

425 (39.4)
452 (41.8)
203 (18.8)

<0.0001

709 (65.7)
371 (34.3)

Patients ≥70 years were more likely to have a higher CCI than younger patients (39.4% versus 23.3%
with CCI >0). Increasing CCI was associated with decreased administration of adjuvant chemotherapy
and oxaliplatin doublet treatments in all patients (p<0000.1), patients <70 years (p=0.04) and patients
≥70 years (p<0.0001).
While the majority of patients on fluoropyrimidine monotherapy received oral capecitabine rather
than intravenous fluorouracil (83.9% versus 16.1%), only a minority patients treated with oxaliplatin
doublet chemotherapy had oral capecitabine (CAPOX) rather than intravenous fluorouracil
(FOLFOX) (13.7% versus 86.3%). There was a similar pattern of use patients ≥70 years and < 70
years.
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6.2.3.2 Complications of chemotherapy
Chemotherapy complications were quantified with hospital admissions for 12 months following
initiation of adjuvant chemotherapy, and 12 month landmark mortality.
In patients who received fluoropyrimidine monotherapy, there was no significant difference in
proportion of patients <70 years admitted to hospital compared to those ≥70 years (49.7% versus
49.8%, p=0.59), or mean duration of admissions (5.92 days versus 5.59, p=0.66). In contrast, patients
≥70 years who received oxaliplatin were more likely to be admitted to hospital (67.0% vs 53.5%, p =
0.0006) and require multiple admissions (37.4% required ≥2 admissions vs 25.5%, p=0.0008) than
younger patients on oxaliplatin. There was a non-significant trend to longer admissions (mean length
of admission 6.1 days vs 4.8, p=0.09).
In patients ≥70 years, those treated with oxaliplatin were more likely to be admitted to hospital
(67.0% vs 49.6%, p<0.0001) and require multiple admissions (37.4% ≥2 admissions vs 26.1%,
p=0.003) than those on fluoropyrimidine monotherapy. While there was no significant difference in
admissions for febrile neutropenia between age groups for patients on oxaliplatin (6.9% vs 4.7%,
p=0.19), patients ≥ 70 years on oxaliplatin were more likely to be admitted for febrile neutropenia
than those on fluoropyrimidine monotherapy (6.9% vs 1.8%, p=0.0008).
Patients ≥70 years were also less likely to complete adjuvant oxaliplatin doublet chemotherapy than
those <70 years, defined as receiving <3 months of treatment (18.7% versus 7.6%, p<0.0001). There
was no difference in completion rates between age groups for patients on fluoropyrimidine alone
(p=0.33).
Patients ≥70 years who received adjuvant oxaliplatin doublet chemotherapy had a significantly poorer
12 month landmark OS than younger patients (5.9% vs 1.7%, p =0.0006). This difference between
age groups was not seen in patients who received fluoropyrimidine monotherapy (8.6% vs 4.5%,
p=0.06). Within patients ≥70 years, there was no significant difference in 12 month OS between those
who received fluoropyrimidine monotherapy compared to oxaliplatin doublet (8.6% vs 5.9%, p
=0.23).
6.2.3.3 Efficacy of adjuvant chemotherapy in the elderly
In all patients who received adjuvant chemotherapy (n=1626), oxaliplatin doublet chemotherapy
improved OS compared to fluoropyrimidine alone (multivariate HR 0.54 95%CI 0.43 – 0.70,
p<0.0001, Table 6, Figure 3). Increasing age, comorbidity score, TNM stage, poorly differentiated
grade, and right sided primary tumor location were all significantly associated with poorer OS in both
univariate and multivariate analyses. Use of capecitabine, rather than 5-fluorouracil, was not
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significantly associated with OS in either the fluoropyrimidine monotherapy (p=0.82) or oxaliplatin
doublet (p=0.48) treatment groups.
Table 6: Univariate and multivariate analyses for overall survival in all patients who received
adjuvant chemotherapy (n=1626)
Characteristic
Univariate HR
P value
Multivariate
(95%CI)
(95%CI)
=<60
1
<0.0001
1
Age
60 – <70
1.0 (0.97 – 1.3)
0.97 (0.7 – 1.3)
70 – 80
2.3 (1.8 – 2.9)
1.4 (1.1 – 1.9)
>80
3.7 (3.0 – 4.8)
1.7 (1.1 – 2.4)
Male
1
0.49
1
Sex
Female
1.05 (0.91– 1.2)
0.9 (0.8 – 1.1)
IIIa
1
<0.0001
1
TNM
IIIb
1.5 (1.1 – 2.0)
2.3 (1.4 – 3.8)
IIIc
3.0 (2.2 – 4.0)
5.3 (3.2 – 8.6)
Well/mod differentiated
1
<0.0001
1
Grade
Poorly differentiated
1.8 (1.6 – 2.2)
1.6 (1.3 – 2.0)
1
<0.0001
1
Primary tumor Right
Left
0.65 (0.56 – 0.75)
0.7 (0.57 – 0.86)
location
0
1
<0.0001
1
Charlson
1-3
1.3 (1.1 – 1.6)
0.8 (0.6 – 1.1)
Comorbidity
4 or more
2.9 (2.3 – 3.7)
1.8 (1.22 – 2.6)
index
2009 – 2009
1
0.79
1
Year
Diagnosed
2010 – 2013
0.98 (0.83– 1.2)
1.0 (0.9 – 1.1)
Fluoropyrimidine only
1
<0.0001
1
Adjuvant
0.50 (0.41– 0.61)
0.54 (0.43–0.70)
Chemotherapy Oxaliplatin doublet
HR – Hazard Ratio; CI – confidence interval;
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P value
0.010

0.43
<0.0001

<0.0001
0.0008
0.0004

0.83
<0.0001

Figure 3: All-cause mortality by adjuvant chemotherapy regimen for all patients (n=1626)
When stratified by age, the addition of adjuvant oxaliplatin demonstrated an OS benefit in patients
<70 years (HR 0.56 95% CI 0.41 – 0.77, p=0.0003) and ≥70 years (HR 0.72 95% CI 0.53 – 0.98, p =
0.037) which remained significant in multivariate analysis (Table 7 and Figure 4). Sex and year of
diagnosis were not significant in univariate analysis and were therefore not included in the final
model.
Table 7. Univariate and multivariate analyses for overall survival stratified by age
Characteristic

TNM

Grade

Primary
tumor
location
Charlson
Comorbi
dity
index
Adjuvant
Chemoth
erapy
Regimen

IIIa
IIIb
IIIc
Well/mod
differentiated
Poorly
differentiated
Right
Left
0
1-3
4 or more
Fluoropyrimidi
ne only
Oxaliplatin
doublet

Pts < 70 years (n=971)
Univariate HR
Multivariate
P
(95% CI)
(95% CI)
value
1
1
<0.000
1
1.6 (0.9– 2.9)
1.7 (0.9 – 3.3)
4.1 (2.3 – 7.1) 4.4 (2.3 – 8.2)
1
1
0.0007

1.5 (1.04 - 2.0)
2.7 (1.9 – 3.9)
1

3.0 (1.4 – 6.4)
6.4 (3.0 – 13.9)
1

2.0 (1.5 – 2.7)

1.7 (1.3 – 2.5)

1.6 (1.4 – 2.0)

1.5 (1.1 – 2.0)

1

1

1

1

0.6 (0.5 – 0.8)
1
0.8 (0.6 – 1.2)
2.4 (1.4 – 3.9)

0.5 (0.4 – 0.7)
1
0.6 (0.4 – 1.0)
1.8 (0.9 – 3.3)

0.80 (0.6– 0.9)
1
1.2 (1.01– 1.5)
2.4 (1.8 – 3.2)

0.9 (0.7 – 1.2)
1
0.9 (0.6 – 1.2)
1.9 (1.2 – 3.1)

1

1

1

1

0.6 (0.4– 0.8)

0.4 (0.3 – 0.6)

0.7 (0.5– 0.9)

0.6 (0.5 – 0.8)

<0.000
1
0.01

<0.000
1
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Pts ≥ 70 years (n=655)
Univariate HR
Multivariate
(95% CI)
1
1

P value
<0.0001

0.01

0.39

0.01

0.005

Figure 4: All cause mortality by adjuvant chemotherapy regimen stratified by patient age at diagnosis

Oxaliplatin doublet chemotherapy was associated with a preserved OS benefit in patients with
significant comorbidity (patients with CCI≥2, univariate HR 0.40 95% CI 0.29 – 0.61, p<0.0001),
including patients<70 (HR 0.38 95% CI 0.16 – 0.94, p=0.02), but not in patients ≥70 years (HR 0.67,
p=0.28). Exploratory subgroup analysis demonstrated a diminishing OS benefit to oxaliplatin with
increasing age, with the hazard ratio becoming approaching 1 (no benefit) for more elderly patients
(Figure 5).

Figure 5: Unadjusted hazard ratio for overall survival benefit to oxaliplatin chemotherapy stratified
by age. The circle on each bar represents the HR for that age group, and the bar shows the
95% confidence interval (CI).
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6.2.4

Discussion

Colon cancer is more common in the elderly, since 67 is the median age at diagnosis, and almost 40%
of patients are ≥75 years old36,37. Despite this, the pivotal phase III trials which demonstrated the
improved OS with adjuvant oxaliplatin chemotherapy in stage III colon cancer included a only small
minority of patients older than 70, and consequently were unable to show a benefit to oxaliplatin in
this population36,51. As a result of this, Australian guidelines recommend fluoropyrimidine
monotherapy as the most appropriate adjuvant chemotherapy regimen in elderly patients, although
European Guidelines recommend a more individualised approach52,53
The principle finding of the current study is a statistically significant improved OS with adjuvant
oxaliplatin doublet chemotherapy compared to fluoropyrimidine monotherapy in patients ≥70 years
with stage III colon cancer (HR 0.72, p=0.037). This difference remained significant in multivariate
analysis which included a comorbidity index (multivariate HR 0.64, p=0.005).
There is no consensus in the literature regarding the benefit of adjuvant oxaliplatin for elderly
patients. Neither DFS nor OS was significantly improved in the small minority of elderly patients in
the MOSAIC or NSABP-07 trials, or ACCENT database39,40,43 In contrast, pooled individual patient
data from four other randomised trials, which included comorbidities as a covariate, demonstrated
improved DFS and OS with oxaliplatin 44. Similarly, there are disparate results seen in “real world”
patient series. Analysis of the SEER database showed a persistent benefit to adjuvant oxaliplatin in
patients >70, although with inconsistent results in patients older than 75, and in those with significant
comorbidities45,46 . Other results from smaller retrospective series are conflicting47,54. One common
criticism of all the above studies, as well as the current work, is the omission of an assessment for
medical frailty, an important and distinct entity to comorbidity55.
It is important to highlight that the elderly patients who received oxaliplatin chemotherapy in the
current study are likely to represent a highly selected subgroup. This is supported by the observed
high completion rate of adjuvant oxaliplatin doublet chemotherapy in patients ≥70 years, although we
note that data regarding chemotherapy dosing, dose reductions, and delays, which may provide further
insight, are not available. Consistent with other published series, we found increasing age was
associated with decreased receipt of any adjuvant chemotherapy and oxaliplatin doublet
chemotherapy, with only 18.8% of patients ≥70 years, and 3% ≥ 80 years, receiving oxaliplatin46,47,56.
Similarly, increasing level of comorbidity, quantified by the CCI, was also associated with decreased
receipt oxaliplatin (p<0.0001), with most of the elderly patients who received oxaliplatin (86.2%)
having minimal comorbidities (CCI <2).
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Despite presumed patient selection for oxaliplatin doublet therapy, hospital admissions were modestly
increased in elderly patients compared to younger patients. Elderly patients who received oxaliplatin
doublet chemotherapy more likely to be admitted to hospital, require multiple admissions to hospital,
or require admissions for febrile neutropenia. These observations were not seen in patients receiving
fluoropyrimidine monotherapy, consistent with current literature which shows increased toxicity in
the elderly from doublet chemotherapy, but not fluoropyriminde monotherapy42,44,47,57,58. We
acknowledge that the hospital admission data do not reflect all toxicity, as at least some complications
are likely to have been managed out of hospital. It also important to highlight we did not find a
significant difference in 12 month landmark OS between chemotherapy regimens in elderly patients.
The decision to proceed with adjuvant chemotherapy in an elderly patient is complicated and depends
on many patient health and social factors. Patients age, comorbidities, and perceived minimal benefit
are the predominant reasons for withholding adjuvant chemotherapy in elderly patients59. While the
average life expectancy of an otherwise healthy 70-year old male and female is approximately 8 years
and 14 years, respectively38, many elderly patients have significant comorbidities that could shorten
survival. While we used the 70yrs age cut-off in our primary analysis for consistency with other
publications, our exploratory subgroup analyses demonstrated, as expected, a diminishing benefit to
adjuvant oxaliplatin with increasing age. Moreover, while the benefit for adjuvant oxaliplatin
increases with time in younger patients, in older patients it decreases, so by three years after surgery
the competing mortality risks eliminate the benefit of doublet adjuvant chemotherapy43. The recently
presented data from the IDEA collaboration supports a risk adapted approach to duration of adjuvant
chemotherapy, with a shorter duration of adjuvant chemotherapy in lower risk disease to reduce
treatment associated toxicities60. These data, along with our study, support the role of individualised
treatment approach, rather than strict age cut-offs, when determining the optimal adjuvant strategy for
elderly patients.
There are limitations to the current study. Firstly, we analysed an observational database and
acknowledge important unmeasured confounders and selection bias between treatment groups.
Secondly, there was no data available regarding chemotherapy dosing, dose reductions, or treatment
delays, for any patients. However while it is likely that most of the elderly patients received dose
modifications to improve tolerability61, we still found an OS benefit.
6.2.5

Conclusion

Our study demonstrates a survival benefit to adjuvant chemotherapy with an oxaliplatin doublet over
fluoropyrimidine alone for patients ≥70 years with stage III colon cancer. However, we also found
evidence of modestly increased hospital admission rates with doublet treatment. The potential for
survival benefit must be weighed against the increased risk of toxicities in this population, as well as
individual patient life-expectancies, based on co-morbidities and other factors.
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Chapter 7

Discussion

This chapter contains an overview of this thesis. The principle findings of each of the previous
chapters are presented, followed by a discussion of the clinical and research implications, and future
directions for research.
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7.1 Summary of principle findings
7.1.1

The urokinase plasminogen activation system, in particular uPAR, is a clinically relevant
biomarker in all stages of gastroesophageal cancer

Chapter 2 presented the first systematic review and meta-analysis of urokinase plasminogen activator
(uPA), urokinase plasminogen activator receptor (uPAR), plasminogen activator inhibitor-1 (PAI1/SerpinE1) and plasminogen activator inhibitor-2 (PAI-2/SerpinB2) expression in primary
oesophageal, gastro-oesophageal junction, and gastric adenocarcinomas. The meta-analysis of
clinicopathological associations, overall survival (OS) and recurrence free survival (RFS) provided
strong evidence that higher expression of uPA, uPAR or PAI-1 is significantly associated with high
risk clinicopathological features and poorer prognosis. High uPA expression was associated with a
shorter RFS (HR 1.90, p=0.01) and OS (HR 2.21, p<0.0001). High uPAR expression was associated
with poorer OS (HR 2.21 p<0.0001). High PAI-1 expression was associated with shorter RFS (HR
1.96 p=0.03) and OS (HR 1.84, p<0.0001). There was no significant association between PAI-2
expression and OS, although data was limited. Thus uPA, uPAR and PAI-1 are proven to be novel
and clinically relevant biomarkers in resected gastro-esophageal cancer and, as such, have the
potential to be developed as prognostic and/or therapeutic targets.
In Chapter 3 uPAR expression was shown to be significantly associated with expression of cancer
stem cell (CSC) makers. Tumours expressing CD44 and ALDH1 were more likely to have high
expression of uPAR (p = 0.02 and 0.03 respectively). These results agree with previous work in other
tumours showing co-expression of CSC markers and uPAR, and provide further evidence
demonstrating the importance of uPAR expression on CSCs. Strong similarities between the uPAR
positive phenotype and CSCs were also noted, including invasive potential, drug resistance, and
poorer prognosis.
These findings are extended in Chapter 3 appendix, where, for the first time, evidence is provided
that expression of uPAR is an independent prognostic factor of metastatic gastroesophageal cancer.
High expression of uPAR on cancer cells at the invasive edge of metastatic deposits was associated
with a shorter OS in multivariate analysis (HR 1.5 95%CI 1.1 - 2.1, p<0.0001). These findings
validate the use of uPAR as a prognostic biomarker across all stages of gastroesophageal cancer.
Despite the above results, the study detailed in Chapter 4 appendix shows that uPAR expression
does not improve the standard CK+/CD45-/DAPI+ phenotype for EpCAM selected CTCs. Only a
weak association between tumour tissue and CTC uPAR expression was found, and there was no
association between % uPAR positive CTCs and tumour stage. Most importantly, % uPAR+ CTCs
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did not have any significant association with OS. These negative results are likely attributable to the
isolation method employed in the study rather than a true depiction of the role of uPAR expression on
CTCs. The CTCs were isolated using EpCAM immunomagnetic separation, which restricted analyses
to high EpCAM expressing CTCs only, thereby omitting CTCs which have downregulated EpCAM
as part of EMT or due to an EMT/CSC phenotype.
7.1.1.1 Significance of findings and future directions
These results provide level 1 evidence for the uPA system as an independent prognostic factor in
primary gastroesophageal cancer, a finding which has immediate clinical applicability.
In addition, these results provide an improved understanding of the molecular underpinnings of
gastroesophageal cancers which is fundamental for the development of improved molecularly targeted
therapeutics. There is an increasing interest in the uPA system, particularly uPAR, as both a
biomarker and treatment target in solid tumours. Local and international research groups continue to
develop agents directed at the uPA system with promising pre-clinical results 1-3. The co-expression of
uPAR and CSC markers provide a strong rationale for anti-uPAR therapies as a novel approach to
target the CSC sub-populations. In addition, promising results from early clinical trials suggest
radiolabelled uPAR as an improved imaging modality for cancer diagnosis, staging, and risk
stratification 4.
Despite the results of the CTC study, there remains a compelling rationale for uPAR to be considered
as a strong candidate marker to improve CTC selection, particularly for isolating EpCAM negative
CTCs with the capacity to invade the extracellular matrix and establish metastasis. Future work
should therefore employ alternative methods to isolate CTCs such as targeting EMT/CSC markers for
isolation, physical properties or negative selection (alternative methods comprehensively reviewed by
Alix-Panabieres et al 5). It is important to note that the widespread expression of uPAR on activated
leukocytes, as would be expected in a pro-inflammatory state such as advanced malignancy, may limit
the specificity of positive selection of CTCs using uPAR 6.
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7.1.2

Expression of the cancer stem cell marker CD44 is an independent prognostic factor in
metastatic gastroesophageal cancer

Chapter 3 provided the first evidence that expression of CSC markers on metastatic disease is an
independent prognostic biomarker in gastroesophageal cancer. This IHC study, using deposits of
metastatic gastroesophageal cancer from 36 patients, found a significant association between OS and
expression of CD44 (HR 2.9 95%CI 1.3 – 6.9, p=0.008) and ALDH1 (HR 2.4 95% CI 1.01 – 5.7,
p=0.04) in univariate analysis. In multivariate analyses, after controlling for tumour grade, ECOG
performance status, and treatment received, CD44 remained an independent predictor of poorer OS
(HR 2.5 95%CI 1.1 – 6.2, p=0.04). The result for ALDH1 was not significant in multivariate analyses,
but it is important to note the limitations of the small sample size.
There was no increased expression of CSC markers in tumours of patients who had received
chemotherapy. Although this result appears contradictory to the well described chemoresistance of
CSC, it is consistent with modern refinements to the CSC theory, which describe a fluid CSC
population regulated by the tumour-cell environment, rather than a rigid hierarchical structure 7,8.
Following enrichment after chemotherapy, the CSCs reconstitute the differentiated bulk of the tumour
mass. As all samples were taken at clinical progression, we posit there was sufficient time for the
equilibrium between the CSC and bulk of tumour to be restored.
7.1.2.1 Significance of findings and future directions
These results provide the first evidence that CD44 CSC marker expression is an important biomarker
in metastatic gastroesophageal cancer, and provide further support to the key role of CSCs in the
molecular pathogenesis of gastroesophageal cancer. It is important to note the small sample size
employed in the study, which necessitates further validation using a larger cohort in the future.
As addressed in Section 1.2.2, there is a growing evidence base to support the incorporation of CSC
targeting in the treatment of cancer. Our results, which are the first to confirm and quantify CSC
expression in metastatic gastroesophageal cancer, provide additional validity to the ongoing
development of clinical trials of CSC directed treatment in metastatic cancers. We eagerly await the
results of numerous trials for CSC targeted agents in gastroesophageal cancer (summarised by BekaiiSaab et al 9).
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7.1.3

Cryopreservation of CTCs is valid strategy for enumeration and biomarker detection in
gastroesophageal cancer

Chapter 4 details a robust protocol for the cryopreservation and thawing of the patient samples for
CTC isolation and characterisation after long term storage. This study was conducted in two phases;
firstly, the reliability of our protocol was confirmed with only a minor loss of CTCs observed between
matched cryopreserved and fresh samples collected at the same blood draw. Secondly, a larger cohort
of cryopreserved specimens was used to validate our method by demonstrating the prognostic
association of CTC enumeration from cryopreserved specimens. In addition, the ability to extensively
characterise CTCs isolated from cryopreserved specimens was shown by staining for a novel
biomarker, uPAR, on the thawed CTCs.
7.1.3.1 Significance of findings and future directions
A persisting challenge to the field of circulating tumour cell (CTC) research has been the requirement
for prompt analysis of samples at specialised centres. This has presented significant logistical
challenges to researchers, compounded by the significant expertise, time and laboratory resources
required for CTC analysis. Our results demonstrate the feasibility and validity of cryopreservation of
CTCs, which has wide ranging and significant impacts on both research and clinical care.
Cryopreservation has the potential to dramatically increase the number and range of studies using
CTC analysis. It will assist with the wider incorporation of CTC collection and analysis in
biobanking, retrospective studies, and large international clinical trials, by facilitating specimen
storage, bulk transporting, and batch processing. It may also help to develop diagnostic settings that
can service even remote patients with diagnostic CTC data potentially relevant for their disease
management.

203

7.1.4

Circulating tumour cell culture provides an accurate in vitro model for the study of
metastasis

Chapter 5 details the establishment and characterisation of two novel CTC cell lines from patients
with gastroesophageal cancer. These two cell lines demonstrate distinct genotypic and phenotypic
profiles providing a unique insight into disparate pathobiological mechanisms in metastatic
gastroesophageal cancers. One of these cell lines (RFCTC), established from a patient with high grade
neuroendocrine tumour, exhibited strong expression of neuroendocrine markers (chromogranin
A+/synaptophysin+/CD56+) but no EpCAM expression and only weak cytokeratin staining. The
other cell line (JICTC), derived from a patient with a distal gastric adenocarcinoma, displayed a
strong CK+/EpCAM+/CD44+ phenotype. Both cell lines demonstrated rapid tumour growth in
immunodeficient mice.
7.1.4.1 Significance of findings and future directions
These newly established CTC cell lines are highly significant for the following key reasons:
They are first CTC cell lines described in metastatic gastroesophageal cancer, and one of the few CTC
cell lines described worldwide. Moreover, RFCTC is one of only several high grade gastrointestinal
neuroendocrine cell lines. Both these cell lines provide a valuable addition to the limited worldwide
resources to facilitate ongoing research into metastasis formation and high throughput drug testing.
The cell lines provide further evidence to support CTC culture as a feasible and clinically relevant
laboratory technique. CTC culture continues to be characterised by modest success rates. This was
consistent with our experience; 2/23 (8%) patient samples successfully developed long term CTC
cultures. However, these CTC cultures were established without highly specialised laboratory
equipment, and have been maintained without the need for highly defined culture media. Our results
support the broad application of CTC culture as a laboratory technique, although further protocol
refinements are needed to improve culture success rates.
Our results highlight the increasingly recognised limitations of EpCAM selection as an isolation
method for CTCs, by demonstrating highly tumourigenic cell lines established form EpCAM+ and
EpCAM- CTCs. Isolation techniques which do not include EpCAM- CTCs are likely to miss
biologically relevant subpopulation of cells. The optimal technique for isolating and defining CTCs
continues to be a rapidly evolving field.
As targeted treatments become more ubiquitous, there is an urgent need to develop improved methods
204

for personalising treatment through preclinical modelling. Ex vivo culturing of CTCs provide a
critical tool to study cancer metastases, in addition to providing an ideal platform for the
individualised preclinical testing for functional drug and radiotherapy testing. While other developing
liquid biopsy techniques, such as ctDNA provide dynamic molecular data on tumour progression and
resistance, CTC culture has the additional benefit of providing viable tumour cells for functional
testing. The long term promise of ex vivo CTC culture is the development of a rapid preclinical “drug
avatar” model for the optimisation of individual treatments, providing assistance for clinical decision
making in real time. While low success rates and delays in confirming successful cultures are key
ongoing challenges to this goal, our success provides assurance that this paradigm is achievable.
7.1.5

Primary tumour location is an independent prognostic factor in locoregional colon cancer

The prognostic role of primary tumour location in locoregional colon cancer remains a hotly debated
and highly relevant topic. Chapter 6.1 used multivariable cox hazard regression on a prospectively
collected database, the New South Wales clinical cancer registry, to demonstrate that primary tumour
location is an independent prognostic indicator in stage II (HR 0.85, p=0.02) and III (HR 1.13,
p=0.032) colon cancer.
This study, using the most comprehensive population based database available in the literature, had
several important distinguishing features from previously published work which reduce bias and
validate the findings;
Firstly, by linking the cancer registry with a second prospectively collected database, the admitted
patient database, a clinically validated measure of comorbidity – the “Charlson Comorbidity Index”was able to be generated for each individual patient. This provides a much more detailed view of
participant’s comorbidities than any other published study, minimising the impact of selection bias in
the results.
Secondly, by linkage to a third prospectively collected database, the births, deaths and marriage
registry, an accurate date and cause of death was obtained for each patient, allowing a hazard
regression models of both overall survival and cancer specific survival. The inclusion of cancer
specific survival provided confirmation of our primary OS results.
Thirdly, the details of adjuvant chemotherapy, including regimen, was included for a subset of
patients (including the majority of patients with stage III disease). Primary tumour location is known
to be a significant factor on chemotherapy effect in colon cancer, and inclusion of the chemotherapy
regimen reduced the confounding seen in most other reported series.
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7.1.5.1 Significance of findings and future directions
The results contribute to a growing body of evidence demonstrating that primary tumour location is an
important prognostic factor in colon cancer. Due to the strengths discussed above, this study provides
the most robust population-level data to support primary tumour location as an independent
prognostic factor in early stage colon cancer. Moreover, these results have immediate clinical
applicability. The included study population was a modern cohort of Australian patients managed
with currently employed treatments, and the results therefore can be directly applied to routine clinical
care.
The observed difference in prognosis between LsCC and RsCC is postulated to be due to differences
in tumour biology. While some differences in the molecular profile between LsCC and RsCC, such as
BRAF mutations and microsatellite instability, are well described, ongoing research is urgently
needed to further characterise and compare molecular profiles of LsCC and RsCC. Primary tumour
location may be a clinical surrogate for further, yet unidentified, predictive biomarkers as highlighted
by the recent data from the FIRE3 and CALGB/SWOG 80405 trials, which suggests a reduced benefit
to anti-EGFR treatment in RsCC independent of currently identified biomarkers

10

.

These results

support the inclusion of primary tumour location as a stratification factor in clinical trials for all stages
in colon cancer.
7.1.6

Adjuvant chemotherapy has a preserved OS benefit in the elderly; A comprehensive clinical
assessment, rather than age alone, should be used when deciding adjuvant chemotherapy
regimens in colon cancer.

Despite recent progress in immunotherapy and targeted agents, chemotherapy is the only adjuvant
treatment shown to improve survival in stage III colon cancer. However, due to poor representation in
clinical trials, the optimum adjuvant treatment is unknown in elderly patients, presenting a daily
clinical dilemma to medical oncologists. Chapter 6.2 provides a critical new source of evidence for
this contentious issue. A large, prospectively collected, comprehensive, cancer registry dataset linked
to governmental hospital data was used to quantify adjuvant chemotherapy rates and regimen choice
for elderly patients. Multivariable cox hazard regression models demonstrated a persistent survival
benefit to adjuvant oxaliplatin doublet chemotherapy for stage III colon cancer in the elderly, although
at a cost of increased toxicity in this age group, demonstrated by an increase in chemotherapy
discontinuation rates and hospital admissions.
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7.1.6.1 Significance of findings and future directions
This study is the first population-level data series to incorporate comorbidities into multivariate
models, and explore the toxicities associated with treatment using hospital admission data, providing a
uniquely comprehensive analysis of benefits and risks of adjuvant oxaliplatin doublet chemotherapy
in the elderly patient. The results support an individualised treatment approach, rather than strict age
cut-offs, when determining the optimal adjuvant strategy for elderly patients.
These results remain limited by the observational design of the study, and the potential for
unmeasured confounders and selection bias between treatment groups. The currently recruiting
PRODIGE34 clinical trial, which randomises elderly patients to adjuvant oxaliplatin doublet or
fluoropyrimidine monotherapy, aims to provide a definitive answer to this question 11.

7.2 Conclusions
Despite recent progress, gastrointestinal cancers remain highly lethal diseases and the predominate
cause of cancer related deaths worldwide. Ongoing research is required to build on recent successes to
improve the care and lives of patients with these cancers. Not only are new biomarkers and targets
desperately needed, but also the optimisation of existing treatments to maximise benefits to patients.
We continue to work with hope to shape a future where patients with early stage disease are cured,
and the majority of patients with metastatic gastrointestinal cancer have long term survival and a good
quality of life.
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ABSTRACT
Background: The urokinase plasminogen activation (uPA) system is a crucial
pathway for tumour invasion and establishment of metastasis. Although there is good
evidence that uPA system expression is a clinically relevant biomarker in some solid
tumours, its role in gastroesophageal cancer is uncertain.
Results: We identified 22 studies encompassing 1966 patients which fulfilled
the inclusion criteria. uPA, uPAR, or PAI-1 expression is significantly associated
with high risk clinicopathological features. High uPA expression is associated with a
shorter RFS (HR 1.90 95% 1.16–3.11, p = 0.01) and OS (HR 2.21 95% CI 1.74–2.80,
p < 0.0001). High uPAR expression is associated with poorer OS (HR 2.21 95%CI
1.82–2.69, p < 0.0001). High PAI-1 expression is associated with shorter RFS (HR
1.96 96% CI 1.07–3.58, p = 0.03) and OS (HR 1.84 95%CI 1.28–2.64, p < 0.0001).
There was no significant association between PAI-2 expression and OS (HR 0.97
95%CI 0.48–1.94, p < 0.92) although data was limited.
Materials and Methods: We undertook a systematic review evaluating expression
of uPA, urokinase plasminogen activator receptor (uPAR), plasminogen activator
inhibitor-1 (PAI-1/SerpinE1) and plasminogen activator inhibitor-2 (PAI-2/SerpinB2)
on primary oesophageal, gastro-oesophageal junction, and gastric adenocarcinomas.
We performed a meta-analysis of clinicopathological associations, overall survival
(OS) and recurrence free survival (RFS).
Conclusions: We conclude that the uPA system is a clinically relevant biomarker
in primary gastroesophageal cancer, with higher expression of uPA, uPAR and PAI-1
associated with higher risk disease and poorer prognosis. This also highlights the
potential utility of the uPA system as a therapeutic target for improved treatment
strategies.
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INTRODUCTION

[5]. High expression of uPAR on the invasive front of
tumours facilitates invasion and other roles in cellular
migration and angiogenesis [6]. uPAR expression may
be a suitable marker for the onset of invasion of both
gastro-intestinal and breast cancer as it is expressed only
on invasive carcinomas, not premalignant states such as
Barrett’s oesophagus [7].
Urokinase-type plasminogen activator is efficiently
inhibited by two subtypes of serpin (serine proteinase
inhibitor) family members, plasminogen activator
inhibitor-1 (PAI-1/SerpinE1) and –2 (PAI-2 /SerpinB2).
Both form a covalent complex with uPA/uPAR leading
to internalisation of the entire complex [8] . Although
believed to have a physiological role as an inhibitor of
the uPA system, PAI-1 has a paradoxical protumourgenic
role, increasing tumour invasion and angiogenesis, and
correlated with poor prognosis [9]. The role of PAI-2 in
cancer is less clear. Although both PAIs mediate uPA/
uPAR endocytosis, the uPA-PAI-2 complex interacts with
endocytosis receptors with different binding kinetics to
those of uPA:PAI-1 and without stimulating intracellular
signalling events over and above that of uPA binding to
uPAR [10].
While the uPA system is expressed on both cancer
cells and the supporting stroma, higher expression is
seen on tumour cells, and is postulated that the tumour
cell specific uPA/uPAR explains the aggressive biology
exhibited by these cancers, and is more relevant for
prognostic outcomes [11–14]. Expression of the uPA
system has been shown to be an important prognostic
marker in a variety of cancers including breast cancer

Gastroesophageal cancer is a common and lethal
malignancy, marked by modest response to systemic
therapies [1]. A deeper understanding of molecular events
characterising carcinogenesis, invasion, progression and
metastasis is central for the development of novel therapies.

The uPA system
A key process in the development and progression
of cancer, including establishment of metastatic disease,
is the invasion of malignant cells into normal tissue. The
plasminogen activation system, particularly the urokinasetype plasminogen activator (uPA) system, is critical for
tumour-associated proteolysis to breakdown extracellular
matrix (ECM) and basement membranes barriers [2]. The
uPA system has a defined role in tissue degradation and
extravascular fibrinolysis, and is responsible for most of
the activated plasminogen associated with cancer invasion
and metastasis [2, 3] (Figure 1).
The uPA protein is secreted as a zymogen and
activated on high affinity binding to its specific cell
surface receptor uPAR. Once activated, uPA catalyses the
activation of co-localised plasminogen to plasmin, which
in turn directly degrades components of the ECM, and
promotes further degradation and tissue remodelling by
activating pro-metalloproteinases and by releasing, thus
activating, latent growth factors from the ECM [4].
The uPA receptor (uPAR) is anchored to the plasma
membrane, localising the uPA system to the cell surface

Figure 1: The uPA system. Schematic representation of the urokinase plasminogen activation (uPA) system. The membrane bound

urokinase receptor (uPAR) binds circulating inactive pro-uPA, facilitating the activation of pro-uPA to uPA which subsequently converts
co-localised plasminogen to plasmin that can directly degrade components of the extracellular matrix (ECM) and activate pro-matrix
metalloproteases (MMP) to further break down ECM. Plasminogen activator inhibitors 1 or 2 (PAI-1, PAI-2) are efficient endogenous
inhibitors of uPA.
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[15], lung cancer [16], and colorectal cancer [17], with the
combination of uPA and PAI-1 expression recommended
to be incorporated into routine clinical care of node
negative breast cancer [18].
In this study we aim to perform a comprehensive
systematic review of expression of the uPA system
encompassing uPA, uPAR, PAI-1, and PAI-2 in primary,
resectable gastro-oesophageal cancer, and undertake
meta-analyses of prognostic outcomes (recurrence free
survival and overall survival), and association with
relevant clinicopathological variables. To the best of our
knowledge, this is the first meta-analysis to examine and
compare the expression of these key components of uPA
system in primary gastro-oesophageal cancer.

population [7, 12, 13, 30–40] and 11 studies did not report
completeness of followup [7, 12, 13, 30–33, 36, 38, 39, 41].
Most studies adequately reported method of measurement of
the uPA system, although 5 studies did not report whether
there was a second independent reviewer or blinding to
clinical information [13, 35, 39, 40, 42]. The followup
protocol was underreported in 14 studies [7, 11–13, 30–
36, 38–40], although this is unlikely to bias the results for
overall survival analyses. Most studies did not report details
of the surgical, medical, or radiation treatments received by
patients, and were Urokinase plasminogen activator (uPA).

Urokinase plasminogen activator (uPA)
uPA expression rates

RESULTS

Expression of uPA was evaluated in 13 studies (1254
patients). The mean expression of uPA was 52.8%, but had
a large range (from 23% to 91%). There was no significant
difference in mean expression for IHC (60.7%) and ELISA
(45.6%) (p = 0.10).

Included studies
The trial flow is provided in Figure 2. We identified
267 reports matching criteria for inclusion in the study,
of which 109 were selected for abstract review, and 60
subsequently for full text review. Forty one studies
(including 2689 patients) fulfilled criteria for inclusion
in the systematic review, with 22 studies (1966 patients)
providing sufficient data for inclusion in the formal
quantitative meta-analysis: 19 studies were excluded
for the following reasons: 12 studies did not examine
prognostic or clinicopathological associations, 3 reports
were matched case control studies, and 4 studies reported
insufficient published data to derive a HR.
The characteristics of the included studies are
summarized in Supplementary Table 1. Eighteen studies
evaluated uPA system expression in gastric cancer (1732
patients), one study included oesophageal, junctional and
gastric cancers (39 patients), and two studies examined
oesophageal cancer only (105 patients). Expression of the
uPA system was assessed using immunohistochemistry (IHC,
12 studies, 1273 patients), enzyme-linked immunosorbent
assay (ELISA, 5 studies, 344 patients), reverse transcription
polymerase chain reaction (RT-PCR, 3 studies, 153 patients),
or in-situ hybridisation (ISH, one study, 105 patients).
Hazard ratios directly extracted for 3 studies
[7, 11, 22]. The multivariate HR was used when univariate
value was not provided [22]. When only subgroup outcome
data (tumour core or peripheral zone) were available, the
results for peripheral “invasion” zone were used [7, 11].
Hazard ratios were estimated for the remaining studies
using published data. 4 studies reported a “non-statistically
significant OS” result for uPA system expression, but did not
publish sufficient data for inclusion in meta-analysis [23–26].

uPA and clinicopathological associations
uPA expression is significantly associated with poorer
clinicopathological features in resected gastroesophageal
cancer including: Advanced T stage (T3/4 vs T1/2) (OR
2.79 95% CI 1.80–4.32, p < 0.0001), nodal metastases
(OR 2.30 95% CI 1.63–3.51, p < 0.0001), liver
metastases (OR 6.77 95% CI 2.70–16.96, p < 0.0001),
peritoneal metastases(OR 2.09 95% CI 1.29–3.36, p =
0.003), lymphatic invasion (OR 2.28 95% CI 1.31–3.97,
p = 0.0003), and vascular invasion (OR = 2.43 95%
CI 1.53–3.86, p = 0.0002) (5 studies, 522 patients,
Supplementary Figure 1). There is no significant association
with histology (poorly differentiated vs well differentiated).
uPA expression and prognosis
uPA expression was significantly associated with
a worse RFS (3 studies, 467 participants, HR 1.90 95%
1.16–3.11, p = 0.01) (see Supplementary Figure 2). There was
no significant difference in RFS seen between studies using
IHC (HR 1.77) or ELISA (HR 2.36) to assess uPA expression
(test for subgroup differences Chi2 = 0.37, p = 0.54).
uPA expression is significantly associated with
poorer OS (12 studies, 1094 participants, HR 2.21 95%
CI 1.74–2.80, p < 0.0001) (see Figure 4). There was no
significant difference in OS between studies which used
IHC (HR 1.94) or ELISA (HR = 2.99) to assess uPA
expression (p = 0.38). Sensitivity analysis showed similar
results when analysis was restricted to gastric cancer only
(HR 2.07, p < 0.00001).

Urokinase plasminogen activator receptor (uPAR)

Bias risk

uPAR expression rates

The risk of bias summary is summarized in Figure 3.
Only 4 studies [22, 27–29] were deemed low risk in all bias
domains. Fourteen studies did not clearly define the study
www.impactjournals.com/oncotarget
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uPAR expression and prognosis

14–90%), with similar mean expressions seen in IHC
(56.8%) and ELISA/RT-PCR (56.7%).

Only one study provided data for uPAR expression
and RFS [42], showing a shorter RFS with uPAR
expression (203 patients, HR 2.69, p = 0.03).
uPAR expression is associated with poorer OS
(11 studies, 1036 patients, HR 2.19 95% CI 1.80–2.66,
p < 0.0001) (Figure 5). There was no significant difference
in OS seen between studies which used IHC (HR 2.13),
ISH (HR 2.34), ELISA (HR 2.19), or RT-PCR (2.66) to
assess uPAR expression (p = 0.96).

uPAR expression and clinicopathological associations
uPAR
expression
on
primary
resected
gastroesophageal cancer is significantly associated with
poorer clinicopathological features including: advanced
TMN stage (stage III/IV vs I/II, OR 3.41 91% CI 1.55–7.53,
p = 0.002), advanced T stage (OR 2.33 95% CI 1.53
to 3.56, p < 0.0001), nodal metastases (OR 2.52 95%
CI 1.70–3.72, p < 0.0001), liver metastases (OR 2.53 95%
CI 1.25–5.13, p = 0.010), peritoneal metastases (OR 3.15
95% CI 1.87–5.28, p < 0.0001), lymphatic invasion
(OR 2.82 95% CI 1.74–4.59, p < 0.0001) and vascular
invasion (OR 3.85 95% CI 2.53–5.88, p < 0.0001) (six
studies, 589 patients, Supplementary Figure 3). There is
no significant association seen with histology (p = 0.6).

Plasminogen activator inhibitor-1 (PAI-1)
PAI-1 expression rate
Twelve studies (1031 patients) examined PAI-1
expression. Mean PAI-1 expression was 53.3%, with no

Figure 2: Study selection flow diagram. HR –hazard ratio; OS–overall survival; RFS–recurrence free survival.
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p = 0.47) and ELISA (HR 2.94, p < 0.0001) or RT-PCR
(HR 2.83, p < 0.0001) (p = 0.02).

statically significant difference in expression between IHC
(61.8%) and RT-PCR/ELISA (44.7%) (p = 0.1).
PAI-1 expression and clinicopathological variables

Plasminogen activator inhibitor-2 (PAI-2)

PAI-1 expression on primary resected gastroesophageal
cancer is significantly associated with poorer
clinicopathological features including: advanced T stage (OR
2.59 95% CI 1.61 to 4.18, p < 0.0001), nodal metastases (OR
2.03 95% CI 1.27–3.22, p < 0.003), lymphatic invasion (OR
2.09 95% CI 1.31–3.34, p < 0.004) and vascular invasion
(OR 1.90 95% CI 1.20–3.03, p < 0.007) (three studies, 317
patients, Supplementary Figure 4). There was no significant
association of PAI-1 expression with presence of liver
metastases (OR 0.52, p = 0.18), peritoneal metastases (OR
1.38, p = 0.31), or histology (OR 0.93, p = 0.74).

PAI-2 expression rate
Two studies (145 participants) assessed PAI-2
expression (all using IHC) (refer to Supplementary
Table 1). Mean expression was 57.5%.
PAI-2 expression and clinicopathological variables
There were no studies with sufficient data analyzing
PAI-2 expression and clinicopathological variables for
inclusion in the meta-analysis.
PAI-2 expression and prognosis

PAI-1 expression and prognosis

No studies published data on PAI-2 expression
and RFS. There was no significant association of PAI-2
expression and OS (2 studies, 145 participants, HR 0.97
95%CI 0.48–1.94, p < 0.92, Supplementary Figure 6).

PAI-1 expression is associated with shorter RFS
(3 studies, 467 patients, HR 1.96 96% CI 1.07–3.58, p =
0.03) (Supplementary Figure 5). There was no significant
difference in RFS between studies which used IHC or
ELISA to detect PAI-1 expression (p = 0.86)
PAI-1 expression is significantly associated with a
shorter OS (10 studies, 839 participants, HR 1.84 95%CI
1.28–2.64, p < 0.0001, Figure 6). Pre-specified subgroup
analysis showed a significant difference between studies
which assessed PAI-1 expression using IHC (HR 1.20,

Publication bias
Examination of the funnel plots for the OS analysis
for uPA, uPAR and PAI-1 showed asymmetrical plots for
all analyses, suggesting absence of smaller negative trials
(example plot for uPA provided in Supplementary Figure 7).

Figure 3: Risk of bias summary. For each bias domain: green = “low risk” means that sufficient data was available to allow assessment

of quality and fulfilled criteria for each domain, and accordingly is deemed low risk of bias. Orange = “unclear risk” means that insufficient
data was presented to adequately assess the quality of the domain and accordingly the study has potentially high risk of bias. There were
no studies deemed high risk of bias.
www.impactjournals.com/oncotarget
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DISCUSSION

this result should be interpreted with caution due to the
following important limitations in our study.
Firstly, only four of the included studies were
deemed low risk for all bias domains as assessed by the
QUIPS tool. In particular, most studies did not report
the treatments patients received which is an important
potential source of confounding for RFS and OS analyses.
Additionally, tumours with higher risk clinicopathologic
features could reasonably be expected to be more likely
to have received neoadjuvant treatment prior to surgery,
which may in turn have impacted on the expression of the
uPA system. Despite this, it should be noted that similar
results were seen in studies deemed low and high risk of
study confounding, and heterogeneity was low in both
the uPA and uPAR OS meta-analyses (I2 = 31% and 0%
respectively, see Figures 4 and 5).
Secondly, there is evidence of underreporting of nonsignificant results. This is demonstrated by both the funnel
plot, as well the selective reporting of only statistically
positive findings from included studies. This important bias
will cause an overestimation of the effect of expression.
Thirdly, as demonstrated above, tumours that
expressed uPA, uPAR and PAI-1 had higher risk features,

This meta-analysis confirms the clinical utility of the
uPA system as a biomarker in resected gastro-oesophageal
adenocarcinoma.
There is good evidence that high expression of
uPA, uPAR, and PAI-1 is associated with most high
risk clinicopathological features, including advanced
T stage, presence of nodal and distant metastases, and
lymphovascular invasion, in primary gastro-oesophageal
adenocarcinoma. This supports the central role of the uPA
system in tumour invasion and metastasis. In contrast,
there was no significant association of expression found
with poorly differentiated histology, consistent with
previously published work which shows that epithelial cell
uPA system expression is higher in malignant than benign
tissue, but decreases as tumour becomes more poorly
differentiated, with a corresponding increase in stromal
expression [43].
We also demonstrated that uPA, uPAR, and PAI-1
expression is associated with poorer prognosis in resected
gastro-oesophageal cancer, with both a shorter RFS and
OS in tumours which expressed these markers. However

Figure 4: Pooled estimate of hazard ratio (HR) for uPA expression and overall survival (OS). Pooled estimate of hazard
ratio (HR) for overall survival. The square on each bar represents the HR for an individual trial, and the bar shows the 95% confidence
interval (CI). The diamond represents a pooled estimate with the centre of the diamond giving the HR estimate, and the extremes of the
diamond representing the 95% CI. 24.
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and RT-PCR (HR 2.83, p = 0.0007). This highlights the
importance of the stromal production of PAI-1 within the
tumour microenvironment [9], as only methods that took into
account both stromal and tumour PAI-1 showed statistically
significant prognostic outcomes. It has been postulated that
in contrast to uPAR, fibroblasts and endothelial cells provide
the major source of PAI-1 within the tumour tissue [45]. It
is possible that the PAI-1 detected on the tumour cells by
IHC may be explained by internalization and accumulation
of stromal produced uPA-PAI-1 complexes mediated by
tumour uPAR [46]. No IHC studies examined the association
between stromal PAI-1 expression and prognostic outcomes
in gastro-oesophageal cancer.
All IHC study results used in the meta-analysis
were restricted to tumour cell expression only. Similar to
other cancers, uPA system expression was highest at the
invasive front of the tumour [7, 11, 12, 31]. Only four

and would be expected to recur or progress sooner than
tumours that did not. The apparent difference in prognostic
outcomes may be due to unequal baseline characteristics
of the included participants.
We did not show a significant difference in the
prognostic outcomes between studies which used a tumour
cell specific technique (e.g. IHC) compared to whole
tissue lysates (e.g. RT-PCR, ELISA) for uPA and uPAR.
This is consistent with other studies which have shown
correlation between IHC score and median ELISA value,
and supports the cancer cells as a major source of uPA and
uPAR expression in the tumour tissue [44].
In contrast, there was a significant different in the
expression methodology subgroups in the analysis for
PAI-1 and OS (p = 0.02), with a non-significant outcome
seen in studies using IHC (HR 1.20, p = 0.47), compared
to significant results with ELISA (HR 2.94, p < 0.0001)

Figure 5: Pooled estimate of hazard ratio (HR) for uPAR expression and overall survival (OS).
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studies reported stromal expression of the uPA system
[7, 11, 12, 42]. Results were conflicting, with only one study
showing a significant association of OS with macrophage
uPAR expression on the invading zone at the periphery of
the tumour [7]. In colorectal cancer, high uPAR expression
on macrophages in the tumour core, rather than the
periphery, is an independent predictor of poor prognosis
[47]. These studies suggest an important supporting role
of the tumour associated macrophages within the tumour
microenvironment. The contrasting pattern of high uPAR
expression (core versus peripheral) may be due to differing
phenotypes of the subpopulations of tumour preventing (M1
macrophages) and tumour promoting (M2 macrophages)
macrophages within the heterogeneous tumour bulk [48]
. Further work is required to elucidate the biology of the
stroma in gastrointestinal cancers.
We were unable to show any significant associations
with PAI-2 expression with either clinicopathological
features or prognostic outcomes, as available data was
much more limited. Similarly only 3 studies examined
oesophageal cancer, which limits applicability of our results
to this subgroup. Sensitivity analysis did not show a different
result when oesophageal cancer was excluded from analysis.

In conclusion, expression of the uPA system is
a clinically relevant biomarker in gastroesophageal
cancer. There is good evidence to support the association
of uPA, uPAR, and PAI-1 expression and high risk
clinicopathological features. While we found a statistically
significant association between uPAR, uPAR and PAI-1
expression and poorer prognosis, our results are tempered
by methodical limitations discussed above. Our findings
also highlight the potential utility of the uPA system as a
therapeutic target for improved treatment strategies.

MATERIALS AND METHODS
Methods are reported according to Preferred
Reporting for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines [19].

Study eligibility/selection criteria
We included all studies which examined the
following components of the urokinase plasminogen
activation system uPA, uPAR, PAI-1 or PAI-2, in resected
primary esophageal, gastroesophageal junction, or

Figure 6: Pooled estimate of hazard ratio (HR) for PAI-1 expression and overall survival (OS).
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gastric adenocarcinomas. Other tumour pathologies were
excluded. A ll methods of assessing expression, including
reverse transcription polymerase chain reaction (RTPCR), enzyme-linked immunosorbent assay (ELISA),
in-situ hybridization (ISH), and immunohistochemistry
(IHC) were included. For inclusion in the metaanalysis, studies were required to report the association
of the following outcomes with uPA system expression:
overall survival (OS), recurrence-free survival (RFS), or
clinicopathological variables.
Two authors (DB, JC) independently performed the
search and screened the studies. The primary outcome was
OS; secondary outcomes were RFS, and correlation of
clinicopathological variables with uPA system expression.

and loss to followup; prognostic factor measurement;
outcome measurement; study confounding; and statistical
analysis and reporting [20].

Statistical analysis
We extracted the hazard ratio (HR) and their
95% confidence intervals (CI) for time-to-event
outcomes including RFS and OS. If both univariate and
multivariate HR were published the univariate results
were preferentially used. Where no HR was provided in
published data, it was estimated from available results or
Kaplan-Meier survival curves using previously described
methods [21].
HRs were synthesized using the generic inverse
variance method and a random effect model using
RevMan5.1 analysis software. Statistical heterogeneity
was assessed using the I2 statistic. We performed prespecified subgroup analysis for overall survival for:
primary location (gastric or oesophageal), cancer cell
specific expression (using IHC) compared to whole cell
lysis (using RT-PCR/ELISA).
Clinicopathological associations were summarized
using odds ratios (OR) derived from published results.
This analysis was limited to studies using IHC, as other
methods presented expression results as means, rather than
percentage of patients expressing. Expression rates were
described with mean and range, and compared using the
student’s t-test.

Study search strategy
We searched the following databases in February
2015 for all trials fulfilling the above criteria: Medline
(1950–present); EMBASE (1966–present); Cochrane
Central Register of Controlled Trials, and Cochrane
Database of Systematic Reviews; PubMed.
To maximize sensitivity the following search terms
were used: Stomach Neoplasms (MESH) OR Esophageal
neoplasms (MESH) OR Gastrointestinal neoplasms
(MESH) OR Gastric cancer.mp OR Gastric carcinoma.
mp OR esophageal cancer.mp OR oesophageal cancer.
mp OR gastroesophageal cancer.mp AND Receptors,
urokinase plasminogen activator (MESH) OR Urokinasetype plasminogen activator (MESH) OR Plasminogen
activator inhibitor 1 (MESH) OR Plasminogen activator
inhibitor.mp OR PAI-1.mp OR PAI-2.mp OR Urokinase*
plasminogen.mp OR uPA*.mp. Reference lists of included
studies and review articles were hand searched. The search
was restricted to studies published in English.
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Abstract

circulating tumor cell (CTC) enumeration from cryopre
served peripheral blood mononuclear cells. Cryopre
servation may assist with the wider incorporation of
CTC collection and analysis in biobanking, retrospec
tive studies, and large international clinical trials, by
facilitating specimen storage, bulk transporting, and
batch processing.

AIM
To demonstrate the feasibility of cryopreservation
of peripheral blood mononuclear cells (PBMCs) for
prognostic circulating tumor cell (CTC) detection in
gastroesophageal cancer.
METHODS
Using 7.5 mL blood samples collected in EDTA tubes
from patients with gastroesopheagal adenocarcinoma,
CTCs were isolated by epithelial cell adhesion molecule
based immunomagnetic capture using the IsoFlux
platform. Paired specimens taken during the same
blood draw (n = 15) were used to compare number
of CTCs isolated from fresh and cryopreserved PBMCs.
Blood samples were processed within 24 h to recover
the PBMC fraction, with PBMCs used for fresh analysis
immediately processed for CTC isolation. Cryopre
servation of PBMCs lasted from 2 wk to 25.2 mo
(median 14.6 mo). CTCs isolated from pre-treatment
cryopreserved PBMCs (n = 43) were examined for
associations with clinicopathological variables and
survival outcomes.

Brungs D, Lynch D, Luk AW, Minaei E, Ranson M, Aghmesheh
M, Vine KL, Carolan M, Jaber M, de Souza P, Becker TM.
Cryopreservation for delayed circulating tumor cell isolation
is a valid strategy for prognostic association of circulating
tumor cells in gastroesophageal cancer. World J Gastroenterol
2018; 24(7): 810-818 Available from: URL: http://www.
wjgnet.com/1007-9327/full/v24/i7/810.htm DOI: http://dx.doi.
org/10.3748/wjg.v24.i7.810

INTRODUCTION
Circulating tumor cell (CTC) analysis continues to be a
rapidly developing field in oncology, offering a promising
tool to both prognosticate and guide managements for
[1]
patients . Despite recent advancements in the field,
one persisting challenge to the widespread adoption
of CTC analysis for translational clinical trials or routine
clinical care is the limited time frame considered
best for blood processing and CTC isolation. Usually
fresh blood is processed for CTCs within 24 h after
blood draw, requiring prompt transfer to specialised
centres for CTC isolation and analysis, which offers
[2]
significant logistical challenges . To overcome this
issue, some studies use blood collection tubes that
contain fixatives. Fixation of blood samples can allow
CTC processing delayed by several days which has
[3,4]
proven very useful for some CTC analyses . However,
fixatives may interfere with down-stream molecular
[5]
analyses that require isolation of nucleic acids . An
alternative is the use of cryopreservation protocols for
peripheral blood mononuclear cells (PBMCs) to allow
delayed CTC isolation from these cells followed by CTC
analysis. Cryopreservation should overcome fixation
related analysis limitations and allow far more flexible
time frames for batched CTC processing. However, a
defined, robust cryopreservation protocol that is proven
to enable analysis of the same or at least a relevant
proportion of CTCs to that found in fresh samples,
needs to be adopted and confirmation is needed
whether cryopreserved CTCs can still predict disease
outcome.
The advantage of cryopreservation of PBMCs is that
it requires only minimal local processing, possible in
most diagnostic settings, as well as feasible cryostorage
and frozen transport of PBMC samples.
While there are a large number of approaches used
to isolate and identify circulating tumor cells (recently

RESULTS
While there was a significant trend to a decrease in
CTC numbers associated with cryopreserved specimens
(mean number of CTCs 34.4 vs 51.5, P = 0.04), this
was predominately in samples with a total CTC count
of > 50, with low CTC count samples less affected (P
= 0.06). There was no significant association between
the duration of cryopreservation and number of CTCs.
In cryopreserved PBMCs from patient samples prior
to treatment, a high CTC count (> 17) was associated
with poorer overall survival (OS) (n = 43, HR = 4.4,
95%CI: 1.7-11.7, P = 0.0013). In multivariate analysis,
after controlling for sex, age, stage, ECOG performance
status, and primary tumor location, a high CTC count
remained significantly associated with a poorer OS (HR
= 3.7, 95%CI: 1.2-12.4, P = 0.03).
CONCLUSION
PBMC cryopreservation for delayed CTC isolation is a
valid strategy to assist with sample collection, trans
porting and processing.
Key words: Cryopreservation; Circulating tumor cells;
Liquid biopsy; Gastroesophageal cancer; Gastric cancer
© The Author(s) 2018. Published by Baishideng Publishing
Group Inc. All rights reserved.

Core tip: This study demonstrates a novel and robust
protocol for the cryopreservation and thawing of patient
blood samples, demonstrating reliable circulating tumor
cell isolation and characterisation after the long term
storage of patient samples. Using the largest patient
cohort reported to date, we validated our method by
confirming the independent prognostic association of
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[6]

reviewed by van der Toom et al ), the best established
TM
and most widely used is the CellSearch system
(Menarini-Silicon Biosystems), which uses positive
immunomagnetic isolation of epithelial cell adhesion
molecule (EpCAM, an epithelial cell marker) expressing
cells followed by cytokeratin (CK), CD45, and DAPI
[2]
staining . The CTCs are then identified with automated
immunofluorescence microscopy, defined by an EpCAM/
CK/DAPI positive and CD45 negative phenotype. Cell
Search CTC counts have shown to be prognostic in
[7-9]
large patient series in a variety of cancers , including
[10-12]
gastroesophageal cancer
, but the instrument offers
limited sensitivity in resectable gastroesophageal cancer,
[10,13]
with CTCs detected in less than 15% of patients
.
The IsoFlux system (Fluxion) uses a similar definition
of CTCs to CellSearch (EpCAM/CK/DAPI positive,
CD45 negative phenotype), but has shown a greater
[14-16]
sensitivity for CTC detection
. This platform uses
EpCAM targeted immunomagnetic isolation of CTCs
within a microfluidic setting, improving isolation of CTCs
with lower EpCAM expression, minimising leukocyte
contamination, and allowing downstream applications
including staining, enumeration, or sequencing, as
[16]
shown for fresh blood samples .
Here, we use a viable method of PBMC cryopre
servation that allows subsequent isolation and immu
nocytochemical analysis of CTCs. We demonstrate
the feasibility of PBMC cryopreservation for delayed
CTC isolation using paired cryopreserved and freshly
processed blood samples drawn at the same time
from patients with gastroesophageal adenocarcinoma.
Importantly, we also provide data confirming that
cryopreserved CTCs remain clinically applicable as a
circulating prognostic marker for overall survival (OS).

participant before sample collection.

Sample preparation

Blood samples were processed within 24 h to recover
the PBMC fraction using 50 mL SepMate tubes and
Lymphoprep according to manufacturer’s instructions
(Stemcell Technologies, Vancouver, BC, Canada).
PBMCs used for fresh analysis were resuspended in
Isoflux Binding Buffer and immediately processed for
CTC isolation (see below).
PBMCs for cryopreservation were well resuspended
in 1 mL of diluted plasma (the supernatant of the
PBMC preparation from the matching patient) with the
addition of 7.5% final DMSO, and stored at -80 ℃ until
further processing. Cryopreserved samples were thawed
according to the protocol from Fluxion Biosciences, San
[17]
Francisco, California, United States . In brief, warmed
(37 ℃) thawing buffer, consisting of RPMI 1640 with
10% Fetal Bovine Serum (FBS, Bovogen Biologicals,
Australia) and 50 Unit/mL Benzonase (Sigma-Aldrich,
Germany), was added to thawed samples, washed once
in thawing buffer, and resuspended in IsoFlux Binding
Buffer with 5% FBS.

Circulating tumor cell isolation, staining, and imaging

As per the Fluxion protocol, immunomagnetic beads
preconjugated with anti-EpCAM antibodies (CTC
Enrichment Kit; Fluxion Biosciences Inc) were added
to PBMCs suspended in IsoFlux Binding Buffer, and
incubated for 90 min at 4 ℃ with passive mixing on a
rotator. Samples were then loaded into the sample well
of the microfluidic cartridge and underwent immuno
magnetic isolation of CTCs with the IsoFlux using the
standard protocol (Fluxion Biosciences Inc).
Recovered CTCs were blocked with a final concen
tration of 1.2 µg/µL mouse IgG in binding buffer (Jackson
ImmunoResearch, Baltimore, PA, United States) for
30 min, washed and fixed in fixing solution (Fluxion
Biosciences Inc). The CTCs were then blocked in 10%
FBS in binding buffer for 15 min, then underwent immu
nofluorence staining for anti-CD45 antibody conjugated
to Alexa Fluor 647 (Biolegend, Clone HI30). The
CTCs were also stained for urokinase plasminogen
activator receptor (uPAR, CD87), a key receptor in the
plasminogen activator system and clinically relevant
[18]
biomarker in primary gastroesophageal cancer , using
anti-uPAR antibody conjugated to AF594 (ThermoFischer,
Clone R4). After permeabilization with 0.1% Triton
X-100, cells were probed with anti-cytokeratin antibody
conjugated to FITC (Sigma-Aldrich, Clone PCK-26). CTCs
were finally stained with Hoechst and mounted using
Isoflux mounting media to 24-well glass bottom plates
(MoBioTec, Goettingen, Germany) for imaging.
Imaging was performed with an inverted epifluo
rescence microscope (Leica DMi8, Leica Microsystems
Pty Ltd) using the Leica Application Suite. Cells were
considered CTCs if they were CK positive, CD45

MATERIALS AND METHODS
Patient population

Blood samples were collected from patients with
histologically confirmed distal oesophageal, gastroe
sophageal junction, or gastric adenocarcinomas treated
at Wollongong Hospital, Australia. Blood samples were
collected in 7.5 mL EDTA Vacutainer tubes (Sarstedt
AG & Co.) and maintained at room temperature until
processing.
In the initial cohort (Cohort 1) to confirm the feasi
bility of cryopreservation, 15 patients with gastroe
sophageal carcinomas had 2 specimens taken during
the one blood draw, one processed within 24 h (“fresh”
specimen), and one cryopreserved with delayed CTC
isolation and analysis (“cryopreserved” specimen). Pretreatment blood samples were cryopreserved from a
second, larger cohort of patients for correlation with
clinical outcomes (Cohort 2). The study was approved
by South Western Sydney Local Health District Human
Research Ethics Committee (Project Number 15/072).
A written informed consent was obtained from each
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DAPI

CK

CD45

uPAR

Merged

Fresh

Cryopreserved

20 μm

Figure 1 Representative images of circulating tumor cell isolation from fresh and cryopreserved samples demonstrating preservation of leukocyte and
circulating tumor cell morphology. The fresh sample demonstrates a nucleated CK+/CD45- CTC which is uPAR negative, as well as a CK-/CD45+ leukocyte. The
cryopreserved sample shows a uPAR positive CTC. CTC: Circulating tumor cell.

negative, nucleated and morphologically intact. The
proportion of uPAR positive CTCs was recorded.

similar to fresh samples (Figure 1). There was a
significant difference between CTC numbers isolated
from the cryopreserved samples compared to fresh
samples (mean number of CTCs 34.4 cryopreserved vs
51.5 fresh, P = 0.04, Figure 2), however this difference
was predominately attributable to a larger fall in CTC
numbers in samples with very high CTC counts (> 50
CTCs in the fresh specimen). There was no significant
difference in CTC count between cryopreserved and
fresh samples for specimens with CTC count less than
50 (n = 11 patients, mean number of CTCs 10.7 vs
16.3, P = 0.06). Thus CTC loss by cryopreservation in
patient samples with low CTC counts appears relatively
minor (mean proportion of CTCs lost in cryopreserved
samples = 23.95%).

Statistical analysis

The CTC recovery from matched cryopreserved and
fresh samples were compared with the paired t-test.
Correlation between cryopreservation time and CTC
number was described with a Pearson correlation
coefficient, and the Fisher exact test and t-test were
used to compare the status of CTCs with categorical
clinicopathologic factors.
For survival analyses, in the absence of established
cut-offs for prognostic CTC numbers, the median CTC
count (17) was used as the discriminator between high
and low CTC counts. Survival analyses are conducted
using Kaplan-Meier methods, with median survival
reported. Unadjusted and multivariable Cox proportional
hazards regression analyses were used to estimate the
association between CTC counts and survival, and to
calculate corresponding hazard ratios (HRs) and 95%
confidence intervals (CIs). The following variables were
included in the multivariate model: age, sex, ECOG,
TNM stage, primary tumor location, and CTC count.
All statistical analyses were performed using SAS 9.2
software (SAS Institute, Inc., Cary, NC, United States).

Cryopreserved circulating tumor cell and clinical
outcomes (cohort 2)

A larger cohort of 43 gastroesophageal cancer
patients (cohort 2) was analyzed to validate whether
detectable CTC counts post cryopreservation correlated
to disease outcomes. All patient samples were taken
prior to treatment commencement and had undergone
cryopreservation before CTC isolation. Cohort 2 included
the 10 treatment naive patients from cohort 1. Patient
characteristics of cohort 2 are summarised in Table 1.
Twenty-four patients had resectable disease (Stage
Ⅱ or Ⅲ). Post CTC evaluation, 11 of these patients
received neoadjuvant chemoradiotherapy prior to
resection (CROSS regimen), 3 received perioperative
chemotherapy (MAGIC regimen), and 10 had surgery
alone. Nineteen patients had metastatic disease (stage
Ⅳ). Most of these patients received chemotherapy
(7 patients: platinum and capecitabine doublet, 3
patients: anthracycline, capecitabine, and platinum
triplet, 1 patient: irinotecan or paclitaxel monotherapy),
immunotherapy (2 patients), and 6 patients received no
active systemic treatments.
CTCs were detected in 42/43 patients (95.5%),

RESULTS
Matched fresh and cryopreserved specimens (cohort 1)

Matching parallel blood samples, collected from 15
gastroesophageal cancer patients (10 patients had
blood taken prior to treatment, 5 patients were already
on treatment), that had either been cryopreserved
before CTC processing or were processed fresh, were
compared. Cryopreservation of PBMCs lasted from 2 wk
to 25.2 mo (median 14.6 mo). There was no significant
correlation between cryopreservation time and CTC
number (Pearson r -0.25, P = 0.09). CTCs isolated
from cryopreserved samples appeared morphologically
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Table 1 Characteristics of patients in cohort 2 n (%)
CTC count

Age
Mean (range)
Sex
Male
Female
ECOG
0-1
2-4
Primary tumor location
Distal oesophageal
Gastroesophageal junction
Gastric
Stage
Ⅱ
Ⅲ
Ⅳ

All patients

Low (CTC ≤ 17)

High (CTC > 17)

n = 43

n = 23

n = 20

64 (39-89)

65 (39-89)

64 (48-83)

32 (74.4)
11 (25.6)

15 (65.2)
8 (34.8)

20 (85.0)
3 (15.0)

36 (83.7)
7 (16.3)

22 (95.6)
1 (4.3)

14 (70.0)
6 (30.0)

12 (27.9)
14 (32.6)
17 (37.5)

8 (34.8)
4 (17.4)
11 (47.8)

4 (20.0)
10 (50.0)
6 (30.0)

18 (41.9)
6 (14.0)
19 (44.2)

13 (56.5)
4 (17.4)
6 (26.1)

5 (25.0)
2 (10.0)
13 (65.0)

CTC: Circulating tumor cell; ECOG: Eastern cooperative oncology group performance status.

250

200
150
Number of CTCs

CTC count

200

150

100
50
0

100

-50
Localised

50

Figure 3 Circulating tumor cell count by stage. CTC processing post
cryopreservation produced a higher mean CTC count in metastatic patients
compared to the resectable patients (mean CTC in metastatic 53.8 vs
resectable 15.8, P = 0.0013). CTC: Circulating tumor cell.

0
Fresh

Cryopreserved

Figure 2 Circulating tumor cell enumeration by processing method.
Mean number of CTCs isolated in the fresh specimens were higher than in the
matched cryopreserved sample (mean difference in CTCs 17.1 95%CI: 0.7-33.6,
P = 0.043). This difference was mostly driven by larger falls in CTC counts in
samples with high numbers of CTCs (> 50 CTCs in fresh samples), with no
significant difference in CTC counts for samples with less than 50 CTC in the
fresh specimen (P = 0.06).

1.7-11.7, P = 0.0013). In multivariate analysis, after
controlling for sex, age, stage, ECOG performance
status, and primary tumor location, a high CTC count
remained an independent prognostic factor associated
with poor OS (Table 2, HR = 3.7, 95%CI: 1.2-12.4,
P = 0.03). This association was stronger when the
analysis was restricted to patients with metastatic
disease (n = 19, HR = 5.5, 95%CI: 1.2-25.5, P = 0.01),
but not observed in patients with resectable disease
(n = 24, P = 0.39), although a high CTC count (> 17)
was associated with a non-significant trend to shorter
recurrence free survival in these patients (HR = 3.1,
95%CI: 0.8-12.6, P = 0.09).
Most patients had some uPAR positive CTCs (40/43,
93.0%), however the proportion of uPAR positive CTCs
was similar between patients with localised and meta
static disease (mean proportion uPAR positive CTCs
48.8% vs 47.7% respectively, P = 0.89), and there was
no association with survival outcomes (Supplementary

with a median CTC of 17 (interquartile range 8-38).
Patients with metastatic disease had a higher number
of CTCs than those with resectable disease (Figure 3,
mean CTC count 53.8 vs 15.8, P = 0.0013).
Currently there are no established cut-offs for
prognostic CTC numbers detected using the IsoFlux
in gastroesophageal adenocarcinoma. Therefore we
opted to divide our patients by their CTC counts, above
versus equal or lower than the median CTC count,
to test for any correlation with clinical outcomes.
Patients with a high CTC count (> 17) had a poorer
OS than those with a lower CTC count (≤ 17) (Figure
4, median OS 2.8 mo vs 23.2 mo, HR = 4.4, 95%CI:
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Table 2 Univariate and multivariate analysis for overall survival for cohort 2 (n = 43)
Univariate

Multivariate

Factor

HR (95%CI)

P value

HR (95%CI)

P value

CTC count (high vs low)
Age (≥ 65 vs <65 yr old)
ECOG (2-4 vs 0-1)
Sex (male vs female)
Stage (Ⅳ vs Ⅱ-Ⅲ)
Primary tumor location (gastric vs oesophageal/GOJ)

4.4 (1.7-11.7)
0.7 (0.3-1.8)
7.2 (2.2-23.7)
1.2 (0.4-3.8)
10.0 (3.3-30.8)
0.3 (0.1-1.01)

0.001
0.46
0.0002
0.7
< 0.0001
0.05

3.7 (1.2-12.4)
1.0 (0.9-1.1)
2.3 (0.5-10.1)
0.7 (0.2-2.1)
9.9 (2.9-33.8)
0.4 (0.2-1.6)

0.03
0.76
0.14
0.49
0.0003
0.22

Significant values are italicised. In both univariate and multivariate analysis, a high CTC count (> 17) remained statistically significant as an independent
factor associated with poorer overall survival. CTC: Circulating tumor cell; ECOG: Eastern cooperative oncology group performance status; GOJ:
Gastroesophageal junction.

central processing. This would be a huge benefit for
larger scale clinical trials as it would allow inclusion of
geographically separated sites.
Previous work has shown that the immunochemical
properties of CK, EpCAM and CD45, central to the
isolation and identification of CTCs, are not affected
[20,21]
by cryopreservation and thawing
. In agreement,
our results demonstrate a similar morphological and
immunofluorescent profile between cryopreserved
and fresh CTCs and leukocytes, suggesting current
techniques are suitable for cryopreserved samples.
This approach is further supported by other work
showing close concordance in genetic alterations seen
[21]
on paired fresh and frozen CTCs .
Our results also show that enumeration of CTCs
isolated from cryopreserved PMBCs is a valid prognostic
biomarker in gastroesophageal cancer. Patients with
metastatic disease had a significantly higher number
of CTCs than those with resectable disease (mean CTC
count 53.8 vs 15.8, P = 0.0013). Moreover, patients
with a high CTC count (> 17) had a much poorer OS
than those with a lower CTC count (≤ 17) (HR = 4.4,
P = 0.0013). High CTC count remained significant in
the multivariate analysis as an independent predictor
of poorer OS (HR = 3.7, P = 0.03), after controlling for
age, ECOG, sex, stage and primary tumour location,
particularly when analysis was restricted to patients with
metastatic disease only (HR = 5.5, P = 0.01). These
results are concordant with other studies which confirm
CTC enumeration as an important prognostic factor in
[10-12]
gastroesophageal cancer
.
Given our previous findings that the uPA system is a
clinically relevant biomarker in primary gastroesophageal
[18]
cancer , we undertook and successfully probed for
uPAR expression in CTCs derived from cryopreserved
and fresh samples. We previously have shown that
higher expression of uPA, uPAR and PAI-1 in the
primary tumour is associated with higher risk disease
and poorer prognosis. However, in this study, there
was no correlation between CTC uPAR expression with
disease parameters. This suggests that the selection of
epithelial (EpCAM-positive) CTCs might have affected
any correlation of uPAR with patient outcome, as
CTCs that present mesenchymal phenotypes, such as

Percent survival

100

50

≤ 17 CTC
> 17 CTC
0

0

6

12

18

24

t /mo

Figure 4 Overall survival by circulating tumor cell count. Patients with >
17 CTCs isolated from cryopreserved specimens had a poorer overall survival
compared to those with ≤ 17 CTCs (median OS 2.8 mo vs 23.2 mo, HR = 4.4,
95%CI: 1.7-11.7, P = 0.0013). OS: Overall survival; CTC: Circulating tumor cell.

Figure 1, median OS 17.0 mo vs 12.8 mo, P = 0.6).

DISCUSSION
In this study we report the reliable isolation, immuno
cytochemical identification, and enumeration of gastroe
sophageal cancer CTCs from cryopreserved PBMCs
using the IsoFlux platform. The included cohort is the
largest reported study analysing cryopreservation of
patient PBMCs for CTC detection. Our data confirms
that CTCs isolated from cryopreserved samples remain
an independent prognostic factor associated with OS.
The timely processing of patient samples for CTC
isolation, usually is recommended within 24 h for most
[19]
isolation methods , presenting significant logistical
challenges for researchers and prohibits inclusion of
patients from remote areas into clinical trials that would
rely on CTCs as outcome measures. This is mainly be
cause current methods of CTC analysis require signifi
cant expertise, instrumentation, time and laboratory
resources, usually performed in specialised research
centres. Protocols using isolation of CTCs from cryop
reserved specimens would require some basic proces
sing and cryopreservation at the site of blood draw, but
offer many advantages, including the ability to biobank
patient samples for prolonged periods of time before
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uPAR expressing cells, can escape standard methods
[22]
of isolation reliant on epithelial markers . Indeed
[23]
Vishnoi et al . has previously reported the isolation
of subsets of EpCAM-negative, uPAR and integrin β1
positive breast cancer CTCs, which further supports the
[23]
concept of CTC heterogeneity . Ultimately, we have
successfully stained for a novel biomarker, uPAR, which
further supports our cryopreservation method as a valid
CTC isolation approach.
One important concern with cryopreservation is the
potential for loss of CTCs due to cell loss during freezing,
[20]
storage, or thawing. In a study by Nejlund et al , tumor
cell recovery from cryopreserved spiked tumor cells in
normal controls was variable, with up to a 40% tumor
cell loss. However in clinical samples using matched
fresh and cryopreserved specimens from the same
patient, there was no consistent loss of CTCs, with the
variation in CTC enumeration similar to those seen in
[2,20]
paired fresh samples in other studies
. Friedlander
[21]
et al
found that cryopreservation of PBMCs had no
significant effect on the cell recovery from patients with
metastatic prostate cancer. We noted a small loss of
CTCs associated with cryopreservation, however this
was predominately in samples with large numbers
of CTCs (> 50), where loss of some CTCs is more
acceptable than samples with low CTC counts. We
noted samples with high numbers of CTCs were more
prone to cell clumping despite benzonase. This is
normally due to the release of viscous DNA from cell
lysis on thawing, leading to aggregates which prevent
accurate CTC counting. We speculate that the higher
disease burden in these patients, coupled with a
corresponding systemic inflammatory response, lead
to poorer cell integrity within the PBMCs of high CTCcount samples. Some loss of CTCs in these samples
will have little impact for prognostic and down-stream
biomarker analysis purposes. There was no significant
loss of CTCs in samples were the total CTC count was
≤ 50 (P = 0.06).
Similar to previously published work, we found that
the duration of cryopreservation was not correlated
[20]
with number of isolated CTCs . Moreover, we were
able to isolate CTCs from specimens stored at -80 ℃
for over two years, suggesting cryopreservation is a
suitable approach for long term projects that involve
biobanking of patient samples.
Even when using cryopreservation prior to CTC
isolation, we found higher numbers of CTCs (median
CTC count 17) and a higher number of patient samples
with CTCs (98%) compared to other studies using
EpCAM based CTC capture in gastroesophageal
[10-12,24]
cancer
. The correlation of CTC numbers with
disease progression implies that the CTCs we identified
are indeed disease related. Increased CTC counts
are consistent with the higher reported sensitivity
of the IsoFlux system compared to other platforms,
particularly in isolating CTCs with a lower expression of
[14-16]
EpCAM
. Our results confirm, in the largest cohort
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of patients reported to date, that a high CTC count (>
17) in cryopreserved specimen was an independent
prognostic factor associated with poorer OS (HR =
3.7). As expected from the minimal CTC loss during
cryopreservation, these data indicate that indeed
our method is suitable for delayed and centralised
CTC analysis which could help recruiting patients for
major clinical trials. In this setting it would be advanta
geous compared to fixation of blood which allows
CTC processing delayed by only several days rather
than long term biobanking. We are currently testing if
cryopreservation is also able to overcome limitations
associated with using fixative for molecular downstream analysis of CTCs that involves nucleic acid
[4,5]
extraction .
In conclusion, we have tested a robust PBMC cryopre
servation protocol that allows successful CTC isolation
even 2 years post freezing. Cryopreservation of CTCs is
feasible, with a small loss of tumor cells predominantly
in samples with a high CTC load. Enumeration of CTCs
from cryopreserved samples remained a clinically im
portant prognostic biomarker. Cryopreservation may
assist with the wider incorporation of CTC collection
and analysis in biobanking, retrospective studies, and
large international clinical trials, by facilitating specimen
storage, bulk transporting, and batch processing. It
may also help to develop diagnostic settings that can
service even remote patients with diagnostic CTC data
potentially relevant for their disease management.

ARTICLEHIGHLIGHTS
HIGHLIGHTS
ARTICLE
Research background

A persisting challenge to the field of circulating tumor cell (CTC) research is the
requirement for prompt analysis of samples at specialised centres. This has
presented significant logistical challenges to researchers, compounded by the
significant expertise, time and laboratory resources required for CTC analysis.

Research motivation

Current methods to overcome this issue, such as fixation of blood samples,
extend the time for CTC processing for several days, but may interfere with
downstream molecular analyses.
Cryopreservation of patient samples permits the wider incorporation of
CTC collection and analysis in biobanking, retrospective studies, and large
international clinical trials, by facilitating specimen storage, bulk transporting,
and batch processing. However, up to now, there has been little research in
how cryopreservation affects CTC recovery, and whether cryopreservation
retains predictive value of CTCs.

Research objectives

The primary objective of our study was to investigate the feasibility and reliability
of delayed CTC isolation from cryopreserved peripheral blood mononuclear
cells (PBMCs) layer. This was determined by percentage of CTC loss during
cryopreservation and thawing, and clinical validity of CTC enumeration from
cryopreserved samples.

Research methods

CTCs were isolated from 7.5 mL blood samples collected from patients with
gastroesophageal adenocarcinoma using EpCAM based immunomagnetic
capture with the IsoFlux platform. CTC loss with cryopreservation was
determined by comparing CTC enumeration from matched cryopreserved
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and freshly processed blood samples collected during the same blood draw.
CTCs isolated from pre-treatment cryopreserved PBMCs were examined for
association with clinicopathological variables and survival outcomes.

9

Research results

We found a minor loss of tumor cells in matched cryopreserved and freshly
processed samples, mostly in samples with high CTC counts. A high CTC
count isolated from cryopreserved PBMCs remained a statistically significant
independent prognostic factor in gastroesophageal cancer.

10

Research conclusions

Our study demonstrates a feasible and robust protocol facilitating CTC isolation
from cryopreserved PBMCs even after 2 years post freezing. Our results have
immediate applicability in the design and conduct of translational studies,
as it facilitates incorporation of CTC analysis in large international trials and
biobanking projects.

11

Research perspectives

12

There is an increasing variety of techniques used for CTC isolation described
in the literature. While the current work confirms the reliability of CTC isolation
from cryopreserved samples using immunomagnetic separation, further work
needs to be undertaken to confirm its suitability for other isolation approaches.

13
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Sidedness is prognostic in locoregional
colon cancer: an analysis of 9509 Australian
patients
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Abstract
Background/Aim: Right sided colon cancer (RsCC) is proposed to be a distinct disease entity to left sided colon
cancer (LsCC). We seek to confirm primary tumour location as an independent prognostic factor in locoregional
colorectal cancer.
Methods: All patients with stage I – III primary adenocarcinoma of colon were identified from the New South
Wales (NSW) clinical cancer registry (2006–2013). Primary tumour location (RsCC vs LsCC) survival analyses were
conducted using the Kaplan-Meier method, and adjusted hazard ratios for 5-year all-cause mortality (OS) and
5-year cancer specific mortality (CSS) were obtained using Cox proportional hazards regression.
Results: We identified 9509 patients including 5051 patients with RsCC and 4458 with LsCC. Patients with RsCC
were more likely to be older, female, have a higher Charlson comorbidity index, and have worse tumour prognostic
factors. In univariate analysis of all stages combined, those patients with RsCC had a worse overall survival (OS, HR
1.20 95% CI 1.11–1.29, p < 0.0001), although this was not significant in the multivariate analysis (HR 0.96 95% CI 0.
89–1.04, p = 0.35). Stage I patients with RsCC had a trend to improved OS (multivariate HR 0.84 95% CI 0.69–1.01,
p = 0.07) and a significantly improved CSS (multivariate HR 0.51 95% CI 0.35–0.75, p = 0.0006). In stage II patients
with RsCC there was a significantly improved OS (multivariate HR 0.85 95% CI 0.75–0.98, p = 0.02) and CSS (multivariate HR
0.59 95% CI 0.45–0.78, p = 0.0002) compared to LsCC. In stage III patients, those with RsCC had a worse OS (multivariate HR
1.13 95% CI 1.01–1.26, p = 0.032) and a trend to worse CSS (multivariate HR 1.12 95% CI 0.94–1.33, p = 0.22).
Conclusions: Primary tumour location is an important prognostic factor in locoregional colon cancer with an effect that
varies by stage. RsCC is associated with lower all-cause mortality in stage II, and higher all-cause mortality in stage III.
Keywords: Colonic neoplasms/mortality, Colonic neoplasms/pathology, Neoplasm staging

Background
Colorectal (CRC) is a common and lethal malignancy,
projected to account for 13% of all new cancer cases
diagnosed in Australia in 2015, and 10% of Australian
cancer deaths [1]. In recent years there has been increasing interest in identifying the differences between right
sided and left sided colon cancer, and the potential for
using this clinical marker as a surrogate marker of
* Correspondence: Daniel.Brungs@health.nsw.gov.au
1
Illawarra Health and Medical Research Institute, University of Wollongong,
Wollongong, NSW, Australia
2
School of Biological Sciences, University of Wollongong, Wollongong, NSW,
Australia
Full list of author information is available at the end of the article

tumour biology, with the intent of improved personalisation of systemic treatments.
There is a growing body of evidence to suggest that
right sided colon cancers (RsCC) follow a different disease process compared to left sided tumours (LsCC).
The proximal and distal colons are physiologically separate, arising from distinct embryological origins, with differences in tumour genetics, histology, presentation, and
clinical features [2–4]. Patients with RsCC are older,
more likely to be female, have more comorbidities, with
poorer tumour histopathological features [5–8].
Despite this, there is ongoing debate whether primary
tumour location is an independent prognostic factor in
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colon cancer. Most, but not all studies have found
poorer survival with RsCC [7–11]. A recent metaanalysis found a statistically significant worse overall
survival in patients with RsCC, although there was significant heterogeneity seen due the spectrum of included
study designs, disease stage, and limited information
about treatment received by patients [12]. Tumour stage
may play a role, with a large Surveillance, Epidemiology,
and End Results (SEER) program study showing worse
overall survival in Stage III RsCC patients, but not in
Stage I or II [7], although these finding have been recently challenged by a propensity score matched analysis
of the SEER database, which showed a better prognosis
in RsCC patients [9].
This current study aims to use a prospectively collected database of Australian patients to determine
whether primary tumour location is an independent
prognostic factor in locoregional colon cancer, and compare our findings to the literature.

patient services provided by New South Wales Public
Hospitals, Public Psychiatric Hospitals, Public MultiPurpose Services, Private Hospitals, and Private Day
Procedures Centres. Comorbidities of each patient were
quantified using the Charlson comorbidity index which
predicts mortality from a range of 22 comorbid conditions
[16]. ICD-10 codes were extracted from admissions prior
to diagnosis, then translated into a Charlson comorbidity
index (modified for cancer) using methods previously described [15, 16].
All data linkage was performed by the Centre for
Health Record Linkage, with only de-identified information provided to the researchers. The data sources used
for this study required ethical and data custodian approval to access, link (by an independent and approved
authority) and release for research. Approval for this
project was provided by the NSW Population & Health
Services Research Ethics Committee (approval HREC/
13/CIPHS/39).

Methods

Statistical analysis

Patient cohort

Our primary outcome was all-cause 5-year overall survival (OS) stratified by stage, defined as death within
5 years of primary diagnosis of colon cancer on basis of
dates recorded in the cancer registry and BDM databases. The secondary outcome was cancer specific 5 year
survival (CSS) stratified by stage, as per cause of death
encoded on BDM data. Median values for OS and CSSOS and corresponding 95% CI were calculated using
Kaplan-Meier methods. Unadjusted and multivariable
Cox proportional hazards regression analyses were used
to estimate the association between tumour location and
survival and to calculate corresponding hazard ratios
(HRs) and 95% confidence intervals (CIs). The following
variables were included in the multivariate model: age,
sex, Charlson Comorbidity Index, TNM stage, year of
diagnosis, grade, and adjuvant treatment (receipt and
type of adjuvant treatment performed in subset of patients only). All statistical analyses were performed using
SAS 9.2 software (SAS Institute, Inc., Cary, NC).

The New South Wales (NSW) clinical cancer registry
contains demographic and clinical data for patients diagnosed or treated for cancer in NSW, covering approximately 30% of the Australian population. Data is
collected from pathological laboratories, hospitals and
oncology departments under mandatory notification of
new cancer cases irrespective of treatment.
We identified all patients with Stage I, II or III colorectal cancer in NSW from Jan 2006 to 2013 (n = 9509)
as per third edition of the International Classification of
Diseases for Oncology (ICD-O-3) [13]. The registry also
contained adjuvant chemotherapy treatment details for a
more limited group of patients with stage II and III disease (n = 4102).
Mortality data, including cause of death, was obtained
with linkage to the NSW registry of Births, Deaths and
Marriages (BDM) by the Centre for Health Record Linkage (CHeReL) [14]. The censor data for survival data
was 1st December 2014. Primary tumour location was
defined right sided (caecum to transverse colon) or left
sided (splenic flexure to rectosigmoid). Patients with rectal cancer were excluded from analysis due to the different treatment paradigm to colon cancer in locoregional
disease. No data was available for cause of death in 935
patients (10.1%) which were therefore excluded from the
cancer specific death analyses. Patients were deemed to
have died as a result of colon cancer only if the underlying cause of death, rather than an associated cause of
death, was coded as C18–20.
Comorbidity data was obtained by CHeReL linkage of
the clinical cancer registry data to the Admitted Patient
Data Collection (APDC). The APDC contains all admitted

Results
Patient characteristics (n = 9509)

The characteristics of the NSW cohort is summarised in
Table 1. The mean follow up was 46 months (interquartile range 27 to 71 months). At the end of 5 years of
follow up, 2686 (28.2%) patients had died, with 913 reported deaths (34.0% of deaths) due to colon cancer.
22% of patients had stage I disease, 39% stage II, and
39% had Stage III. There were slightly more RsCC (53%)
than LsCC (47%). Patients with RsCC were older (61%
vs 47% older than 70 years), more likely to be female
(54% vs 42% female), had higher Charlson comorbidity
indices (CCI, 40% vs 34% CCI ≥ 1), and had worse
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Table 1 Patient characteristics (n = 9509)
All Patients (%)

Right sided tumour (%)

Left sided tumour (%)

P value

I

2104 (22)

1055 (21)

1049 (24)

<0.0001

II

3684 (39)

2059 (41)

1625 (36)

III

3721 (39)

1937 (38)

1784 (40)

1

1526 (16)

715 (14)

811 (18)

2

1030 (11)

558 (11)

472 (11)

3

5075 (53)

2741 (54)

2334 (52)

4

1868 (20)

1031 (20)

837 (19)

0

5788 (61)

3114 (62)

2674 (60)

1

3065 (32)

1576 (31)

1489 (33)

2

656 (7)

361 (7)

295 (7)

Characteristic
TNM stage

T stage

N Stage

Grade

Age group

Sex

Charlson Comorbidity Index

Adjuvant Chemotherapy

Year Diagnosed

Well differentiated

1244 (13)

635 (13)

609 (14)

Mod. differentiated

6648 (70)

3278 (65)

3370 (76)

Poorly Differentiated

1617 (17)

1138 (23)

479 (11)

≤60

1925 (20)

798 (16)

1127 (25)

61–70

2423 (25)

1189 (24)

1234 (28)

71–80

2814 (30)

1600 (32)

1214 (27)

>80

2347 (25)

1464 (29)

883 (20)

Male

4913 (52)

2317 (46)

2596 (58)

Female

4596 (48)

2734 (54)

1862 (42)

0

5957 (63)

3027 (60)

2930 (66)

1–2

5083 (22)

1172 (23)

911 (20)

3–4

1023 (11)

596 (12)

427 (10)

5

446 (5)

256 (5)

190 (4)

None

1775 (19)

955 (46)

820 (40)

Fluorouracil based

1098 (12)

553 (27)

545 (27)

Oxaliplatin doublet

1233 (13)

568 (27)

665 (33)

Unknowna

5403

2975

2428

2006–2009

5018 (53)

2644 (52)

2374 (53)

2010–2013
Totals

4491 (47)

2407 (48)

2084 (47)

9509

5051 (53)

4458 (47)

<0.0001

0.06

<0.0001

<0.0001

<0.0001

<0.0001

0.0002

0.38

a

Not included in multivariate analysis in chemotherapy cohort

prognostic features including higher TNM stage (79% vs
76% stage II/III), and higher grade tumour (23% vs 11%
poorly differentiated).

5 year all-cause mortality by primary tumour location

The observed 5 year OS for patients with RsCC was
66% (95% CI 65–67%) compared to 70% (95% CI 69–
72%) for LsCC. Unadjusted survival analysis demonstrated a higher mortality with RsCC in all stages
combined (Fig. 1, univariate HR 1.20 95% CI 1.11–
1.29, p < 0.0001). When stratified by stage there was
significant difference in OS seen only in stage III,
with a higher mortality seen in RsCC (Fig. 1, HR 1.46
95% CI 1.31–1.63, p < 0.0001) (Fig. 1).

After adjusting for sex, age, comorbidities, stage,
grade, and year of diagnosis there was no significant difference in OS between RsCC and LsCC in patients from
all stages (multivariate HR 0.96 95% CI 0.89–1.04
p = 0.35) (Table 2). When the multivariate analysis was
stratified by stage, patients with RsCC had a trend to improved survival in stage I (HR 0.84 95% CI 0.69–1.01,
p = 0.069), a statistically significant improved survival in
stage II (HR 0.85 95% CI 0.75–0.98, p = 0.02), but a
shorter survival in stage III (HR 1.13 95% CI 1.01–1.26,
p = 0.03) (see Table 3.)
Cancer specific survival (CSS) primary tumour location

The 5 year cancer specific survival (CSS) was similar for
RsCC (89%; 95% CI 88–90%) and LsCC (89%; 95% CI
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Fig. 1 5 year all-cause mortality by primary tumour location n = 9509 patients with 2686 deaths (Stage I = 2104 patients with 440 deaths, Stage
II = 3684 patients with 883 deaths, Stage III = 3721 patients with 1363 deaths)

Table 2 Multivariate model for overall survival for NSW cohort
(n = 9509)
Characteristic
Sided

Age

Grade

TNM stage

Sex

Charlson Comorbidity
Index

Year Diagnosed

Multivariate
HR (95% CI)
Left

1

Right

0.96 (0.89–1.04)

≤60

1

61–70

1.34 (1.15–1.56)

71–80

2.23 (1.93–2.56)

>80

3.97 (3.46–4.56)

Well differentiated

1

Moderately differentiated

1.22 (1.06–1.39)

Poorly Differentiated

1.87 (1.60–2.17)

I

1

II

1.05 (0.96–1.21)

III

2.00 (1.80–2.24)

87–90%). Unadjusted CSS analysis did not show a significant difference between RsCC and LsCC in all stages
combined (Fig. 2, univariate HR 1.03 95% CI 0.91–1.18,
p = 0.64). When stratified by stage, there was a significantly improved CSS seen with RsCC in stage I (HR 0.66
95% CI 0.45–0.95, p = 0.024) and stage II (HR 0.68 95%
CI 0.52–0.88 p = 0.0032), but a significantly poorer survival for stage III patients (HR 1.43 95% CI 1.21–1.66,
p < 0.0001) (Fig. 2, Table 3).
In the multivariate analysis, after adjusting for sex, age,
comorbidities, stage, grade, and year of diagnosis, patients
with RsCC had a statistically significant improved CSS in
all stages combined (HR 0.84, 95% CI 0.73–0.96, p = 0.011),
and for stage I (HR 0.51 95% CI 0.35–0.75, p = 0.0006) and
stage II (HR 0.59 95% CI 0.45–0.78, p = 0.0002) patients,
but a trend to worse survival in stage III (HR 1.12 95% CI
0.94–1.33, p = 0.22) (Table 3).

Male

1

Female

0.90 (0.83–0.97)

Effect of adjuvant chemotherapy

0

1

1–2

1.64 (1.49–1.79)

Adjuvant treatment details were available for 1631 (44%)
of patients with stage II and 2441 (66%) of patients with
stage III disease (4102 patients total). Most patients in
stage II disease did not receive adjuvant chemotherapy
(72%), with only a minority receiving fluorouracil monotherapy (24%) or an oxaliplatin doublet combination
(usually FOLFOX, 5%). In contrast, the majority of patients
with stage III disease received adjuvant chemotherapy

3–4

1.81 (1.62–2.03)

5

3.02 (2.63–3.46)

2006–2009

1

2010–2013

0.98 (0.90–1.06)

HR Hazard Ratio, CI confidence interval
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Table 3 Univariate and multivariate Hazard Ratios for NSW cohort (n = 9509) stratified by stage. Statistically significant values in bold
Overall Survival HR (95% CI)

Cancer Specific Survival HR (95% CI)

Univariate

Multivariatea

Univariate

Multivariatea

1

1

1

1

All Patients

Left Sided
Right Sided

1.20 (1.11–1.29)

0.96 (0.89–1.04)

1.03 (0.91–1.18)

0.84 (0.73–0.96)

Stage I (n = 2104)

Left Sided

1

1

1

1

Right Sided

1.03 (0.91–1.18)

0.84 (0.69–1.01)

0.66 (0.45–0.95)

0.51 (0.35–0.75)

Left Sided

1

1

1

1

Right Sided

1.002 (0.88–1.14)

0.85 (0.75–0.98)

0.68 (0.52–0.88)

0.59 (0.45–0.78)

Left Sided

1

1

1

1

Right Sided

1.46 (1.31–1.63)

1.13 (1.01–1.26)

1.43 (1.21–1.69)

1.12 (0.94–1.33)

Stage II (n = 3684)

Stage III (n = 3721)
a

Following variables were used in the multivariate analysis: age, sex, year diagnosed, Charlson Comorbidity Index, TNM stage, grade

(75%), with 28% treated with fluorouracil monotherapy,
and 47% with an oxaliplatin/ fluorouracil doublet. Higher
TNM-substage was associated with treatment with oxaliplatin doublet within both stage II (p < 0.0001) and III
(p = 0.0001). Consistent with current practice no patients
received adjuvant treatment with monoclonal antibodies.
Patients with RsCC were less likely to receive adjuvant
chemotherapy (p = 0.0002, Table 1) despite higher risk
tumour features. Adjuvant chemotherapy improved survival
in both RsCC (univariate OS HR 0.68; 95% CI 0.58–0.80)
and LsCC (univariate OS HR 0.48; 95% CI 0.40–0.58,
Additional file 1: Figure S1 and Additional file 2: Figure S2.

Inclusion of the adjuvant chemotherapy regimen into
the multivariate model did not alter the effect of primary
tumour location, although the results for RsCC in stage
II disease became non-significant (multivariate OS HR
0.86 95% CI 0.69–1.09 p = 0.19; multivariate CSS HR
0.67 95% CI 0.43–1.04, p = 0.07, Table 4). Patients with
RsCC in stage III colon cancer continued to have a significantly inferior OS compared to LsCC even after adjustment for all above factors including receipt and type
of adjuvant chemotherapy (multivariate OS HR 1.29 95%
CI 1.11–1.50 p = 0.0012; multivariate CSS HR 1.16 95%
CI 0.92–1.47, p = 0.22, Table 4). When analyses were

Fig. 2 5 year cancer specific mortality by primary tumour location n = 9509 patients with 2686 deaths (Stage I = 2104 patients with 116 deaths,
Stage II = 3684 patients with 224 deaths, Stage III = 3721 patients with 573 deaths)
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Table 4 Multivariate model for overall survival for chemotherapy
cohort (n = 4102)
Characteristic

Sided

Age

Grade

TNM stage

Sex

CCI

Year Diagnosed

Adjuvant
Chemotherapy

Stage II
(n = 1631)

Stage III
(n = 2441)

Multivariate

Multivariate

HR (95% CI)

HR (95% CI)

Left

1

1

Right

0.86 (0.68–1.09)

1.29 (1.11–1.50)

≤60

1

1

61–70

1.90 (1.20–2.99)

1.21 (0.94–1.54)

71–80

2.97 (1.92–4.58)

1.81 (1.43–2.30)

>80

5.92 (3.82–9.19)

2.00 (1.54–2.60)

Well/mod
differentiated

1

1

Poorly
Differentiated

1.43 (1.08–1.90)

1.49 (1.26–1.75)

IIIa

1

1

IIIb

2.20 (1.71–2.82)a

1.79 (1.33–2.43)

IIIc

-

3.86 (2.84–5.24)

Male

1

1

Female

0.85 (0.68–1.07)

0.94 (0.82–1.10)

0

1

1

1–2

1.42 (1.09–1.52)

1.15 (0.96–1.38)

3–4

1.60 (1.12–2.28)

1.20 (0.94–1.53)

5

2.31 (1.45–3.69)

1.83 (1.36–2.46)

2006–2009

1

1

2010–2013

0.99 (0.79–1.26)

1.00 (0.86–1.17)

Nil

1

1
b

Fluorouracil
monotherapy

0.79 (0.51–1.10)

0.48 (0.40–0.57)

Oxaliplatin
doublet

-

0.38 (0.27–0.42)

HR Hazard Ratio, CI confidence interval, CCI Charlson Comorbity index
a
IIa vs IIb/IIc, bchemotherapy vs no chemotherapy

restricted to only those stage III patients who received
adjuvant oxaliplatin doublet chemotherapy (n = 1233),
RsCC remained associated with a poorer OS (univariate
OS HR 1.8 95% CI 1.4–2.4, p < 0.0001).

Discussion
There are well established differences in patient
demographics, tumour factors and clinical presentation between RsCC and LsCC [7, 9, 10, 17, 18]. However it remains uncertain whether primary tumour
location is an independent prognostic factor in locoregional colon cancer.
The strongest evidence comes from a recent metaanalysis of 66 studies including 1,437,846 patients which
showed LsCC is associated with a significantly reduced
risk of death compared to RsCC (HR 0.82; 95% CI 0.79–
0.84, P < 0.01) [12]. This study included all stages of

colon cancer and found that, based on meta-regression,
the effect of primary tumour location was independent
of stage, race, year of study, and quality of study.
It is important to consider the limitations of the above
meta-analysis. Firstly, there was significant heterogeneity
seen in the results (I2 = 93%), which is likely due to the
variety of included study designs, differing multivariate
covariates from source studies, and patient populations,
with the estimate derived from overall populations with
no stratification by stage.
Secondly, while most of the included studies controlled for tumour factors (such as stage and grade), and
patient demographic factors (eg., age, sex), only three
studies included a comorbidity index in the multivariate
model [7, 17, 19], and only 21% (14 of 66 studies) included performance status. RsCC is more likely to occur
in older patients who have more associated comorbidities [17], and the substantial imbalances in the baseline
characteristics between LsCC and RsCC patients in
these trials may be an unmeasured confounder which
explains the improved survival with LsCC. This issue
has been directly addressed by Warschkow et al. [9]
who, in order to minimise confounding, used propensity
score matching to analyse survival in RsCC versus LsCC
in 91,416 patients with stage I-III colon cancer from the
SEER database. These authors showed that RsCC had a
better OS (HR 0.89, p < 0.001) and CSS (HR 0.71,
p < 0.001) in stage I and II, but a similar prognosis in
stage III (OS HR 0.99, p = 0.49; CSS HR 1.04,
p = 0.129).
Our current study, using a large series of Australian
patients from a prospectively collected database, and
controlling for patient factors (including comorbidities),
tumour factors, and adjuvant chemotherapy, confirmed
previous studies showing that RsCCs are more likely to
have a more advanced stage (p < 0.0001) and grade
(p < 0.0001), and occur in older patients (p < 0.0001)
with more comorbidities (p < 0.0001). Despite higher
risk tumour features, patients with RsCC are less likely
to receive adjuvant chemotherapy (p < 0.0001) or oxaliplatin doublet chemotherapy (p = 0.0002).
In the survival analysis, patients with RsCC have a lower
all-cause mortality in stage II (HR 0.85, p = 0.02), but a
higher mortality in stage III (HR 1.13, p = 0.032). Moreover, patients with RsCC had an improved 5-year CSS in
Stage I (HR 0.51,p = 0.0006) and Stage II (HR 0.59,
p = 0.0002), and a trend to inferior CSS in Stage III.
As adjuvant chemotherapy has been shown to have a
larger benefit in RsCC than LsCC [20], we subsequently
undertook further multivariate analysis in a subset of patients with known adjuvant chemotherapy protocols to
validate our findings. Adjuvant chemotherapy improved
survival in both RsCC and LsCC. We found incorporation of adjuvant chemotherapy into the multivariate
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model did not alter the effect of primary tumour location. Although definitive conclusions were limited in
stage II as chemotherapy regimens where only available
in 44% of patients, there were similar hazard ratios
showing improved OS and CSS with RsCC (multivariate
HR 0.86 and 0.67 respectively), although statistically
non-significant in the chemotherapy cohort. In stage III,
where chemotherapy data was available for the majority of patients (66%), the results of multivariate
analysis was very similar to overall cohort, with a significantly higher all-cause mortality with RsCC (HR
1.29, p = 0.0012) and trend to higher cancer specific
mortality (HR 1.16, p = 0.21).
Our findings are consistent with the results of Wiess
et al. [7], a large multivariate retrospective analysis of
53,801 patients from the SEER database linked to
Medicare data, and controlled for comorbidities using
Hierarchical Condition Categories risk score. Similar to
our findings, in multivariate analysis, patients with RsCC
had a non-significant trend to lower mortality in stage I
(HR 0.95, p = 0.21), a lower mortality in stage II (HR
0.92, p < 0.0001), but a higher mortality in stage III (HR
1.12, p < 0.001), and a non-significant difference in mortality overall (HR 1.01, p = 0.60). This stage dependant
effect, with an improved survival in RsCC in stage II,
but higher mortality in stage III, has been reported by
multiple other series [8–10, 18, 21].
The cause of the demonstrated inconsistent effect of
primary tumour location by stage is unclear. Our study,
and the quoted literature, are retrospective analyses of
large population databases, and are susceptible to the inherent bias of confounding associated with this study design. However an alternative explanation to consider is
the increasingly described differences in tumour biology
between RsCC and LsCC. RsCCs are more likely to have
adverse histological features (such as advanced T stage,
higher grade, or lymophvascular invasion) and mucinous
histology [2, 22–24]. Perhaps more importantly, there
are also marked differences in the molecular profile between these tumours [25]. RsCC has a higher rate of
BRAF mutations and high microsatellite instability
(MSI-H), both which have established prognostic
importance, with MSI-H tumours shown to have a
favourable prognosis, and BRAF a strong poor prognostic marker in non-MSI-H but not in MSI-H tumours
[22, 23, 26, 27]. In addition even within MSI-H tumours
there are known differences in prognosis, with hereditary
MSI-H colon cancers shown to have a better survival
than sporadic cases [28]. It is important to note that
these biomarkers are not uniformly distributed by stage,
with MSI-H tumours associated with lower stage (21%
in stage II vs 14% stage III and 4% stage IV), and BRAF
mutant tumours more likely to occur at a higher stage
[22, 29, 30]. Furthermore, previous studies have shown a
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differential effect of adjuvant chemotherapy in between
molecular subtypes. There is a reduced benefit with fluorouracil based chemotherapy in MSI-H tumours, but
preserved efficacy of oxaliplatin in MSI-H stage III colon
cancer patients [31, 32]. Although our study demonstrated a persistent effect of primary tumour location
even when OS analysis was restricted to those patients
who received adjuvant oxaliplatin doublet chemotherapy,
it is important to note that fewer patients with RsCC received oxaliplatin as part of the adjuvant treatment.
Therefore, in the absence of both family history and
molecular profiles in these population series, it is reasonable to hypothesise that some of the observed survival difference in stage II and III may be due to unequal
distribution of these biomarkers. However, emerging evidence suggests that primary tumour location may be a
clinical surrogate for further, yet unidentified, predictive
biomarkers as highlighted by the recent data from the
FIRE3 and CALGB/SWOG 80405 trials, which suggests
a reduced benefit to anti-EGFR treatment in RsCC independent of currently identified biomarkers [33]. A limitation of our study is the lack of associated molecular
data which is a potential source of unmeasured confounding to the results.

Conclusion
This population based study provides further evidence
that primary tumour location is an important independent clinical prognostic factor in stage II and III colon
cancer with immediate implications for clinical practice
and trial design. This clinical biomarker is likely acting
as a surrogate for as yet unidentified molecular factors.
Further studies with associated tumour molecular profiles are required to clarify the underlying biological differences between RsCC and LsCC.
Additional files
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Safety and Efﬁcacy of Oxaliplatin Doublet
Adjuvant Chemotherapy in Elderly Patients With
Stage III Colon Cancer
Daniel Brungs,1,2,3,4 Morteza Aghmesheh,1,3,4 Paul de Souza,4,5,6,7,8
Martin Carolan,1,3,4 Philip Clingan,1,3 June Rose,3 Marie Ranson1,2,4
Abstract
Owing to poor representation in trials, the optimum adjuvant regimen for elderly patients with stage III colon
cancer is uncertain. We employed data from a cancer registry to show a survival beneﬁt with the addition of
oxaliplatin to ﬂuoropyrimidine in patients ‡ 70 years. We note an increased rate of hospital admissions and
early chemotherapy cessation in elderly patients on oxaliplatin.
Background: Colon cancer is common in the elderly, but owing to under representation in clinical trials, the beneﬁt of
standard therapies is uncertain in this age group. We aimed to clarify the efﬁcacy and complications of adjuvant
oxaliplatin and ﬂuoropyrimidine chemotherapy for patients 70 years and older with stage III colon cancer. Patients and
Methods: All patients with stage III colon adenocarcinoma were identiﬁed from an Australian cancer registry
(2006-2013). Multivariable Cox hazard regression was used to determine prognostic factors for all-cause mortality.
Chemotherapy complications were quantiﬁed using discontinuation rates, hospital admissions, and mortality for 12
months after starting chemotherapy. Results: A total of 2164 patients fulﬁlled our inclusion criteria, including 1080
(49.9%) patients  70 years. Patients  70 years were less likely to receive adjuvant chemotherapy (60.7% vs.
89.6%) or oxaliplatin doublet chemotherapy (18.8% vs. 71.2%). Older patients receiving oxaliplatin were more likely
to cease treatment early (18.7% vs. 7.6%) and require hospital admission (67.0% vs. 53.5%). The addition of
oxaliplatin provided an overall survival beneﬁt for patients < 70 years (hazard ratio, 0.44; 95% conﬁdence interval,
0.3-0.6; P < .0001) and for patients  70 years (hazard ratio, 0.64; 95% conﬁdence interval, 0.5-0.9; P ¼ .005).
Conclusions: Despite a modestly increased rate of hospital admission and early chemotherapy cessation, we
demonstrate a persistent survival beneﬁt for the addition of oxaliplatin to a ﬂuoropyrimidine as adjuvant treatment
for stage III colon cancer in elderly patients.
Clinical Colorectal Cancer, Vol. 17, No. 3, e549-55 ª 2018 Elsevier Inc. All rights reserved.
Keywords: Aged, Age groups, Colonic neoplasms, Comorbidity, Medical record linkage
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Colon cancer is a common and lethal malignancy, with about
100,000 new cases diagnosed annually in the United States.1 It is a
disease related to aging, with almost 40% of colon cancer diagnosed
in patients > 75 years.2-4
Surgical resection is the only curative treatment for locoregional
disease, although many patients will develop disease recurrence
owing to micrometastases present at surgery. In resected stage III
colon cancer, standard treatment includes adjuvant doublet
chemotherapy with oxaliplatin and a ﬂuoropyrimidine,5 following
the results of several large phase III randomized controlled trials that
showed a 30% reduction in disease recurrence and 22% reduction
in risk of death with the addition of oxaliplatin to ﬂuoropyrimidine
alone.6-8
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Table 1 Patient Characteristics
All Patients,
n [ 2164 (%)

Patients < 70 Years,
n [ 1084 (50.1%)

Patients ‡ 70 Years,
n [ 1080 (49.9%)

P Value

IIIa

272 (12.6)

141 (13.0)

131 (12.1)

.81

IIIb

1284 (59.3)

638 (59.9)

646 (59.8)

IIIc

608 (28.1)

305 (28.1)

303 (28.1)

TNM stage

Charlson comordibity index
1485 (68.6)

831 (76.7)

654 (60.6)

1-2

0

403 (18.6)

165 (15.2)

238 (22.1)

3-4

195 (9.0)

63 (5.8)

132 (12.2)

81 (3.7)

25 (2.3)

56 (5.2)

5 or more

< .0001

Primary tumor location
Right

1053 (48.7)

463 (42.7)

590 (54.6)

Left

1111 (51.3)

621 (57.3)

490 (45.4)

< 60

513 (23.7)

513 (47.3)

60-69

571 (26.4)

571 (52.7)

70-79

709 (32.8)

709 (65.7)

 80

371 (17.1)

371 (34.3)

< .0001

Age group, y

Gender
Male

1125 (52.0)

577 (53.2)

548 (50.8)

Female

1039 (48.0)

507 (46.8)

532 (49.3)

.25

Grade
Well-differentiated

220 (10.2)

112 (10.3)

108 (10.0)

1484 (68.6)

774 (71.4)

710 (65.7)

460 (21.3)

198 (18.3)

262 (24.3)

2006-2009

1096 (50.7)

570 (52.6)

526 (48.7)

2010-2013

1068 (49.4)

514 (47.4)

554 (51.3)

Moderately differentiated
Poorly differentiated

.0028

Year diagnosed
.07

Adjuvant chemotherapy
None

538 (24.9)

113 (10.4)

425 (39.4)

Fluoropyrimidine monotherapy

651 (30.1)

199 (18.4)

452 (41.8)

Oxaliplatin doublet

975 (45.0)

772 (71.2)

203 (18.8)

Elderly patients appear to gain a similar beneﬁt to
ﬂuoropyrimidine-based adjuvant chemotherapy compared with
younger patients.9 However, as only a minority of patients in
clinical trials are older than 70 years, the efﬁcacy and safety of
adjuvant chemotherapy with an oxaliplatin doublet in elderly
patients is unclear. For example, in the Adjuvant Colon Cancer End
Points (ACCENT) database, which includes individual patient data
from 14,500 participants in 18 ﬂuoropyrimidine-based adjuvant
trials, only 18% are older than 70 years.10
Currently available trial data is conﬂicting. Subgroup analyses
from the pivotal phase III MOASIC and NSABO-07 trials show a
survival beneﬁt only in patients < 70 years.6,7 Similarly, there was
no disease-free survival (DFS) or overall survival (OS) improvement
with the addition of oxaliplatin in the 2575 patients  70 years in
the ACCENT database.10 In contrast, however, pooled individual
patient data from 904 patients  70 years from the NSABP C-08,
XELOXA, X-ACT, and AVANT studies showed an attenuated but
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statistically signiﬁcant beneﬁt to the addition of oxaliplatin,
including those with comorbidities.11
Similarly, retrospective patient series demonstrate contrasting
results. Although the largest series, drawn from multiple United
States databases including the Surveillance, Epidemiology, and End
Results (SEER) database, found a statistically signiﬁcant beneﬁt to
adjuvant oxaliplatin in elderly patients (70-74 years old) and those
with comorbidities,12 this was less clear in patients > 75 years13 and
was not seen in other, smaller studies.14,15
As a consequence of these uncertainties, current guidelines
recommend discussing the incorporation of oxaliplatin with patients
over 70 years based on individual circumstances, although ﬂuoropyrimidine monotherapy is an appropriate choice for adjuvant
therapy in the elderly.5,16
The current study employs data from an Australian cancer registry to investigate the comparative effectiveness of the addition of
oxaliplatin to ﬂuoropyrimidine monotherapy as adjuvant treatment

Daniel Brungs et al
Table 2 Univariate and Multivariate Analyses for Overall Survival in all Patients Who Received Adjuvant Chemotherapy (N [ 1626)
Characteristic

Univariate HR (95% CI)

P Value

1

< .0001

Multivariate (95% CI)

P Value

Age, y
 60
60 to < 70

1.0 (0.97-1.3)

1

.010

0.97 (0.7-1.3)

70-80

2.3 (1.8-2.9)

1.4 (1.1-1.9)

> 80

3.7 (3.0-4.8)

1.7 (1.1-2.4)

Gender
Male
Female

1

.49

1.05 (0.91-1.2)

1

.43

0.9 (0.8-1.1)

TNM
< .0001

IIIa

1

IIIb

1.5 (1.1-2.0)

2.3 (1.4-3.8)

1

IIIc

3.0 (2.2-4.0)

5.3 (3.2-8.6)

< .0001

Grade
Well/moderately differentiated
Poorly differentiated

1

< .0001

1.8 (1.6-2.2)

1

< .0001

1.6 (1.3-2.0)

Primary tumor location
Right

1

Left

0.65 (0.56-0.75)

< .0001

1

.0008

0.7 (0.57-0.86)

Charlson comorbidity index
0

1

< .0001

1

1-3

1.3 (1.1-1.6)

0.8 (0.6-1.1)

4 or more

2.9 (2.3-3.7)

1.8 (1.22-2.6)

.0004

Year diagnosed
2009
2010-2013

1

.79

0.98 (0.83-1.2)

1

.83

1.0 (0.9-1.1)

Adjuvant chemotherapy
Fluoropyrimidine only
Oxaliplatin doublet

1
0.50 (0.41-0.61)

< .0001

1

< .0001

0.54 (0.43-0.70)

Abbreviations: CI ¼ conﬁdence interval; HR ¼ hazard ratio.

for stage III colon cancer in a “real world population” of patients
older than 70 years.

Patients and Methods
Patient Cohort
The New South Wales (NSW) clinical cancer registry contains
demographic and clinical data for patients diagnosed or treated for
cancer in NSW, covering approximately 30% of the Australian
population. Data is collected from pathologic laboratories, hospitals,
and oncology departments under mandatory notiﬁcation of new
cancer cases. We included all patients  18 years with colon cancer
as per the third edition of the International Classiﬁcation of Diseases
for Oncology (ICD-O-3).17 We identiﬁed 2220 patients with stage
III colon cancer with complete ﬁles including adjuvant chemotherapy details. Fifty-six patients were excluded owing to death
within 30 days of surgery (n ¼ 23) or delay starting chemotherapy
past 120 days (n ¼ 33) (ﬁnal sample, n ¼ 2164).
Date of death was obtained with linkage to the NSW registry of
Births, Deaths, and Marriages (BDM) by the Centre for Health
Record Linkage (CHeReL).18 The censor date for survival data was
December 1, 2014.

Comorbidity data and admissions during chemotherapy were
obtained by CHeReL linkage of the clinical cancer registry data to
the Admitted Patient Data Collection (APDC). The APDC
contains all admitted patient services provided by NSW Public
Hospitals, Public Multi-Purpose Services, Private Hospitals, and
Private Day Procedures Centers. Comorbidities of each patient were
quantiﬁed using the Charlson Comorbidity Index (CCI), which
predicts mortality from a range of 22 comorbid conditions.16
ICD-10 codes were extracted from admissions prior to diagnosis,
then translated into a CCI (modiﬁed for cancer) using methods
previously described.19,20
For quantiﬁcation of chemotherapy complications, all admissions
for 12 months following initiation of chemotherapy were included
apart from admissions for vascular implantation, chemotherapy,
routine surgery follow-up, and dialysis (ICD-10 codes Z45.2, Z51,
Z48.815, and Z49, respectively). Admissions for febrile neutropenia
were identiﬁed using neutropenia (ICD-10 D70) with fever and/or
sepsis (ICD-10 R50.8, R50.9, A419) and/or infection (ICD-10
Chapter A, B) as previously described for Australian patients.21
Linkage and use of the data from the NSW clinical cancer
registry, the NSW registry of BDM, and APDC was approved by
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Figure 1 All-Cause Mortality by Adjuvant Chemotherapy
Regimen for all Patients (n [ 1626)

chemotherapy and oxaliplatin doublet treatments in all patients
(P < .001), patients < 70 years (P ¼ .04), and patients  70 years
(P < .0001).
Although the majority of patients on ﬂuoropyrimidine monotherapy received oral capecitabine rather than intravenous
ﬂuorouracil (83.9% vs. 16.1%), only a minority of patients treated
with oxaliplatin doublet chemotherapy had oral capecitabine
(CAPOX) rather than intravenous ﬂuorouracil (FOLFOX) (13.7%
vs. 86.3%). There was a similar pattern of use in patients  70 years
and < 70 years.

Complications of Chemotherapy

the NSW Population and Health Services Research Ethics Committee (approval HREC/13/CIPHS/39).

Statistical Analysis
Our primary outcome was all-cause mortality, on the basis of
dates recorded in the cancer registry and BDM databases. Median
values for OS and corresponding 95% conﬁdence interval (CI) were
calculated using Kaplan-Meier methods. To determine the impact
of age, 2 separate Cox proportional hazard models were used to
compare the effect of combination chemotherapy regimens on OS
for patients  70 years and < 70 years. This age cut-off was used for
consistency with previous publications and international guidelines.
The following variables were included in the multivariate model:
age, gender, CCI, TNM stage, primary tumor location (deﬁned as
right-sided [cecum to transverse colon] or left-sided [splenic ﬂexure
to rectosigmoid]), year of diagnosis, grade, and adjuvant treatment.
Our secondary objectives were complications of adjuvant
chemotherapy by age group, as measured by number and length of
admissions for 12 months after starting treatment, 12-month
landmark mortality, and treatment discontinuation rate by
chemotherapy regimen. The number of admissions was compared
using the c2 test, and the mean duration of each admission by the
t test. All statistical analyses were performed using SAS 9.2 software
(SAS Institute, Inc, Cary, NC).

Results
Patient Characteristics (n ¼ 2164) and Impact of Age on
Receipt of Chemotherapy
The characteristics of patients are summarized in Table 1.
Approximately one-half (49.9%) of the patients were  70 years.
Patients  70 years were more likely to have right-sided primary tumors (54.6% vs. 42.7%) and poorly differentiated histology (24.3%
vs. 18.3%), but despite these higher risk features, were less likely to
receive adjuvant chemotherapy (60.7% vs. 89.6%) or oxaliplatin
doublet chemotherapy (18.8% vs. 71.2%). Patients  80 years
(n ¼ 371) were even less likely to receive chemotherapy; only 29.4%
received adjuvant ﬂuoropyrimidine monotherapy and 3.0% received
oxaliplatin doublet. Increasing TNM stage was signiﬁcantly associated with receipt of oxaliplatin chemotherapy in patients < 70 years
(P ¼ .0006) but not in those  70 years (P ¼ .08).
Patients  70 years were more likely to have a higher CCI than
younger patients (39.4% vs. 23.3% with CCI > 0). Increasing CCI
was associated with decreased administration of adjuvant

e552

-

Clinical Colorectal Cancer September 2018

Chemotherapy complications were quantiﬁed with hospital admissions for 12 months following initiation of adjuvant chemotherapy and 12-month landmark mortality.
In patients who received ﬂuoropyrimidine monotherapy, there
was no signiﬁcant difference in proportion of patients < 70 years
admitted to hospital compared with those  70 years (49.7% vs.
49.8%; P ¼ .59) or the mean duration of admissions (5.92 vs. 5.59
days; P ¼ .66). In contrast, patients  70 years who received
oxaliplatin were more likely to be admitted to hospital (67.0% vs.
53.5%; P ¼ .0006) and require multiple admissions (37.4%
required  2 admissions vs. 25.5%; P ¼ .0008) than younger patients on oxaliplatin. There was a nonsigniﬁcant trend to longer
admissions (mean length of admission, 6.1 vs. 4.8 days; P ¼ .09).
In patients  70 years, those treated with oxaliplatin were more
likely to be admitted to hospital (67.0% vs. 49.6%; P < .0001) and
require multiple admissions (37.4%  2 admissions vs. 26.1%;
P ¼ .003) than those on ﬂuoropyrimidine monotherapy. Although
there was no signiﬁcant difference in admissions for febrile neutropenia between age groups for patients on oxaliplatin (6.9% vs.
4.7%; P ¼ .19), patients  70 years on oxaliplatin were more likely
to be admitted for febrile neutropenia than those on ﬂuoropyrimidine monotherapy (6.9% vs. 1.8%; P ¼ .0008).
Patients  70 years were also less likely to complete adjuvant
oxaliplatin doublet chemotherapy than those < 70 years, deﬁned as
receiving < 3 months of treatment (18.7% vs. 7.6%; P < .0001).
There was no difference in completion rates between age groups for
patients on ﬂuoropyrimidine alone (P ¼ .33).
Patients  70 years who received adjuvant oxaliplatin doublet
chemotherapy had a signiﬁcantly poorer 12-month landmark OS
than younger patients (5.9% vs. 1.7%; P ¼ .0006). This difference
between age groups was not seen in patients who received ﬂuoropyrimidine monotherapy (8.6% vs. 4.5%; P ¼ .06). Within
patients  70 years, there was no signiﬁcant difference in 12-month
OS between those who received ﬂuoropyrimidine monotherapy
compared with those who received oxaliplatin doublet (8.6% vs.
5.9%; P ¼ .23).

Efﬁcacy of Adjuvant Chemotherapy in the Elderly
In all patients who received adjuvant chemotherapy (n ¼ 1626),
oxaliplatin doublet chemotherapy improved OS compared with
ﬂuoropyrimidine alone (multivariate hazard ratio [HR], 0.54; 95%
CI, 0.43-0.70; P < .0001) (Table 2, Figure 1). Increasing age,
comorbidity score, TNM stage, poorly differentiated grade, and
right-sided primary tumor location were all signiﬁcantly associated
with poorer OS in both univariate and multivariate analyses. Use of
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Table 3 Univariate and Multivariate Analyses for Overall Survival Stratiﬁed by Age
Patients < 70 Years (n [ 971)
Characteristic

Univariate HR
(95% CI)

Patients ‡ 70 Years (n [ 655)

Multivariate
(95% CI)

P Value
< .0001

Univariate HR
(95% CI)

Multivariate

P Value
< .0001

TNM
IIIa

1

1

1

1

IIIb

1.6 (0.9e 2.9)

1.7 (0.9-3.3)

1.5 (1.04- 2.0)

3.0 (1.4-6.4)

IIIc

4.1 (2.3-7.1)

4.4 (2.3-8.2)

2.7 (1.9-3.9)

6.4 (3.0-13.9)

Grade
Well/moderately differentiated
Poorly differentiated

1
2.0 (1.5-2.7)

1

.0007

1.7 (1.3-2.5)

1

1

1.6 (1.4-2.0)

1.5 (1.1-2.0)

.01

Primary tumor location
Right
Left

1
0.6 (0.5-0.8)

1

< .0001

0.5 (0.4-0.7)

1

1

0.80 (0.6-0.9)

.39

0.9 (0.7-1.2)

Charlson comorbidity index
0

1

1

1-3

0.8 (0.6-1.2)

1

0.6 (0.4-1.0)

1

.01

1.2 (1.01-1.5)

0.9 (0.6-1.2)

4 or more

2.4 (1.4-3.9)

1.8 (0.9-3.3)

2.4 (1.8-3.2)

1.9 (1.2-3.1)

.01

Adjuvant chemotherapy regimen
Fluoropyrimidine only
Oxaliplatin doublet

1
0.6 (0.4-0.8)

1
0.4 (0.3-0.6)

< .0001

1

1

0.7 (0.5-0.9)

0.6 (0.5-0.8)

.005

Abbreviations: CI ¼ conﬁdence interval; HR ¼ hazard ratio.

capecitabine, rather than 5-ﬂuorouracil, was not signiﬁcantly
associated with OS in either the ﬂuoropyrimidine monotherapy
(P ¼ .82) or oxaliplatin doublet (P ¼ .48) treatment groups.
When stratiﬁed by age, the addition of adjuvant oxaliplatin
demonstrated an OS beneﬁt in patients < 70 years (HR, 0.56; 95%
CI, 0.41-0.77; P ¼ .0003) and  70 years (HR, 0.72; 95% CI,
0.53-0.98; P ¼ .037), which remained signiﬁcant in multivariate
analysis (Table 3, Figure 2). Gender and year of diagnosis were not
signiﬁcant in univariate analysis and were therefore not included in
the ﬁnal model.
Oxaliplatin doublet chemotherapy was associated with a preserved OS beneﬁt in patients with signiﬁcant comorbidity (patients
with CCI  2, univariate HR, 0.40; 95% CI, 0.29-0.61;
P < .0001), including patients < 70 years (HR, 0.38; 95% CI,
0.16-0.94; P ¼ .02), but not in patients  70 years (HR, 0.67;
P ¼ .28). Exploratory subgroup analysis demonstrated a diminishing OS beneﬁt to oxaliplatin with increasing age, with the HR
approaching 1 (no beneﬁt) for more elderly patients (Figure 3).

Discussion
Colon cancer is more common in the elderly, because 67 is the
median age at diagnosis, and almost 40% of patients are  75 years
old.3,4 Despite this, the pivotal phase III trials that demonstrated the
improved OS with adjuvant oxaliplatin chemotherapy in stage III
colon cancer included a only small minority of patients older than
70 years, and consequently were unable to show a beneﬁt to
oxaliplatin in this population.3,22
The principle ﬁnding of the current study is a statistically
signiﬁcant improved OS with adjuvant oxaliplatin doublet chemotherapy compared with ﬂuoropyrimidine monotherapy in
patients  70 years with stage III colon cancer (HR, 0.72;

P ¼ .037). This difference remained signiﬁcant in multivariate
analysis, which included a comorbidity index (multivariate HR,
0.64; P ¼ .005).
There is no consensus in the literature regarding the beneﬁt of
adjuvant oxaliplatin for elderly patients. Neither DFS nor OS was
signiﬁcantly improved in the small minority of elderly patients in
the MOSAIC or NSABP-07 trials, or in the ACCENT database.6,7,10 In contrast, pooled individual patient data from 4 other
randomized trials, which included comorbidities as a covariate,
demonstrated improved DFS and OS with oxaliplatin.11 Similarly,
there are disparate results seen in “real-world” patient series. Analysis of the SEER database showed a persistent beneﬁt to adjuvant
oxaliplatin in patients > 70, although with inconsistent results in
patients older than 75, and in those with signiﬁcant comorbidities.12,13 Other results from smaller retrospective series are conﬂicting.14,23 One common criticism of all the above studies, as well
as the current work, is the omission of an assessment for medical
frailty, an important and distinct entity to comorbidity.24

Figure 2 All-Cause Mortality by Adjuvant Chemotherapy
Regimen Stratiﬁed by Patient Age at Diagnosis

Clinical Colorectal Cancer September 2018

- e553

Adjuvant Chemotherapy for Stage III Colon Cancer in the Elderly
Figure 3 Unadjusted Hazard Ratio for Overall Survival Beneﬁt
to Oxaliplatin Chemotherapy Stratiﬁed by Age. The
Circle on Each Bar Represents the Hazard Ratio for
That Age Group, and the Bar Shows the 95%
Conﬁdence Interval

Abbreviation: CI ¼ conﬁdence interval.

It is important to highlight that the elderly patients who received
oxaliplatin chemotherapy in the current study are likely to represent
a highly selected subgroup. This is supported by the observed high
completion rate of adjuvant oxaliplatin doublet chemotherapy in
patients  70 years, although we note that data regarding chemotherapy dosing, dose reductions, and delays, which may provide
further insight, are not available. Consistent with other published
series, we found increasing age was associated with decreased receipt
of any adjuvant chemotherapy and oxaliplatin doublet chemotherapy, with only 18.8% of patients  70 years, and 3%  80
years, receiving oxaliplatin.13,14,25 Similarly, increasing level of
comorbidity, quantiﬁed by the CCI, was also associated with
decreased receipt of oxaliplatin (P < .0001), with most of the
elderly patients who received oxaliplatin (86.2%) having minimal
comorbidities (CCI < 2).
Despite presumed patient selection for oxaliplatin doublet therapy, hospital admissions were modestly increased in elderly patients
compared with younger patients. Elderly patients who received
oxaliplatin doublet chemotherapy were more likely to be admitted
to hospital, require multiple admissions to hospital, or require
admissions for febrile neutropenia. These observations were not
seen in patients receiving ﬂuoropyrimidine monotherapy, consistent
with current literature that shows increased toxicity in the elderly
from doublet chemotherapy, but not ﬂuoropyriminde monotherapy.9,11,14,26,27 We acknowledge that the hospital admission
data do not reﬂect all toxicity, as at least some complications are
likely to have been managed out of hospital. It also important to
highlight we did not ﬁnd a signiﬁcant difference in 12-month
landmark OS between chemotherapy regimens in elderly patients.
The decision to proceed with adjuvant chemotherapy in an
elderly patient is complicated and depends on many patient health
and social factors. The patient’s age, comorbidities, and perceived
minimal beneﬁt are the predominant reasons for withholding
adjuvant chemotherapy in elderly patients.28 Although the average
life expectancy of an otherwise healthy 70-year-old male and female
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is approximately 8 years and 14 years, respectively,5 many elderly
patients have signiﬁcant comorbidities that could shorten survival.
Although we used the 70-year age cut-off in our primary analysis for
consistency with other publications, our exploratory subgroup analyses demonstrated, as expected, a diminishing beneﬁt to adjuvant
oxaliplatin with increasing age. Moreover, although the beneﬁt for
adjuvant oxaliplatin increases with time in younger patients, in older
patients it decreases, so by 3 years after surgery, the competing
mortality risks eliminate the beneﬁt of doublet adjuvant chemotherapy.10 The recently presented data from the IDEA collaboration
supports a risk-adapted approach to duration of adjuvant
chemotherapy, with a shorter duration of adjuvant chemotherapy in
lower risk disease to reduce treatment-associated toxicities.29 These
data, along with our study, support the role of an individualized
treatment approach, rather than strict age cut-offs, when determining the optimal adjuvant strategy for elderly patients.
There are limitations to the current study. First, we analyzed an
observational database and acknowledge important unmeasured
confounders and selection bias between treatment groups. Second,
there was no data available regarding chemotherapy dosing, dose
reductions, or treatment delays, for any patients. However, although
it is likely that most of the elderly patients received dose modiﬁcations to improve tolerability,30 we still found an OS beneﬁt.

Conclusion
Our study demonstrates a survival beneﬁt to adjuvant chemotherapy with an oxaliplatin doublet over ﬂuoropyrimidine alone for
patients  70 years with stage III colon cancer. However, we also
found evidence of modestly increased hospital admission rates with
doublet treatment. The potential for survival beneﬁt must be
weighed against the increased risk of toxicities in this population, as
well as individual patient life-expectancies, based on comorbidities
and other factors.

Clinical Practice Points
 The optimum adjuvant chemotherapy regimen for elderly











patients with stage III colon cancer is unknown, with conﬂicting
results from clinical trials and population studies.
Data from an Australian cancer registry (n ¼ 2164) was interrogated to examine the utilization, safety, and efﬁcacy of adjuvant chemotherapy in elderly patients with stage III colon cancer.
Patients  70 years are less likely to receive any adjuvant
chemotherapy than younger patients (61% vs. 90%) or oxaliplatin doublet adjuvant chemotherapy (19% vs. 71%).
Addition of oxaliplatin to ﬂuoropyrimidine as adjuvant chemotherapy improves survival in patients  70 years (HR, 0.64;
P ¼ .005). This beneﬁt remained signiﬁcant in the multivariate
analysis after adjusting for age, comorbidity, TNM stage, grade,
and primary tumor location (multivariate HR, 0.72; P ¼ .037).
The survival beneﬁt appears to reduce with increasing age.
Patients  70 years who received oxaliplatin chemotherapy are
more likely to be admitted to the hospital or cease treatment
early, reﬂecting increased toxicity in this population.
Adjuvant oxaliplatin should be considered in elderly patients
with stage III colon cancer. Rather than use strict age cut-offs, we
recommend a comprehensive geriatric assessment of elderly
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patients, followed by a detailed discussion of the risks and beneﬁts of adjuvant treatment, to permit optimal individualization
of treatment for each patient.
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